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Abstract 
Colorectal cancer is the second most common cause of cancer death in the western world. 
Despite improvements in diagnosis and treatment, 50% of patients still die from this 
disease. It is now recognised that postoperative infective complications contribute to poor 
cancer specific survival following resection for colorectal cancer. The basis of this 
observation is not clear. One hypothesis is that the presence of a raised systemic 
inflammatory response may be responsible. Whether a raised postoperative inflammatory 
response is the result of an early underlying infection at a preclinical stage, or whether a 
raised inflammatory response leads to increased susceptibility to subsequent infection is 
not known. If the former proves true, it is possible that targeting at risk patients with pre-
emptive antibiotics may reduce infective complications and improve patient outcomes. 
Conversely, if the latter is the case, perioperative intervention to reduce the postoperative 
inflammatory response may reduce infective complications and hence improve outcomes, 
both short and long term, for patients undergoing colorectal cancer resection.  
The work presented in this thesis further examines the relationship between the systemic 
inflammatory response and postoperative infective complications following resection for 
colorectal cancer, determines predictive thresholds for the development of postoperative 
infective complications, assesses the impact of the peak systemic inflammatory response 
on these thresholds and investigates the determinants of the peak response. Finally, the 
question as to whether a raised postoperative systemic inflammatory response is the cause 
or consequence of infective complications is examined. 
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Patients with colorectal cancer who have a raised systemic inflammatory response prior to 
surgery have been shown to have poorer long term and short term outcomes.  The presence 
of an ongoing systemic inflammatory response in these patients may be due to impaired 
cortisol production.  Chapter 3 examines the relationship between the perioperative 
systemic inflammatory response and endogenous cortisol production by assessment of 
adrenocortical function preoperatively in 80 patients undergoing resection for colorectal 
cancer.   
 
Infective complications particularly in the form of surgical site infections including 
anastomotic leak represent a serious morbidity after colorectal cancer surgery.  Systemic 
inflammation markers, including C-reactive protein and white cell count, have been 
reported to provide early detection.  However their relative predictive value is unclear.  
Chapter 4 examines the diagnostic accuracy of serial postoperative white cell count, 
albumin and C-reactive protein in detecting infective complications in 454 patients 
undergoing surgery for colorectal cancer. It demonstrates that postoperative C-reactive 
protein measurement, particularly a threshold of 170 mg/l on day 3 postoperatively, is 
clinically useful in predicting surgical site infective complications, including an 
anastomotic leak, in patients following colorectal cancer resection.   
 
Chapter 5 compares the value of daily C-reactive protein concentrations in the prediction 
of postoperative infective complications in patients undergoing open versus laparoscopic 
resection for colon cancer. Although the magnitude of the systemic inflammatory response, 
as evidenced by C-reactive protein, following surgery was greater in open compared with 
laparoscopic resection, the threshold concentrations of C-reactive protein for the 
development of postoperative infective complications were remarkably similar on days 3 
and 4.  
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The postoperative systemic inflammatory response, as evidenced by C-reactive protein on 
days 3 and 4, is shown in chapters 4 and 5 to be associated with the development of 
infective complications following surgery for colorectal cancer.  However, patients in 
enhanced recovery after surgery programmes require earlier assessment at day 2, at the 
peak inflammatory response to surgery. Chapter 6 assesses the impact of day 2 C-reactive 
protein, on concentrations at days 3 and 4. A day 2 C-reactive protein concentration >190 
mg/L was associated with day 3 and 4 concentrations above established thresholds for the 
development of infective complications.   
 
Chapter 7 examines the clinicopathological determinants of the postoperative systemic 
inflammatory response, as evidenced by C-reactive protein concentrations on day 2, day 3 
and day 4 in patients following resection of colorectal cancer. Chapter 7 demonstrates that 
several clinical factors are independently associated with the peak systemic inflammatory 
response, as evidenced by postoperative day 2 C-reactive protein concentration and 
threshold, following resection of colorectal cancer.  In particular, emergency presentation, 
socioeconomic deprivation and preoperative systemic inflammation are associated with a 
higher peak systemic inflammatory response.  In contrast, laparoscopic surgery is 
associated with a lower peak systemic inflammatory response.   
 
Enhanced Recovery After Surgery (ERAS) programmes aim to attenuate the stress 
response to surgery, reduce the length of hospital stay and have been proposed to be 
associated with reduced morbidity and mortality.  However, data on the effect of enhanced 
recovery on the systemic inflammatory response and infective complications remains 
limited.  Chapter 8 examines the impact of enhanced recovery on the systemic 
inflammatory response and the rate of infective complications following elective surgery 
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for colorectal cancer. Enhanced recovery was associated with a significant reduction in 
length of hospital stay.  In contrast, the postoperative systemic inflammatory response was 
similar to that of conventional care.  Overall complication rates, both non-infective and 
infective, were also similar.  
  
Chapter 9 examines the relationships between postoperative predictive thresholds of C-
reactive protein and infective complications, in the context of the administration of pre-
emptive antibiotic therapy, for patients undergoing resection for colorectal cancer. 
The administration of pre-emptive antibiotics guided by C-reactive protein thresholds 
predictive of infective complications did not reduce infective complication rates or the 
magnitude of the postoperative inflammatory response following elective resection for 
colorectal cancer.  
 
In summary, the objective measurement of the postoperative systemic inflammatory 
response and its relationship with postoperative outcomes has profound implications for 
assessment and treatment of the surgical stress response in patients with colorectal cancer.  
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1 Introduction 
1.1 Epidemiology of Colorectal Cancer 
In the UK, the incidence of colorectal cancer is increasing.  It is the fourth most common 
cancer with approximately 41,600 people diagnosed each year (CRUK, 2014).  Around 
16,000 deaths occur annually from colorectal cancer in the UK, second only to lung cancer 
as a cause of cancer death in the combined male and female population.  Incidence 
increases with age with over 80% of cases occurring in patients over 60 years old.  
Colorectal cancer is the second most common cancer to affect women and the third most 
common to affect men.  Men in the UK have a lifetime risk of 1 in 14 of developing 
colorectal cancer, and women a risk of 1 in 19 (CRUK, 2014).  Survival from colorectal 
cancer has improved over the past 30 years in the UK (Shack et al., 2007, Mitry et al., 
2008), mainly owing to improved treatment and increased surgical specialisation, and to a 
lesser extent, earlier presentation and diagnosis.  However, outcome following diagnosis 
remains poor, with around half of those undergoing potentially curative procedures 
surviving to 5 years (CRUK, 2014). 
 
Worldwide, colorectal cancer is the third most common cancer with a prevalence of over 3 
million people in 2006 (Kamangar et al., 2006).  The annual incidence is estimated at over 
1.2 million with the highest rates seen in Australasia, Western Europe and North America.  
The African nations have the lowest incidence although countries with a rapid 
“westernisation” of diet and lifestyle, such as Japan, have seen a substantial increase in the 
number of new cases of colorectal cancer.  Worldwide, the disease accounts for more than 
600,000 deaths each year, making it the fourth commonest cause of cancer death (Parkin et 
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al., 1999).  Despite the increased number of new cases diagnosed each year, mortality from 
colorectal cancer has fallen since the 1970’s, decreasing more rapidly since the 1990’s. 
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1.2 Aetiology of Colorectal Cancer 
The aetiology of colorectal cancer is poorly understood.  The majority of colorectal 
tumours (>90%) are termed “sporadic” and are thought to result from complex interactions 
between host and environmental factors.  Approximately 10% represent well defined 
hereditary cancer syndromes.  A number of factors have been implicated in the 
development of sporadic colorectal cancer. 
 
1.2.1 Colorectal carcinogenesis pathways 
There are thought to be at least three molecular pathways in colorectal carcinogenesis.  The 
first occurs due to chromosomal instability and allelic losses (the adenoma-carcinoma 
sequence) causing the mucosa to undergo malignant transformation resulting in sporadic 
colorectal cancer.  It is believed to develop gradually over a period of time through the 
sequential accumulation of genetic alterations due to environmental and lifestyle factors 
(CRUK, 2014).  The second occurs in approximately 15% of all colorectal cancers and is 
due to microsatellite instability.  Microsatellites are repetitive sequences of DNA randomly 
distributed throughout the genome. Microsatellite instability is caused by mutations in the 
genes that are involved in DNA repair (mismatch repair genes). This leads to base-pair 
mismatches during DNA replication, ultimately leading to protein truncations (Boland et 
al., 1998). In addition to chromosomal and microsatellite instability, a third carcinogenic 
pathway, known as hypermethylation, has been described. The precursor lesions for 
development of carcinomas via this route are not adenomas but serrated polyps. These 
tumours are thought to develop along a pathway where hypermethylation rather than 
genetic mutation is responsible for the inactivation of tumour suppressor gene function 
(Ferracin et al., 2008).  
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1.2.2 Age 
Age remains the single biggest risk factor for the development of colorectal cancer, with 
over 85% of tumours diagnosed in patients aged over 60 years (CRUK, 2014).  Possible 
reasons behind this association are the increased length of exposure to environmental risk 
factors, as well as increased time for chromosomal mutations to develop.  As infectious 
diseases have waned, and healthcare has improved, we are faced with diseases that occur at 
ages not previously attained. 
 
1.2.3 Deprivation 
Socioeconomic deprivation has been shown to be a risk factor associated with colorectal 
cancer, particularly in males, with those in more affluent categories having 20% lower 
incidence compared to those in the most deprived (Oliphant et al., 2011).  Furthermore, 
there is also evidence that patients with colorectal cancer who are more socioeconomically 
deprived have poorer short term outcomes, as well as cancer specific and overall survival 
(Hole and McArdle, 2002).  The underlying causes for socioeconomic inequalities in 
survival from colorectal cancer remain unclear. 
 
1.2.4 Diet and lifestyle 
The highest rates of colorectal cancer are found in western countries.  Studies on migrant 
populations have demonstrated that the incidence rates of the host country are adopted 
within a generation (Haenszel and Kurihara, 1968, Potter et al., 1993).  This has led to a 
widely held belief that a western lifestyle is responsible for the development of colorectal 
cancer in many cases.  
25 
 
A “westernised” diet has been associated with the development of colorectal cancer, in 
particular consumption of red meat and diets low in fibre.  It is thought to be the reason for 
increasing incidence in countries such as Japan, where a “western” diet and lifestyle has 
been adopted over recent years (CRUK, 2014). Epidemiological studies have consistently 
observed that countries with a high intake of red meat and animal fat have a higher 
incidence of colorectal cancer (Armstrong and Doll, 1975, Graham and Mettlin, 1979), 
however information on the mechanism underlying this relationship is sparse and overall 
the association between red meat intake and the development of colorectal cancer is 
unclear.  With reference to fibre, a pooled analysis of over 13 prospective studies 
(>700,000 men and women) concluded that, after accounting for other dietary risk factors, 
high fibre intake was not associated with a reduced risk of colorectal cancer (Park et al., 
2005). 
Individuals with high levels of daily activity have a significantly lower risk than those who 
have sedentary lifestyles (Samad et al., 2005). Regular exercise has been shown to reduce 
the risk of colon cancer by almost 25% (Wolin et al., 2007). Furthermore, this affect 
appears to be independent of potentially confounding variables such as cardiovascular 
health, diet and obesity (Colditz et al., 1997). 
 
1.2.5 Obesity 
Obesity is a well established risk factor for the development of colorectal cancer. A Body 
Mass Index (BMI) ≥30 kg/m2 has been shown to confer a 20% greater risk of developing 
colorectal cancer compared to normal BMI. In particular, in men with central obesity, for 
every 2cm increment in waist circumference the risk of colorectal cancer increased by 4% 
(Moghaddam et al., 2007). Mechanisms are poorly understood but it is suggested that 
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adipocytes produce pro-inflammatory cytokines resulting in a chronic systemic 
inflammatory response predisposing to cancer (McMillan et al., 2006). 
1.2.6 Smoking and alcohol 
Cigarette smoking is well known to be associated with an increased risk of colorectal 
cancer. This is thought to be due to the increase in the likelihood of cancer precursor 
adenomas following years of exposure to cigarette smoking.  
Studies have shown that both lifetime and baseline alcohol intake can increase the risk of 
colorectal cancer (Ferrari et al., 2007). The mechanisms through which alcohol leads to 
tumour development have yet to be determined. One hypothesis is that metabolites of 
alcohol (e.g. acetaldehyde) may be carcinogenic and may generate free radicals (Poschl 
and Seitz, 2004). Heavy alcohol consumption is also associated with a systemic 
inflammatory response which may influence cancer risk (Imhof et al., 2001). 
 
1.2.7 Medication 
A number of medications have been shown to confer a protective effect regarding the risk 
of developing colorectal cancer. A large meta-analysis reported that the risk of developing 
colorectal cancer was significantly lower in postmenopausal women who had taken 
Hormone Replacement Therapy compared to those who had never received such treatment 
(Grodstein et al., 1999).  
There is also good evidence that patients taking non-steroidal anti-inflammatory drugs 
(NSAIDs) reduce their risk of developing colorectal cancer. A randomised control trial in 
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2003 concluded that taking aspirin daily reduced the risk of colorectal adenoma formation 
in patients with a history of polyps (Baron et al., 2003). Precise mechanisms to explain 
these effects have yet to be elucidated, however one hypothesis is that these drugs work by 
modulating the local and systemic inflammatory responses, recognised to be associated 
with the development and progression of colorectal cancer (McMillan et al., 2003b). 
Preoperative administration of glucocorticoids has been shown to reduce postoperative 
length of stay and systemic inflammation, as evidenced by serum Interleukin-6 following 
hepatic resection, and reduced length of stay following colorectal surgery. The proposed 
mechanism of action to explain this is that preoperative administration of glucocorticoids 
attenuates the postoperative systemic inflammatory response (Srinivasa et al., 2011). 
 
1.2.8 Systemic inflammatory response 
A number of studies have suggested that the risk of colorectal cancer is higher in 
individuals with evidence of a pre-existing systemic inflammatory response (Crozier et al., 
2007, Roxburgh and McMillan, 2010). In two studies of over 22,000 patients, plasma C-
reactive protein concentrations were consistently elevated among people who subsequently 
developed colorectal cancer (Erlinger et al., 2004, Proctor et al., 2010). It is of particular 
interest that inflammation has been associated with many other individual risk factors for 
colorectal cancer and raises the possibility that a final common pathway is responsible for 
both tumour development and the generation of a systemic inflammatory response. It 
remains to be established whether inflammation is a cause or consequence of cancer 
development, but their intimate relationship has led to inflammation being proposed as an 
inherent hallmark of cancer (Colotta et al., 2009).  
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1.2.9 Pre-existing conditions 
In a small number of cases the pathogenesis of colorectal cancer can be attributed to 
specific aetiological factors such as inherited genetic mutations or inflammatory bowel 
disease (Ponz de Leon et al., 2004). The natural history of colorectal cancer differs in 
individuals with a hereditary predisposition: with an abbreviated length of tumorigenesis, 
often presenting at an earlier age. 
 
1.2.9.1 Inflammatory bowel disease 
Patients with inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis, 
have an increased risk of developing colorectal cancer. A meta-analysis of over 60,000 
patients concluded that cumulative risk of colorectal cancer in patients with Crohn’s 
disease was 2.9% at ten years (Canavan et al., 2006). The risk of colorectal cancer in 
patients with ulcerative colitis is related to the severity and duration of symptoms and is 
estimated at 2% after 10 years, 8% after 20 years and 18% after 30 years (Eaden et al., 
2001).  The predisposition to cancer in patients with inflammatory bowel disease does not 
appear to have a specific genetic basis but instead is assumed to be the result of chronic 
inflammation as the precursor of tumour development (Triantafillidis et al., 2009).  
 
1.2.9.2 Hereditary Non-Polyposis Colon Cancer 
Hereditary non-polyposis colon cancer (HNPCC), also referred to as Lynch syndrome, is 
the most common autosomal dominant cancer predisposition syndrome responsible for at 
least 50% of hereditary disease and about 3% of all cancer cases and results from a defect 
in one of the mis-match repair genes (mainly hMSH2 on chromosome 2p and hMLH1 on 
chromosome 3p). Incidence is approximately 1:1000 of the general population. A marked 
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70-80% increase in proximal colon cancers is observed in carriers (Lynch et al., 1977). 
Colorectal cancers are the most frequent cancers associated with HNPCC; endometrial 
cancers have been identified as the second-leading cancer associated with the syndrome. 
Patients with HNPCC have an 80% lifetime risk of colorectal cancer and women have a 
60% risk of endometrial cancer. In addition they have an elevated risk of other cancers 
including stomach, biliary, ovarian and urogenital cancers. Cardinal features of Lynch 
syndrome colorectal cancer include early age of onset, proximal colon involvement, 
increased incidence of synchronous and metachronous colon cancers, and an autosomal 
dominant inheritance pattern. Tumours tend to be poorly differentiated with an increased 
frequency of local inflammatory reaction around the tumour termed “Crohns-like reaction” 
alongside an abundance of tumour infiltrating lymphocytes (Jass, 1998). With current 
detection and treatment options, it is felt that no one with HNPCC should die of colorectal 
cancer, assuming that the patient at increased risk has been identified, has a knowledgeable 
physician, and has been referred to a gastroenterologist or surgeon who prescribes frequent 
(annual) screening colonoscopies initiated at age 25.  
 
1.2.9.3 Familial Adenomatous Polyposis 
Familial Adenomatous Polyposis (FAP) is an autosomal dominant disease found in less 
than 1% of patients with colorectal cancer, but will lead to cancer almost 100% of the time. 
Incidence is estimated to be 1:8000 of the general population. It is caused by mutations in 
the adenomatous polyposis (APC) gene, a tumour suppressor gene, located on 
chromosome 5 and characterized by large numbers of adenomatous polyps (hundreds to 
thousands) throughout the colon. Classical FAP is defined clinically by 100 or more 
adenomatous colon and rectal polyps, and typically occurs in patients younger than age 40. 
A variant of FAP called attenuated FAP (AFAP) is characterized by less than 100 colon 
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polyps and the onset of polyposis and cancer occurs later than in FAP. AFAP is generally 
defined in individuals with 10-99 colonic adenomatous polyps, or those with 100 or more 
colonic polyps occurring at an older age, or those with a history of colorectal cancer before 
age 60 and a family history of multiple adenomatous polyps. The latter group of patients 
will usually have rectal sparing, have right-sided colonic adenomas, and lack extra colonic 
manifestations. People with FAP should undergo regular surveillance and, ultimately, 
prophylactic colectomy. Despite this, the association with duodenal polyps and 
extracolonic malignancies including pancreatic mucinous adenocarcinoma, hepatoblastoma 
and desmoid tumours means that a significant number of patients with FAP still die from 
malignant disease (Belchetz et al., 1996).  
 
1.2.9.4 Hamartomatous polyposis syndromes 
A number of different syndromes have been described whereby patients have a propensity 
to develop multiple hamartomatous polyps in the gastrointestinal tract. The majority of 
these syndromes are inherited in an autosomal dominant fashion and include Juvenile 
Polyposis syndrome (JPS), Peutz-Jeghers syndrome (PJS), hereditary mixed polyposis 
syndrome (HMPS) and the PTEN hamartoma tumour syndromes (Cowden disease). 
Although the clinical features of these syndromes are variable, all give patients an 
increased risk of developing colorectal cancer. The lifetime risk of colorectal cancer in JPS 
is 60% and in PJS it is 30%. Colon cancer develops in up to 10% of people with PTEN. In 
addition, patients with multiple hamartomatous polyps are prone to malignancies of the 
stomach, pancreas and small bowel. The progression of hamartomatous polyps to cancer is 
poorly understood.   
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1.3 Presentation and Diagnosis of Colorectal Cancer 
The presentation of colorectal cancer varies depending on the site of the tumour and the 
stage of disease. Early tumours may be asymptomatic and detected via population 
screening. Patients with proximal colonic tumours may present with iron deficiency 
anaemia secondary to occult blood loss, a right-sided abdominal mass or abdominal pain. 
In contrast, patients presenting with left-sided colonic tumours may suffer from a change in 
bowel habit, large bowel obstructive symptoms, colicky left-sided lower abdominal pain, 
intermittent distension and bloating, or dark blood mixed with stool. Patients with distal or 
rectal tumours may complain of urgency and frequency of stools, sensation of incomplete 
evacuation, pelvic pain or tenesmus, and fresh bleeding. Occasionally, presentation is as an 
emergency with intestinal obstruction, fistulation or perforation. 
 
The Scottish Bowel Screening Programme was first introduced in Scotland in 2007. It is a 
biennial programme which involves both men and women between the ages of 50 and 74 
years. Recently it has been extended to allow those over the age of 74 to opt into the 
programme. Individuals are invited to participate in screening for colorectal cancer using at 
home faecal occult blood testing kits. Screening for colorectal cancer increases the number 
of early stage cancers diagnosed and consequently reduces cancer specific mortality, and 
may also reduce the incidence of colorectal cancer by removing pre-cancerous polyps. 
 
In the elective setting, a histological diagnosis should be made and the disease fully staged 
before treatment is commenced. Flexible sigmoidoscopy or colonoscopy and biopsy 
chosen according to symptoms have the highest diagnostic sensitivity and specificity. If 
colorectal cancer is diagnosed at sigmoidoscopy, a full colonoscopy is indicated to check 
for synchronous bowel lesions (present in 4-5%). Colonoscopy is the gold standard 
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investigation of the colon and rectum allowing direct visualisation of the mucosal surface 
and offering the capacity to obtain tissue for histological diagnosis. CT colonography is a 
less invasive technique increasingly used as an alternative for frail or elderly patients.  
 
It has long been recognised that emergency presentation is associated with a high 
postoperative mortality rate (McArdle and Hole, 2004). Furthermore, compared to those 
who undergo elective resection, there is also a reduction in overall and cancer specific 
survival, independent of other clinicopathological factors including tumour stage (McArdle 
et al., 2006). Indeed, it is of interest that the presence of a systemic inflammatory response 
prior to surgery, as evidenced by an elevated C-reactive protein concentration, predicts 
overall and cancer specific survival, independent of tumour stage, in patients undergoing 
potentially curative resection for colorectal cancer (McMillan et al., 2003b). 
 
The main determinant of colorectal cancer survival is stage at presentation (Dukes and 
Bussey, 1958). Older age, stage at diagnosis, deprivation and emergency presentation are 
associated with increased mortality following resection. 
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1.4 Staging of Colorectal Cancer 
Colorectal cancer staging quantifies the extent of the disease and provides a framework for 
selecting the appropriate treatment. Staging is usually by the Tumour, Node, Metastases 
(TNM) classification system, produced by the Union for International Cancer Control 
(UICC) and the American Joint Committee on Cancer (AJCC) (Brierley, 2006, UICC, 
2015, AJCC, 2015). Scores are given based on the extent of the primary tumour (T), the 
number of regional lymph nodes involved (N), and the presence of metastatic disease (M), 
which are combined to form stage groupings. In the UK, the alternative Dukes’ 
classification is often still quoted (Dukes, 1937). Pathological reporting following surgery 
should include staging, tumour differentiation, margins, and extramural vascular invasion. 
The prognosis of colorectal cancer is often summarised according to tumour stage at 
diagnosis. Five year survival rates in the UK vary from over 90% for patients with tumours 
confined to the mucosa, to less than 10% for those with metastatic disease (CRUK, 2014). 
 
Pre-treatment staging relies on a combination of visualisation of the colon, radiological 
imaging of the chest, abdomen and pelvis, and histopathology from biopsies where 
possible. A CT scan of the chest, abdomen and pelvis is the radiological investigation of 
choice to define the extent of local tumour invasion and establish the presence or absence 
of regional lymphatic spread and metastatic disease. In rectal cancers further investigation 
with MRI of the pelvis to assess local extension of rectal cancer or transrectal ultrasound to 
assess depth of invasion of particularly early rectal cancer may also be required. If there is 
diagnostic uncertainty regarding the presence of distant metastatic disease, additional 
modalities such as MRI or PET scans may also be used. Pre-treatment staging helps to 
guide selection of the most appropriate management strategy as well as planning the 
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operative approach, and decision making regarding the provision of neo-adjuvant therapy, 
if surgery is indicated. 
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1.5 Pathology and tumour characteristics 
The pathological stage of the tumour is widely regarded as the single biggest determinant 
of outcome in colorectal cancer. The staging systems most commonly employed in the UK 
are the Dukes and TNM classifications. In addition, a number of other pathological 
characteristics have been reported to affect prognosis and may help to stratify patients with 
node negative disease for the allocation of adjuvant treatment. Assessment of these 
characteristics depends almost exclusively on accurate pathological processing and 
reporting.  
 
Histological subtypes of colorectal cancer are as follows: 98% adenocarcinomas, 2% 
adenosquamous carcinoma or adenocarcinoid carcinoma. Spread may be directly into 
adjacent organs (e.g. duodenum, bladder, uterus), haematogenous (liver and lungs 
preferential sites), lymphatic (pericolic and mesenteric nodes) or transcoelomic. In terms of 
distribution, left sided tumours are more common with 30% arising in the sigmoid or 
descending colon and 40% in the rectum. 
 
1.5.1 Tumour grade 
Tumour grade describes how well the tumour is differentiated and is reported subjectively 
by the pathologist. Colorectal tumours are generally categorised as low grade (well or 
moderately differentiated) or high grade (poorly differentiated). Reduced 5 year survival 
and increased risk of local recurrence have been reported in high grade tumours. 
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1.5.2 Venous invasion 
The microscopic diagnosis of venous invasion is made when tumour cells are identified 
within an endothelium lined space surrounded by a rim of smooth muscle and / or 
containing red blood cells (Sternberg et al., 2002). Venous invasion is an established 
predictor of poor prognosis in colorectal cancer and its presence is associated with an 
increased incidence of disease recurrence and reduced survival (Roxburgh et al., 2009a). 
The presence of venous invasion is associated with an increased risk of developing distant 
metastases (particularly hepatic) in the future and cancer related death. Clinical application 
is hampered by variations in reporting rates and techniques of assessment (Roxburgh and 
Foulis, 2011).  
 
1.5.3 Perineural invasion 
Perineural invasion is a pathological process whereby tumour cells invade nervous tissues 
and spread along nerve sheaths. It is recognised to represent an aggressive tumour 
phenotype and its presence in colorectal tumours is reported to be a poor prognostic sign 
associated with local recurrence and reduced survival (Ueno et al., 2001).  
 
1.5.4 Peritoneal involvement 
Peritoneal involvement is said to be present if tumour cells are visible either on the 
peritoneal surface or free in the peritoneal cavity. It is regarded as a poor prognostic sign in 
both colon and rectal cancer and is associated with disease recurrence and metastatic 
spread (Petersen et al., 2002).  
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1.5.5 Tumour perforation 
Tumour perforation is defined as a visible defect through the tumour such that the bowel 
lumen is in communication with the external surface of the resected specimen. It is widely 
recognised as a high risk pathological characteristic and has been associated with increased 
risk of disease recurrence and reduced survival, independent of tumour stage, in patients 
with colorectal cancer (Petersen et al., 2002). 
 
1.5.6 Margin involvement 
Tumour cells present at or within 1mm of the surgical margin indicate inadequate tumour 
excision and are an exceedingly poor prognostic indicator (Petersen et al., 2002).  
1.5.7 Petersen index 
Petersen and coworkers set out to identify objective and easily determined pathological 
features that could help identify which patients with Dukes B colon cancer may benefit 
from chemotherapy. After a meticulous pathological review of 268 consecutive cases the 
authors concluded that four factors – venous invasion, peritoneal involvement, tumour 
perforation and margin involvement – were independent prognostic markers on 
multivariate analysis (Petersen et al., 2002). Combining these factors into a cumulative 
scoring system stratified patients effectively into low risk (score 0-2) or high risk (score 3-
5) categories. The prognostic value of the Petersen Index was subsequently confirmed in a 
large validation cohort of patients with Dukes B disease (Morris et al., 2007).  
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1.5.8 Tumour necrosis 
Tumour necrosis has been reported to be associated with decreased local inflammatory 
infiltrate and with elevated markers of systemic inflammation in colorectal cancer and is 
related to poorer prognosis. The extent of tumour necrosis is assessed semi-quantitatively 
and graded as ‘absent’ (none), ‘focal’ (less than 10% of tumour area), ‘moderate’ (10-30% 
of tumour area), or ‘extensive’ (>30% of tumour area) (Pollheimer et al., 2010).  
 
In conclusion, a number of prognostic criteria in addition to the widely used TNM 
classification have been validated, however their subjective nature leads to difficulties in 
reproducibility and hence many are not widely reported or utilised. Therefore, an objective 
prognostic indicator would be beneficial. 
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1.6 Management of Colorectal Cancer 
1.6.1 Surgery 
Approximately 80% of colorectal cancers are localised to the bowel wall and can be 
surgically resected with curative intent. These operations involve complete removal of the 
tumour, the vascular pedicle and the lymphatic drainage of the affected colonic segment. 
The aim is to remove all macroscopic disease with an adequate margin of normal tissue. 
The nature of the resection is dependent on tumour site and blood supply. Primary 
anastomosis is usual unless there is acute obstruction, significant peritonitis, a severely ill 
or grossly malnourished patient. Low rectal anastomoses are often protected by a 
temporary loop ileostomy. Surgery may be undertaken as an open procedure or 
laparoscopic-assisted. Small rectal cancers confined to the mucosa may be effectively 
managed by local excision using transanal endoscopic microsurgery (TEMS) while larger 
tumours require more radical resection. For low-lying rectal cancers with confirmed 
sphincter invasion or where a clear distal resection margin cannot be guaranteed, the 
operation of choice is an abdominoperineal resection (APR). Resection of the primary 
tumour remains the principle element of treatment and potential cure for patients diagnosed 
with colorectal cancer. However, surgery itself is only one component of a series of 
assessments and investigations that make up the patients management. All patients with a 
diagnosis of colorectal cancer should be discussed with a multi-disciplinary team, 
including surgeons, oncologists, radiologists, pathologists and colorectal nurse specialists. 
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1.6.2 Enhanced Recovery After Surgery 
Over the past decade, there has been a revolution in the nature of perioperative care with 
the introduction of enhanced recovery after surgery (ERAS) protocols (Kehlet, 1997).  
More recently, this has been proposed for cancer surgery, particularly colorectal cancer 
resection.  Enhanced recovery programmes aim to attenuate the stress response to surgery, 
accelerate recovery, reduce the length of hospital stay and have been proposed to be 
associated with reduced hospital morbidity and mortality (Teeuwen et al., 2010).  For 
example, patients undergoing colorectal resection within an enhanced recovery programme 
have been reported to stay in hospital half as long as those receiving conventional care 
(King et al., 2006).   
 
1.6.3 Neo-adjuvant therapy  
For patients with large or low-lying rectal tumours initially precluding sphincter sparing 
surgery, neo-adjuvant treatment may reduce tumour bulk and enhance the prospect of 
resection with curative intent but its provision is unlikely to avoid the need for 
abdominoperineal resection. The indications for neo-adjuvant chemoradiotherapy include 
T3/4 tumours, positive mesorectal nodes on preoperative imaging and tumours threatening 
or involving the mesorectal fascia. Radiotherapy acts to downsize the tumour and reduce 
the chance of positive margins remaining after surgery. 
 
1.6.4 Adjuvant chemotherapy  
In patients with colorectal cancer who have undergone potentially curative surgery, disease 
recurrence is thought to be the result of clinically occult metastases that are present at the 
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time of resection. The goal of adjuvant chemotherapy is to eliminate these tumour cells and 
thereby increase the likelihood of cure. A 5 year survival advantage after adjuvant 
chemotherapy has been clearly demonstrated in node positive colon cancer but its benefit 
in node negative disease has yet to be confirmed and only those with high risk pathological 
features are usually considered. There is uncertainty as to whether adjuvant chemotherapy 
offers a survival advantage to patients who have previously undergone preoperative 
treatment. Radiotherapy for rectal cancer is usually only given for unexpected positive 
surgical margins where neo-adjuvant treatment has not been given. 
 
1.6.5 Metastatic disease 
Approximately 15% of patients presenting with colorectal cancer will have advanced 
disease (CRUK, 2014). Resection of isolated liver or lung metastases can offer significant 
survival advantage. If potentially curative resection is not an option, these patients are 
managed with palliative treatments. For example, stenting, local resection or creation of a 
defunctioning stoma may be considered for symptom palliation. Alternatively, oncological 
palliation with chemotherapy or radiotherapy may be administered via the oncologist.  
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1.7 Inflammation and cancer 
It is now recognised that disease progression in colorectal cancer is not only influenced by 
tumour characteristics but that patient characteristics also play an important role in cancer 
progression and survival. The tumour characteristics alone, while providing a degree of 
prognostic information, cannot fully explain the survival differences observed in patients 
with cancers of the same pathological stage. It is increasingly apparent that patient 
characteristics such as chronological age as well as potentially modifiable traits such as 
exercise tolerance relate to survival in colorectal cancer.  In addition, the presence or 
absence of local or systemic inflammatory responses have received particular attention in 
relation to cancer outcomes and may represent the intrinsic ability of a person to generate 
an anti-tumour response.  
 
Links between inflammation and cancer are already established. For example, chronic 
inflammatory bowel disease is known to increase the risk of developing colorectal cancer, 
and the administration of anti-inflammatory drugs has been shown to reduce the risk of 
colorectal malignancy. These links between inflammation and cancer are further 
strengthened by the fact that immune cells and inflammatory mediators are often observed 
in tumour tissue and the cellular processes usually associated with chronic inflammation 
are also active in the tumour microenvironment (Mantovani et al., 2008). Inflammation is 
now recognised as a key component of the biological capabilities that are acquired during 
tumour development (Colotta et al., 2009). These capabilities, described as the “hallmarks” 
of cancer, enable tumour cells to survive, proliferate and disseminate (Hanahan and 
Weinberg, 2011).  
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1.7.1 The host immune response  
The human immune system works to protect the body from foreign pathogens and is 
broadly categorised into innate (non-specific) and adaptive (acquired) immunity.  The 
immune system can also recognise cancer-specific antigens, allowing the identification and 
destruction of tumour cells in a process known as immunosurveillance. Paradoxically, 
some non-specific processes associated with inflammation can promote tumour 
progression and it is therefore the balance of pro- and anti-tumour factors that many 
believe to be of primary importance in determining cancer outcomes.  
 
1.7.1.1 Innate immunity  
In addition to epithelialised barriers such as skin and mucosa, the innate immune system, 
comprising phagocytic cells (neutrophils and macrophages), degranulating cells (basophils, 
eosinophils and mast cells) and natural killer (NK) cells as well as humoral (complement) 
components, provides a crucial (non-specific) first line of defence against pathogens.  
Bacteria that successfully penetrate the epithelial surfaces of the body attract macrophages, 
are bound by cell surface receptors and engulfed in a process known as phagocytosis. This 
is followed by the release of biologically active molecules, known as chemokines and 
cytokines, which generate an inflammatory response. Although most pathogens and/or 
tissue damage initially induce this non-specific response, the innate system may 
subsequently activate an adaptive immune response (Janeway and Medzhitov, 2002, 
Medzhitov, 2007). 
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1.7.1.2 Adaptive immunity  
The adaptive immune system is composed primarily of lymphocytes and is a specific 
antibody response in recognition of “non-self” antigens, enabling a stronger, more 
focussed response to eliminate specific pathogens and produce and develop immunological 
memory. Adaptive immunity can be divided into humoral and cell-mediated immunity 
although many of the processes and cell types are inter-dependent.  Activation of adaptive 
immunity is usually triggered by the presentation of antigens by specialised cells 
associated with the innate immune system known as antigen-presenting cells. B cells are 
the major cell types in humoral immunity and produce antibodies, known as 
immunoglobulins, which recognise and bind to specific antigens, making them easy targets 
for phagocytes and triggering the complement cascade (Janeway, 2001). T lymphocytes 
are responsible for coordinating cell-mediated immunity and can be categorised into a 
number of subsets; helper T cells (CD4+), cytotoxic T cells (CD8+), memory T cells 
(CD45R0+) and regulatory T cells (FOXP3+). Each subset plays a specific role in the 
identification and destruction of antigens. CD8+ T cells are the effector cells of adaptive 
immunity, inducing cell death through the release of cytotoxins (Janeway, 2001).   
 
1.7.1.3 Cancer immunosurveillance  
Cancer immunosurveillance is the process whereby tumour-specific antigens provoke an 
effective immunological reaction and remove transformed cells thereby preventing the 
development of otherwise inevitable malignancy (Burnet, 1957). The concept is not new 
but advances in genetic understanding have now validated the hypothesis and expanded it 
to include contributions from both the innate and adaptive immune systems (Dunn et al., 
2004). This is thought to be further evidenced by the fact that the immunocompromised 
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state is associated with increased development of malignancy (Dunn et al., 2002). 
However, there is growing recognition that the relationship between cancer and the 
immune response is yet more complex still and may involve the promotion as well as 
prevention of tumourigenesis. The immune response in cancer is thus now recognised as a 
complex relationship between pro- and anti-tumour factors with the potential to impact 
outcome in either a positive or negative manner.  
 
1.7.2 The tumour microenvironment  
The tumour microenvironment can be defined as the tissue medium in which tumour cells 
grow and develop. It is a complex and unique environment comprised of the invasive 
margin, proliferating tumour cells, tumour stroma, blood vessels, tissue cells and 
inflammatory cells. The tumour microenvironment represents a dynamic interface between 
tumour and host and it is postulated that the molecular events which occur here dictate 
whether a tumour is successfully eliminated by the host or a tumour progresses (Whiteside, 
2008). The local inflammatory response can be considered an attempt to destroy tumour 
cells but it is often attenuated. Pro-inflammatory cytokines are produced which alter the 
microenvironment to benefit the tumour. This cascade of cytokines influences a variety of 
key events including angiogenesis, cellular proliferation and matrix re-modelling, 
ultimately resulting in tumour growth and progression (Balkwill and Coussens, 2004). 
Indeed, the nature, function, density and localization of immune cells within the tumour 
microenvironment have all been reported to influence tumour progression and clinical 
outcomes in colorectal cancer (Pages et al., 2008).  
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1.7.3 The local inflammatory response  
A strong inflammatory response at a local level has been consistently associated with 
improved clinical outcomes in patients with colorectal cancer. Over the past 40 years, a 
number of studies, often using different methodologies, have examined the prognostic 
implications of the local inflammatory response in colorectal cancer. Several studies have 
shown an inverse relationship between the degree of local inflammatory infiltrate and 
survival in patients with colorectal tumours.   
 
In 1987 Jass described a prognostic classification based on four characterisitics: the 
presence or absence of lymphocytic infiltration, the tumour margin characterisitics 
(infiltrating or expanding), tumour growth beyond the bowel wall and increasing nodal 
involvement (Jass et al., 1987). A pronounced peritumoural infiltrate, which describes the 
stromal / inflammatory response at the tumour’s invasive edge, was associated with good 
outcome. The subjective nature of these assessments led to problems with reproducibility, 
particularly with the assessment of lymphocytic infiltrate, and as a result the classification 
has not been adopted widely. 
 
Using a semi-quantitative assessment of peritumoural inflammatory infiltrate on 
haematoxylin and eosin (H&E) stained sections, Klintrup and Makinen reported high-
grade inflammation at the invasive margin to be an important prognostic indicator in 
patients with node negative colorectal cancer (Klintrup et al., 2005). These findings were 
subsequently validated in an external cohort of patients with node-negative disease 
(Roxburgh et al., 2009c). Overall, there is consistent evidence that a generalised increase in 
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inflammatory cell infiltrate is associated with improved prognosis in patients with 
colorectal cancer.  
 
The Galon immune score, an immunohistochemistry based score grading specific T cell 
subtypes at both the invasive margin and the centre of the tumour has also been proposed 
more recently. A high density of these cytotoxic and memory T cells in the centre and the 
invasive margin of the primary tumour is associated with long disease free and overall 
survival and low risk of recurrence and metastasis (Mlecnik et al., 2011, Galon et al., 
2012). 
 
Increased levels of faecal calprotectin, a calcium and zinc binding protein of the S-100 
family with antimicrobial and apoptotic properties, and thought to be a marker of local 
inflammation, have been described for patients with colorectal cancer as well as for 
patients with colonic inflammation (Kristinsson et al., 1998). 
 
1.7.4 The systemic inflammatory response  
It is now widely recognised that outcomes in patients with cancer are not determined by 
tumour characteristics alone, and that patient related factors are also key to outcome. In the 
last decade, it has become increasingly apparent that cancer associated inflammation is a 
key determinant of disease progression and survival in most cancers (Hanahan and 
Weinberg, 2000, Hanahan and Weinberg, 2011). In particular, the host response in the 
form of systemic inflammation has been shown to independently predict outcome. 
Inflammation is a normal and usually beneficial physiological response to injury. Problems 
for the host can arise however if the normal tight controls of the inflammatory response are 
lost. Loss of these controls results in an exaggerated inflammatory response. With a failure 
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of normal homeostasis there is a flood of inflammatory mediators and the predominant 
effects of cytokines start to become destructive rather than protective.  
 
The presence of a systemic inflammatory response in patients with cancer is almost 
universally considered an indicator of poor prognosis. There is evidence that systemic 
inflammation is associated with the cachexia and functional decline of patients with 
advanced disease (McMillan et al., 1994) and measures of the systemic inflammatory 
response have been reported as prognostic markers in a variety of tumour types including 
lung (Forrest et al., 2004), breast (Al Murri et al., 2006) and pancreatic cancer (Glen et al., 
2006).  
 
Biochemical and haematological tests are carried out routinely for patients with cancer in a 
variety of clinical scenarios, and as such represent an easily measurable objective 
parameter to enable assessment of the severity of the systemic inflammatory response. 
 
Inflammation can be detected by measuring serum concentrations of acute phase proteins; 
a class of proteins synthesised in the liver whose concentrations change in the presence of 
inflammation. Positive acute phase proteins including C-reactive protein increase during an 
inflammatory response while negative acute phase proteins such as albumin decrease 
(Gruys et al., 2005). The measurement of changes in acute phase proteins is important 
clinically in indicating the presence and severity of inflammation. The level of this 
inflammatory response is usually best seen by measuring C-reactive protein because of 
large changes from its initial concentration in the presence of inflammation (Thompson et 
al., 1992).  
 
49 
 
1.7.4.1 C-reactive protein 
C-reactive protein was first described in 1930 and was named due to its ability to bind to 
the C-polysaccharide in the pneumococcal cell wall. It is a non-specific positive acute 
phase protein which is secreted by the liver in response to a variety of inflammatory 
cytokines, mainly interleukin-6 (IL-6), interleukin-1 (IL-1) and tumour necrosis factor 
(TNF) (Du Clos and Mold, 2004). C-reactive protein is widely used to monitor the 
systemic inflammatory response and therefore the extent, activity and prognosis of various 
diseases. 
 
The function of C-reactive protein is felt to be related to its role in the innate immune 
system. It activates complement, binds to Fc receptors and acts as an opsonin for various 
pathogens. Interaction of C-reactive protein with Fc receptors leads to the generation of 
pro-inflammatory cytokines that enhance the inflammatory response. It is thought to act as 
a surveillance molecule for altered self and certain pathogens. This recognition provides 
early defence and leads to a pro-inflammatory signal and activation of the humoral, 
adaptive immune system (Pepys and Hirschfield, 2003).  
 
Specifically in colorectal cancer, the presence of a systemic inflammatory response, as 
evidenced by elevated circulating concentrations of C-reactive protein, is associated with 
increased recurrence and poor survival, independent of tumour stage, in patients 
undergoing potentially curative surgery for colorectal cancer (McMillan et al., 1995, 
McMillan et al., 2003b). 
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1.7.4.2 Albumin 
Albumin is a major negative acute phase protein. It appears to be primarily mediated in the 
acute phase response by the altered protein and energy metabolism that occurs. In the acute 
phase response there is an increased demand for specific amino acids for mediator and 
acute phase protein synthesis and immune and antioxidant defences. This promotes the 
progressive loss of the available protein components including albumin. As the albumin 
pool size is modest in relation to body cell mass its loss is noticeable at an earlier stage 
(McMillan et al., 2001). 
 
It has long been recognised that there is an association between reduced serum albumin 
and elevated C-reactive protein concentrations with severity of illness and poor outcome.  
 
1.7.4.3 Interleukin-6 
Interleukin-6 is a multifunctional pro-inflammatory cytokine which plays a major role in 
regulating the immune and inflammatory responses via the synthesis of most acute phase 
proteins including C-reactive protein. Elevated interleukin-6 production is seen in 
infectious disease, inflammatory diseases and malignant disease (Gabay and Kushner, 
1999). In patients with colorectal cancer increased concentrations of circulating 
interleukin-6 have been shown to reflect disease status and correlates with cancer stage, C-
reactive protein concentrations, tumour necrosis and survival.  
 
1.7.4.4 White cell count 
Measuring the numbers of inflammatory cells present in the bloodstream represents an 
alternative technique for quantifying the presence of an inflammatory response in patients. 
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Total white cell count, neutrophils, lymphocytes and platelets can all be detected using 
standard laboratory tests.  
 
In an effort to standardise the measurement of the systemic inflammatory response in 
patients with cancer, a number of inflammatory scores have been described whose values 
have been shown to correlate directly with clinical outcomes. The modified Glasgow 
Prognostic Score (mGPS) combines circulating CRP and albumin concentrations 
(McMillan et al., 2007). Alternative inflammatory scores include the neutrophil 
lymphocyte ratio (NLR), which measures the relative values of neutrophil and lymphocyte 
counts (Walsh et al., 2005), and the platelet to lymphocyte ratio (PLR) (Smith et al., 2008). 
 
1.7.4.5 Modified Glasgow prognostic score 
Indeed, the last decade has seen the evolution of a prognostic scoring system, the Glasgow 
prognostic score (mGPS) based on the combination of acute phase proteins albumin and C-
reactive protein that provides objective, reliable prognostic information for both operable 
and inoperable cancers. This scoring system is the most extensively validated systemic 
inflammation based prognostic score. It has been validated in a variety of clinical 
scenarios, in over 60 studies (>30,000 patients) and is now recognised to have prognostic 
value, independent of tumour based factors. 
 
1.7.4.6 Neutrophil-Lymphocyte ratio 
It is also well established that the systemic inflammatory response is associated with 
alterations in circulating white blood cells, specifically the presence of neutrophilia with a 
relative lymphocytopenia (Gabay and Kushner, 1999). One routinely available marker of 
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the systemic inflammatory response is the neutrophil-lymphocyte ratio (NLR), which is 
derived from the absolute neutrophil and absolute lymphocyte counts of a full blood count. 
To date, over 60 studies (>37,000 patients) have examined the clinical utility of the NLR to 
predict patient outcomes in a variety of cancers. Studies have shown that NLR is elevated 
in patients with advanced or aggressive disease evidenced by increased tumour stage, 
nodal stage, number of metastatic lesions and as such these patients may represent a 
particularly high risk population. Furthermore, NLR may be of prognostic value in those 
patients who require adjuvant therapy. 
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1.8 The postoperative systemic inflammatory response  
Operative injury to the body from all procedures causes a stereotypical cascade of 
neuroendocrine, cytokine, myeloid and acute phase responses. Surgery, both elective and 
emergency, produces local trauma and results in a response with pro- and anti-
inflammatory components. This response may be of an appropriate magnitude, and 
appropriately down-regulated. An explanation of how these processes work together and, 
paradoxically, how they can cause a systemic inflammatory response leading to 
immunological dissonance was first described by Bone in five stages, as summarised 
below (Bone, 1996) (Figure 1).  
 
1.8.1 Local response to surgery 
An insult such as trauma from a surgical incision prompts release of pro-inflammatory 
mediators in the microenvironment. These mediators limit new damage and ameliorate 
whatever damage has already occurred. They destroy damaged tissue, promote new tissue 
growth, and combat pathogenic organisms, neoplastic cells and foreign antigens. To ensure 
that the effects of pro-inflammatory mediators do not become destructive, an anti-
inflammatory response ensues. Anti-inflammatory agents are known to alter monocyte 
function, impair antigen-presenting activity, and reduce the ability of cells to produce pro-
inflammatory cytokines. Some of them have been shown to downregulate their own 
production. 
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1.8.2 Initial systemic response 
If the original insult is sufficiently severe, pro-inflammatory, and, later, anti-inflammatory 
mediators appear in the systemic circulation. At this stage, the presence of these mediators 
in the circulation is seen as part of the normal response to injury. These agents signal that 
the microenvironment cannot control the initiating insult and that more help is needed. Pro-
inflammatory mediators recruit neutrophils, lymphocytes, platelets, and coagulation factors 
to the local site. There is a compensatory systemic anti-inflammatory response to 
downregulate the pro-inflammatory reaction and, if all goes well, few (if any) clinical signs 
and symptoms are produced. 
1.8.3 Pro-inflammatory state 
In some patients, regulation of the inflammatory response is lost resulting in a massive 
systemic reaction. Activation of the sympathetic nervous system results in a 
neuroendocrine response of increased secretion of catecholamines (adrenaline and 
noradrenaline) into the circulation. In most cases, this reaction is initially pro-inflammatory 
and produces clinical findings such as hypotension, pyrexia and tachycardia, known as the 
systemic inflammatory response syndrome. At the same time there is also increased 
secretion of pituitary hormones such as corticotrophin, growth hormone, and arginine 
vasopressin. Corticotrophin acts on the adrenal cortex to stimulate cortisol secretion. There 
is often a subsequent increase in the production of pro-inflammatory cytokines such as 
tumour necrosis factor alpha (TNF-α) and interleukins, in particular interleukin 6 (IL-6). 
These cytokines are produced by many cells throughout the body in response to injury and 
form a complex signalling system for subsequent production of  acute phase proteins from 
the liver and increased stimulation of myeloid tissue (Gabay and Kushner, 1999). There are 
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increases in circulating white cells, particularly neutrophils, as well as myeloid derived 
suppressor cells and platelets. Plasma concentrations of actue phase proteins change, in 
particular C-reactive protein, which peaks at 48-72 hours following injury. The net effect 
of the evolution of the systemic inflammatory response is increased catabolism of skeletal 
muscle to provide energy and substrates for the liver, to maintain fluid and cardiovascular 
homeostasis and for healing. Therefore, although this response to injury has been referred 
to as the operative stress or acute phase response, it is more informatively known as the 
systemic inflammatory response because of its effects on all organs and tissues of the body 
(Gabay and Kushner, 1999). Various pathophysiologic changes underlie these effects, the 
net result of which can be severe shock. Unless homeostasis is restored, organ dysfunction 
and, ultimately, failure can develop. 
1.8.3.1 Systemic inflammatory response syndrome criteria 
≥ 2 of the following: 
• Temperature >38◦C or <36◦C 
• Heart rate >90 beats per minute 
• Respiratory rate >20 breaths per minute or PaCO2 <32 mmHg 
• White cell count >12 or <4 (x109/L) 
1.8.4 Over production of anti-inflammatory mediators 
In those patients with persistent or overwhelming inflammation who survive, anti-
inflammatory mechanisms may be able to control inflammation. Once healing is 
established, anti-inflammatory components of the systemic inflammatory response become 
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prominent, causing it to return to the normal non-inflammatory state. In some patients, 
however, the compensatory reaction may be as excessive as the pro-inflammatory 
response, and immunosuppression ensues. Patients without an overwhelming pro-
inflammatory response may also develop immunosuppression if release of anti-
inflammatory mediators is excessive or if the balance between pro- and anti-inflammatory 
mediators is lost. This may lead to increased susceptibility to infection.  
1.8.5 Immunologic dissonance 
At this stage the balance of pro- and anti-inflammatory mediators has been lost. Some 
patients may have persistent, massive inflammation, others may have continuing 
immunosuppression and secondary infections. Furthermore, some may oscillate between 
periods of inflammation and immunosuppression. The pro-inflammatory and anti-
inflammatory forces may ultimately reinforce each other, creating a state of increasingly 
destructive immunological dissonance (Bone, 1996). It has been suggested that 
inflammatory reactions may result in anti-tumour activity. Alternatively, an inflammatory / 
immunocompromised state may promote and maintain tumour growth (Colotta et al., 
2009). Surgery for the treatment of cancer in this context may be seen as a double-edged 
sword.  
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Figure 1-1 - Stages of the inflammatory response, leading to immunological 
dissonance (adapted from Bone, 1996)  
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1.9 The role of the systemic inflammatory response in 
predicting infective complications following colorectal 
cancer resection 
In patients with colorectal cancer, the presence of both systemic and/ or local inflammatory 
responses are predictors of survival independent of tumour stage (Roxburgh and McMillan, 
2010, Richards et al., 2010, Roxburgh et al., 2011, Hanahan and Weinberg, 2011, Colotta 
et al., 2009, Roxburgh et al., 2009b).  The relationship between a raised perioperative 
systemic inflammatory response and the development of postoperative infective 
complications is also well established (MacKay et al., 2011, Dutta et al., 2011).  
Furthermore, it has become clear that the development of infective complications, in 
particular anastomotic leak, is also associated with increased recurrence and poorer cancer 
specific survival (McArdle et al., 2005, Jung et al., 2008, Marra et al., 2009).  Therefore, 
infective complications can be catastrophic for the patient, in both short and long term 
outcomes. 
 
Resection for colorectal cancer is associated with relatively high rates of postoperative 
infective complications. Of these cancer patients, 20-40% (Velasco et al., 1996) are at risk 
of complications such as; respiratory, wound, or urinary tract infection, anastomotic 
leakage, intra-abdominal abscess and septicaemia of unknown origin. During the early 
postoperative period, sepsis can be difficult to distinguish from the normal postoperative 
systemic inflammatory response related to surgical trauma. Recognition during this period 
is challenging and lacks sensitivity at a stage when early diagnosis may significantly 
improve outcome (Welsch et al., 2007). 
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C-reactive protein is an acute phase protein found in the blood in response to 
inflammation. It is thought to play an important role in innate immunity as an early defence 
against infection, assisting complement binding to foreign and damaged cells and 
enhancing phagocytosis by macrophages (Gabay and Kushner, 1999). Its short half-life of 
19 hours makes it a valuable marker to detect disease activity, inflammatory response and 
post-operative recovery (Pepys and Hirschfield, 2003). 
 
A number of studies have investigated the association of the systemic inflammatory 
response with postoperative complications, with previous studies suggesting that an 
abnormally elevated C-reactive protein level or persistent elevation may be a useful 
predictor of infective complications (Welsch et al., 2007, Bianchi et al., 2004, Matthiessen 
et al., 2008, Welsch et al., 2008). 
 
One Glasgow based study has investigated the sensitivity and specificity of C-reactive 
protein as an early marker for postoperative infective complications in patients undergoing 
elective colorectal resection for cancer. Looking at data from 150 patients, this study 
concluded that a C-reactive protein concentration greater than 145mg/l on postoperative 
day 4 has a high specificity and sensitivity for infective complications following elective 
colorectal resection, and could therefore be used to aid clinical decision making (MacKay 
et al., 2011). Multiple similar studies have been carried out internationally, dating as far 
back as 1979. 
 
A further prospective study of elective colorectal cancer resection patients in France 
concluded that C-reactive protein was a good early predictor of infective complications, 
with a concentration >125mg/l on day 4 detecting 80% of infective complications. They 
also suggest that patients with values >125mg/l on the fourth postoperative day should not 
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be discharged (Ortega-Deballon et al., 2010). This pre-clinical warning is of particular 
importance in an era of enhanced recovery and early discharge. 
 
A study of 231 patients in a university teaching hospital in Norway also confirmed that 
increased C-reactive protein concentrations on day 3 strongly indicate a high risk of 
developing an anastomotic leak after colorectal resection (Korner et al., 2009). This 
supported previous findings that a raised C-reactive protein is an early indicator of 
anastomotic leakage in colorectal surgery (Matthiessen et al., 2008, Woeste et al., 2010). 
Their results also agreed with others that white cell count had low sensitivity and 
specificity at an early stage. 
 
In Germany, a study of 688 consecutive pancreatic resection patients concluded that 
persistence of C-reactive protein elevation above 140mg/l  on postoperative day 4 is 
predictive of inflammatory postoperative complications and should prompt an intense 
clinical search for major septic processes (Welsch et al., 2008). They also demonstrated 
that a rise in white cell count and temperature develop several days later, along with 
clinical symptoms. 
 
Another Glasgow based study, looking at oesophagogastric cancer resections, also 
concluded that postoperative C-reactive protein measurements on days 3 and 4 were 
predictive of infective complications, particularly anastomotic leaks (Dutta et al., 2011). 
Again this was more useful than white cell count.  
 
If it is possible to predict an infective complication at a pre-clinical stage, it may also be 
possible to intervene pre-emptively (Rivers et al., 2001, Chromik et al., 2006). C-reactive 
protein could be used to identify a group at high risk of infective complications, or as a 
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discharge criteria. It is possible that by administering pre-emptive antibiotics directed by 
C-reactive protein thresholds that potential postoperative morbidity could be attenuated or 
even avoided (MacKay et al., 2011). 
 
An appropriately sized, prospective, multi-centre trial is indicated to establish whether 
early prediction of infective complications can be treated empirically to improve the short 
term morbidity and mortality for patients undergoing potentially curative colorectal cancer 
resection.  
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2 Summary and Aims 
Colorectal cancer remains the second most common cause of cancer death in western 
Europe (CRUK, 2014). Despite advances in surgical techniques, perioperative care and 
adjuvant chemoradiotherapy, overall survival remains poor with only 50% of patients 
surviving to 5 years after potentially curative resection (McArdle and Hole, 2002). It is 
now recognised that postoperative complications contribute to poor cancer specific 
survival (Rizk et al., 2004, Khuri et al., 2005, McArdle et al., 2005, Law et al., 2007). In 
particular, anastomotic leak following potentially curative colorectal cancer resection is 
associated with poorer cancer specific survival, independent of tumour stage (Law et al., 
2007, McArdle et al., 2005). The basis of this observation is not clear. One hypothesis is 
that the presence of a raised postoperative systemic inflammatory response may be 
responsible (McArdle et al., 2005), as the postoperative systemic inflammatory response 
has been reported to be associated with increased postoperative complications, including 
anastomotic leak. 
 
Furthermore, preoperative systemic inflammation, as evidenced by the mGPS, has been 
shown to predict postoperative infective complications (Moyes et al., 2009).  Moreover, C-
reactive protein concentrations postoperatively predict the development of infective 
complications and anastomotic leak (Welsch et al., 2007, Matthiessen et al., 2008). It has 
been suggested that early postoperative infective complications might lead to a rise in C-
reactive protein prior to the development of clinical symptoms, and that this infection leads 
to decreased long term survival. However it has been reported that preoperative, but not 
postoperative, elevated C-reactive protein concentrations are associated with cancer 
specific survival (Crozier et al., 2007).  
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Resection for colorectal cancer is associated with high rates of postoperative infective 
complications. Of these cancer patients, 20-40% (Velasco et al., 1996) are at risk of 
complications such as; respiratory, wound, or urinary tract infection, anastomotic leakage, 
intra-abdominal abscess and septicaemia of unknown origin. During the early 
postoperative period, sepsis can be difficult to distinguish from the normal postoperative 
systemic inflammatory response related to surgical trauma. Recognition during this period 
is challenging and lacks sensitivity at a stage when early diagnosis may significantly 
improve outcome (Welsch et al., 2007). 
 
It is increasingly appreciated that the “immunological hit” caused by surgery may 
compromise the antitumour immune defences of the host. Furthermore, this “hit” can be 
compounded by various perioperative factors  and the development of postoperative 
infective complications further augments the recurrence risk (Richards et al., 2011). It is 
considered that these conditions result in a further immunological insult and lead to a 
compromised immune response to residual disease as well as prolonged recovery. It is 
apparent that a range of patient related factors influence disease outcome in the 
perioperative period, such as age, emergency presentation, comorbidity and postoperative 
complications. Therefore, the perioperative period represents an opportunity for clinicians 
to intervene early, acting to suppress high-grade non-specific systemic inflammation and 
maintaining effective immunological competence of the host.  
 
However, whether a raised postoperative systemic inflammatory response is the result of 
an early underlying infection, or whether a raised inflammatory response leads to increased 
susceptibility to subsequent infection is not clear. If the former is the case, it is possible 
that intervention targeting at risk patients may reduce infective complications, or the extent 
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of them, and therefore improve patient outcomes. If the later is the case, perioperative 
intervention to reduce the postoperative inflammatory response may in turn reduce 
postoperative complications and hence improve outcomes, both short and long term, for 
patients undergoing surgery for colorectal cancer. 
 
The present thesis aims to further examine the nature of the postoperative systemic 
inflammatory response and its relationship with infective complications following 
potentially curative resection for colorectal cancer, specifically: 
1. To determine whether the perioperative systemic inflammatory response is the 
result of an impaired anti-inflammatory response by assessing adrenocortical 
function. 
2. To examine the diagnostic accuracy of serial postoperative white cell count, 
albumin and C-reactive protein in detecting infective complications. 
3. To compare the value of daily C-reactive protein concentrations in the prediction of 
infective complications following open versus laparoscopic colorectal cancer 
resection. 
4. To examine the impact of an enhanced recovery programme on the systemic 
inflammatory response and rate of infective complications postoperatively. 
5. To assess the impact of the peak systemic inflammatory response, as evidenced by 
postoperative day 2 C-reactive protein, on C-reactive protein thresholds predictive 
of infective complications. 
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6. To examine the determinants of the peak systemic inflammatory response in 
patients following resection for colorectal cancer. 
7. To examine the relationships between postoperative predictive C-reactive protein 
thresholds and infective complications in the context of pre-emptive antibiotic 
therapy.  
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3 Is perioperative systemic inflammation the result of 
insufficient cortisol production in patients with 
colorectal cancer? 
3.1 Introduction 
Colorectal cancer is the second most common cause of cancer death in the UK, accounting 
for 16,000 deaths annually (CRUK, 2014).  Even with modern treatments, of those deemed 
suitable candidates for curative resections approximately 50% suffer disease recurrence 
and die at 5 years. 
 
It is increasingly recognised that disease progression and cancer specific survival in 
colorectal cancer patients is not solely determined by the intrinsic characteristics of the 
tumour but also by host characteristics and responses to the tumour.  In terms of the host, 
age, comorbidity and the presence of both systemic and/ or local inflammatory responses 
are stage independent predictors of survival (Roxburgh and McMillan, 2010, Richards et 
al., 2010, Roxburgh et al., 2009b, Roxburgh and McMillan, 2012, Colotta et al., 2009, 
Hanahan and Weinberg, 2011).  The presence of a systemic inflammatory response in 
particular has been consistently demonstrated to predict poorer survival independent of 
stage in all gastrointestinal cancers with most published reports in colorectal cancer 
(Roxburgh and McMillan, 2010, Roxburgh et al., 2009b).  Furthermore, following 
apparently curative resection, persistent postoperative evidence of systemic inflammation 
has previously been associated with earlier recurrence and reduced survival (McMillan et 
al., 1995, Moyes et al., 2009).  It may be that the systemic inflammatory response is 
initially a defence mechanism, which, when exacerbated beyond a certain point, becomes 
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harmful. Such observations have given rise to development of prognostic scores for 
systemic inflammation in cancer patients, namely the Glasgow Prognostic Score, based on 
C-reactive protein (CRP) and albumin and the neutrophil lymphocyte ratio, both of which 
are widely validated in different cohorts of colorectal cancer as well as other cancer types 
(Roxburgh et al., 2009a, Roxburgh and McMillan, 2010, Walsh et al., 2005).  
 
The information provided by such prognostic scores provides clinicians with information 
to more accurately determine speed of disease progression and survival.  However, it 
remains to be seen whether such information may also guide allocation of further 
treatment.  One possibility is that therapies could be developed that reduce cancer-
associated systemic inflammation, in particular, in the perioperative period.  In order to 
take this next step, further work is required to determine the underlying stimulus or basis of 
the systemic inflammatory response.   
 
One possibility is that the presence of a systemic inflammatory response represents failure 
of innate anti-inflammatory mechanisms.  The glucocorticoids are an important group of 
endogenous anti-inflammatory agents.  These hormones have many effects including down 
regulation of pro-inflammatory cytokines and promotion of anti-inflammatory cytokines 
produced by monocytes and macrophages, in addition to the induction of apoptosis of cells 
recruited by inflammatory responses (Tuckermann et al., 2005).  Their release from the 
adrenal cortex is stimulated by adrenocorticotrophic hormone (ACTH) from the anterior 
pituitary gland, which is in turn regulated by corticotrophin releasing hormone from the 
hypothalamus forming the Hypothalamic-Pituitary-Adrenal (HPA) axis (Tuckermann et 
al., 2005) (Figure 3).  It is well recognised that the HPA axis plays an important role in 
moderating the systemic inflammatory response to tissue injury and hypoxia (Gabay and 
Kushner, 1999).   
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Previous work in cancer patients has suggested that poorer outcomes can be expected when 
there is a failure of normal HPA axis function.  Flattening of the diurnal rhythm of cortisol 
release was reported to be associated with advanced stage of disease and elevation of pro-
inflammatory cytokines (Rich et al., 2005, Mussi et al., 2006).  Indeed, the systemic 
inflammatory response in cancer has been previously reported to be associated with normal 
or slightly raised serum cortisol levels (Scott et al., 1996).  Of interest, previous work by 
Jenkins et al reported a significant increase in size of adrenal glands in patients with cancer 
(Jenkins et al., 1999) a feature associated with low ACTH levels and resistance to 
dexamethasone suppression.  Normal / raised serum cortisol with low ACTH levels implies 
a secondary over-riding stimulus to cortisol production.  Indeed, it would appear that pro-
inflammatory cytokines such as IL-2, IL-6 and IL-1 can exert stimulatory effects on the 
adrenal cortex production of glucocorticoids (Roh et al., 1987, Salas et al., 1990, Tominaga 
et al., 1991).  Subversion of innate anti-inflammatory feedback mechanisms may occur as a 
result of desensitization of receptors due to high cytokine/ chemokine levels (Coussens and 
Werb, 2002). One hypothesis, therefore, is that the presence of a systemic inflammatory 
response is representative of a state in which endogenous anti-inflammatory feedback 
mechanisms are lost resulting in pro-inflammatory cytokine mediated cortisol release from 
the adrenal cortex.  In such a state inflammation could persist unchecked.  Diurnal cortisol 
rhythmicity would be lost and cortisol response to synthetic ACTH (synacthen) may be 
lost.  
 
The aim of the present prospective study was to examine whether patients undergoing 
potentially curative surgery for colorectal cancer exhibit evidence of impairment of 
endogenous cortisol release and feedback mechanisms (measured using the short synacthen 
test and diurnal salivary cortisols).  Furthermore, whether an impaired cortisol response 
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was associated with the presence of a perioperative systemic inflammatory response was 
examined.    
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3.2 Patients and Methods 
Patients with a histologically proven diagnosis of colorectal cancer who, on the basis of 
pre-operative staging, underwent elective resection with curative intent between February 
2008 and December 2011 in a single surgical unit at Glasgow Royal Infirmary were 
prospectively included in the study.  The assessment of adrenocortical function using 
synthetic ACTH, a short synacthen test, was carried out as part of the pre-operative 
assessment of patients. Short synacthen tests were performed on the morning of surgery, at 
approximately 06:00am. 
 
Patients were excluded if they had inoperable or metastatic disease where a curative 
operation was not possible, neo-adjuvant treatment, emergency presentation, concurrent 
steroid use and conditions associated with impaired HPA axis function (e.g. Addison's 
Disease, Cushing's Disease, pituitary tumours), or significant chronic inflammatory 
diseases requiring long term medication (e.g. rheumatoid arthritis, inflammatory bowel 
disease, connective tissue disease), or if they were using oral contraceptives or hormone 
replacement therapy (as oestrogen induces cortisol binding globulin and leads to elevation 
in measured serum cortisol).  Consecutive patients admitted for potentially curative 
colorectal cancer resection were approached and given written information prior to the day 
of surgery. Eighty patients agreed to participate within the time period, no formal power 
calculation was undertaken. Written informed consent was obtained from all patients.  The 
study was approved by the Research Ethics Committee, Glasgow Royal Infirmary. 
 
Patient co-morbidity was classified using the American Society of Anaesthesiologists 
(ASA) grading system, where ‘1’ represents a normal healthy patient, ‘2’ a patient with 
mild systemic disease, ‘3’ a patient with severe systemic disease and ‘4’ a patient with 
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severe systemic disease that is a constant threat to life.  This assessment was carried out by 
the anaesthetist preoperatively. 
 
The tumours were staged according to conventional tumour, node, metastases (TNM) 
classification.  Assessment of tumour necrosis, a stage-independent prognostic marker in 
colorectal cancer, was undertaken using methodology previously described.  The sections 
were examined at magnification x40 for evidence of tumour necrosis.  The extent of 
tumour necrosis was assessed semi-quantitatively and graded as ‘absent’ (none), ‘focal’ 
(less than 10% of tumour area), ‘moderate’ (10-30% of tumour area), or ‘extensive’ (>30% 
of tumour area) in each section before an assessment was made of the overall extent of 
necrosis (Richards et al., 2012, Pollheimer et al., 2010).  
 
The inflammatory reaction at the invasive margin, another prognostic indicator in 
colorectal cancer, was analysed using the Klintrup-Makinen criteria as previously 
described (Klintrup et al., 2005).  Briefly, tumours were scored according to a 4-point 
score.  Scores were allocated based on appearances at the deepest area of tumour invasion.  
A score of ‘0’ was given where there was no increase in inflammatory cells at the deepest 
point of the invasive margin; ‘1’ denoting a mild and patchy increase in inflammatory cell; 
‘2’ denoting a prominent inflammatory reaction forming a band at the invasive margin 
with some evidence of destruction of cancer cell islands; and ‘3’ denoting a florid cup-like 
inflammatory infiltrate at the invasive edge with frequent destruction of cancer cell islands.  
 
 To test consistency of scoring, sections for 30 patients were examined independently by 2 
observers (MLR and GG, intra-class correlation coefficient [ICC] 0.59 for tumour necrosis 
and ICC 0.57 for Klintrup-Makinen criteria, demonstrating moderate agreement of a 
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subjective score).  One observer (MLR) then scored all sections and this data was used in 
the analysis. 
 
Preoperative systemic inflammatory response was assessed using the modified Glasgow 
Prognostic Score (mGPS) and the neutrophil lymphocyte ratio (NLR).  Briefly, to 
determine mGPS patients with both an elevated C-reactive protein (>10mg/l) and 
hypoalbuminaemia (<35g/l) were allocated a score of ‘2’.  Patients in whom neither of 
these abnormalities was present were allocated a score of ‘0’.  Patients with an elevated C-
reactive protein alone were scored as ‘1’ while those with hypoalbuminaemia alone were 
scored as ‘0’.  The NLR was calculated from the differential white cell count by dividing 
the neutrophil count by the lymphocyte count (Table 3.1).  All measurements of C-reactive 
protein (CRP), albumin and differential white cell count were taken on admission, prior to 
surgery.  The perioperative systemic inflammatory response was assessed using pre and 
postoperative CRP concentrations, either until the patient was discharged or up to day 7. 
 
The use of the short Synacthen test in the diagnosis of cortisol insufficiency has been 
validated and widely used (Grinspoon and Biller, 1994, Dickstein and Shechner, 1997).  
Fasting blood samples were taken for baseline cortisol, then a 250mcg dose of synacthen 
(tetracosactide acetate Ph. Eur., Alliance Pharmaceuticals), an analogue of corticotropin 
(ACTH), was administered intravenously.  After 30 minutes a further blood sample was 
taken to measure post-synacthen peak cortisol levels.  Biochemical criteria defining a 
“normal” serum cortisol or an adequate cortisol response to ACTH have been variously 
proposed.  In the recent National UK audit of the short synacthen test 69% of laboratories 
stated that a baseline cortisol of more than 200 nmol/L would be considered a “normal” 
response; 73% of laboratories consider a peak cortisol of at least 450 nmol/L a “normal” 
response and 89% of laboratories consider an incremental increase of 200 nmol/L a 
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“normal” response to a short Synacthen test (Chatha et al., 2010).  Cut-off values for 
cortisol insufficiency were recommended by our hospital expert (Dr Dinesh Talwar, 
Biochemistry Consultant) in keeping with the National UK audit and local laboratory 
policy (baseline cortisol <200 nmol/L, peak cortisol <450 nmol/L, and a change in cortisol 
<200 nmol/L). As a surrogate measure of plasma free cortisol, patients were also asked for 
salivary samples, only 30 patients returned these as many forgot to bring an evening 
sample from the night before. 
 
Statistics 
Grouping of variables was carried out using standard or previously published thresholds. 
Associations between categorical and continuous variables were examined using X2 tests 
for linear trend and non-parametric tests.  A p-value <0.05 was considered statistically 
significant.  Statistical analyses were performed using SPSS version 19.0 (IBM SPSS, 
Chicago, IL, USA).   
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3.3 Results 
The clinicopathological characteristics of patients undergoing potentially curative resection 
for colorectal cancer are shown in Table 2.  A total of 80 patients underwent short 
Synacthen testing.  All patients had macroscopically curative resections.  Eleven patients 
also underwent synchronous resection of liver metastases.  The majority of patients were 
under 75 years old (79%), were male (59%), had an ASA of 1 or 2 (60%), had colon 
cancer (75%) and had TNM stage I/II disease (54%) (Table 3.2). Approximately 40% had 
an elevated mGPS or NLR. 
 
In terms of adrenal insufficiency, there were no patients in whom this was clearly 
diagnosed on discussion with our hospital expert (Dr Dinesh Talwar, Biochemistry 
Consultant). 11 patients had a baseline serum cortisol of <200 nmol/L. There is no clearly 
established upper limit for a baseline cortisol, but 3 patients had a seemingly high result of 
>650 nmol/L (675, 701 and 850 nmol/L). At 30 minutes, a different 3 patients had a peak 
cortisol <450 nmol/L (398, 411 and 433 nmol/L) and an absolute change <200 nmol/L (69, 
29 and 191 nmol/L), but these all had a baseline >200 nmol/L. There were 24 patients with 
an absolute change in cortisol <200 nmol/L, however all but 3 (as above) of these had a 
baseline >200 nmol/L and a peak >450 nmol/L. 
 
The relationship between patient and tumour related factors and standard thresholds 
(Chatha et al., 2010) for cortisol (a baseline cortisol <200 nmol/L, a change in cortisol 
<200 nmol/L and a 30 minute cortisol <450 nmol/L) are shown in Table 3.3.  There were 
no significant associations between these thresholds and patient related factors such as age 
(all p>0.10), sex (all p>0.10), ASA grade (all p>0.10), white cell count (all p>0.10), CRP 
(all p>0.10), albumin (all p>0.10), mGPS (all p>0.05), or NLR (all p>0.10).  There were 
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no significant associations between these thresholds and tumour related factors such as 
TNM stage (all p>0.10), venous invasion (all p>0.10), tumour site (all p>0.10), Klintrup-
Makinen criteria (all p>0.10), or tumour necrosis (all p>0.10, Table 3.3).  The relationship 
between the perioperative systemic inflammatory response, as demonstrated by CRP 
concentrations, and cortisol is also shown in Table 3.3.  There were no significant 
associations between the above thresholds and the CRP concentrations pre and 
postoperatively on days 1 to 7 (all p>0.05). 
 
The relationship between patient and tumour related factors and salivary free cortisol was 
examined in 30 patients.  In terms of patient related factors, there were no significant 
associations between the late night, morning, or change in salivary cortisol and age (all 
p>0.10), sex (all p>0.05), ASA grade (all p>0.10), white cell count (all p>0.10), CRP (all 
p>0.10), albumin (all p>0.10), mGPS (all p>0.10), or NLR (all p>0.05).  In terms of 
tumour related factors, there were no significant associations between the late night, 
morning, or change in salivary cortisol and TNM stage (all p>0.05), venous invasion (all 
p>0.10), tumour site (all p>0.10), Klintrup-Makinen criteria (all p>0.05), or tumour 
necrosis (all p>0.10, Table 3.4).  Only 57 patients (approximately 70%) had pathology 
slides available for review and the assessment of the tumour inflammatory cell infiltrate 
and tumour necrosis. This may have influenced the results obtained. 
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3.4 Discussion 
The results of the present study demonstrate, for the first time, that impaired cortisol 
production, as evidenced by the short Synacthen test, was uncommon in patients with 
potentially curable colorectal cancer.  Moreover, they indicate that neither tumour related 
factors or the presence of a systemic inflammatory response in the perioperative period 
were associated with impaired cortisol production in these patients. 
 
In the present study, it was of interest that in the group of 11 patients with liver metastases 
there was an elevated baseline plasma cortisol.  This may suggest that there was 
disregulated cortisol production in these patients, however no other measures of cortisol 
response to Synacthen were different.  Therefore, it would appear that there was not 
consistent evidence of impaired cortisol production in patients with operable colorectal 
cancer.  
 
The presence of a systemic inflammatory response in patients with colorectal cancer has 
been shown to be common and associated with poorer clinical outcome in both localized 
and advanced disease (McMillan et al., 1995, Nozoe et al., 1998, Nielsen et al., 2000, 
Moyes et al., 2009), independent of tumour stage (McMillan et al., 1995, Moyes et al., 
2009, Roxburgh and McMillan, 2010).  Indeed, the presence of a systemic inflammatory 
response is thought to be beneficial to the tumour in creating an environment where tumour 
growth and spread are promoted (Coussens and Werb, 2002).  It has also been suggested 
that the tumour itself may act in suppressing the immune response, by driving the 
recruitment of regulatory T cells, as a strategy of immunoevasion (Sellitto et al., 2011). At 
present, the underlying stimulus of the systemic inflammatory response in cancer patients 
remains to be elucidated.  Systemic inflammation persists in cancer patients following 
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apparently curative resection (Galizia et al., 2002, Moyes et al., 2009, Ramsey et al., 
2006).  Thus, the basis or stimulus for the ongoing systemic inflammatory response 
appears to be independent of the tumour and more likely due to host responses.  Pre-
existing immune or physiological abnormalities may even pre-date development of 
malignancy, possibly an immune dissonance leading to impaired cytokine responses.   
 
Indeed, it is of interest that results from prospective nested case controlled studies report 
pre-diagnostic raised levels of C-reactive protein are associated with the subsequent 
development of colorectal cancer (Erlinger et al., 2004, Otani et al., 2006, Gunter et al., 
2006), and that chronic administration of aspirin and other non-steroidal anti-inflammatory 
drugs confers a protection against subsequent development of colorectal cancer. Clearly, if 
the basis of this response could be identified it would aid attempts to moderate the 
systemic inflammatory response and tumour progression in primary operable colorectal 
cancer. 
 
Furthermore, it has been suggested that preoperative administration of corticosteroids is 
associated with a decrease in postoperative morbidity in patients undergoing surgery for 
oesophageal cancer (Sato et al., 2002), and may attenuate the inflammatory response to 
surgery following oesophageal (Sato et al., 2002) and liver (Schmidt et al., 2007) resection.  
However, there remains a lack of consensus on the utility of perioperative steroids in 
alleviating surgical stress and further study is required. 
 
In summary, the presence of a systemic inflammatory response would appear not to be due 
the lack of an anti-inflammatory response in patients with colorectal cancer.  In contrast to 
impaired cortisol production, elevated pro-inflammatory cytokine release has been 
consistently reported (Kantola et al., 2012).  The present results therefore suggest that the 
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systemic inflammatory response is mainly a result of a pro-inflammatory stimulus rather 
than an impaired anti-inflammatory response.  Further work examining the nature of such 
pro-inflammatory cytokine release is warranted.  
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Figure 3-1 - The HPA axis and negative feedback  
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Table 3-1 Calculation of the modified Glasgow Prognostic Score (mGPS) and the 
Neutrophil to Lymphocyte ratio (NLR) 
 
The modified Glasgow Prognostic Score Score 
C-reactive protein ≤10 mg/l and albumin ≥35 g/l 0 
C-reactive protein ≤10 mg/l and albumin <35 g/l 0 
C-reactive protein > 10 mg/l 1 
C-reactive protein >10 mg/l and albumin <35 g/l 2 
  
Neutrophil Lymphocyte Ratio  
Neutrophil count : lymphocyte count <5:1 0 
Neutrophil count : lymphocyte count ≥5:1 1 
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Table 3-2 The clinicopathological characteristics of patients undergoing potentially 
curative resection for colorectal cancer (n=80) 
 
Variable Patients (n=80) 
Age <65 / 65-74 / ≥75 years 34 / 29 / 17 
Sex - Male / Female 47 / 33 
ASA (1+2 / 3+4) a 48 / 30 
White Cell Count ≤11 / >11 (x109/L) 75 / 5 
C-reactive protein <10 / ≥10 (mg/L) 55 / 25 
Albumin  ≥35 / <35 (g/L) 23 / 57 
mGPS 0 / 1 / 2 55 / 14 / 11 
NLR <5 / ≥5 67 / 13 
T stage (I / II / III) 17 / 46 / 17 
TNM stage (I / II / III / IV) 16 / 27 / 26 / 11 
Venous Invasion b (No / Yes) 37 / 40 
Tumour Site - Colon / Rectum 60 / 20 
Klintrup c (0-1 / 2- 3) 18 / 39 
Tumour Necrosis c (absent - focal / moderate - extensive) 39 / 18 
 
an=78, bn=77, cn=57 
 
Table 3-3 Relationship between patient and tumour related variables and standard thresholds for baseline, 30 minute and change in cortisol 
(n=80) 
Patient Related Variable  
(number of patients)  
Baseline Cortisol (nmol/L)  p 
value 
Peak Cortisol (nmol/L) p 
value 
Change in Cortisol (nmol/L) p value 
  >200 <200  >450 <450  >200 <200  
Age (years) <65 27 7  33 1  22 12  
65 – 74 26 3  29 0  22 7  
≥ 75 16 1 0.125 15 2 0.213 12 5 0.549 
Sex Female 39 8  32 1  31 16  
Male 30 3 0.314 45 2 0.778 25 8 0.349 
ASA a 1 + 2 39 9  47 1  33 15  
 3 + 4 28 2 0.136 29 1 0.734 22 8 0.666 
White Cell Count (x109/L) ≤ 11 65 10  72 3  51 24  
> 11  4 1 0.677 5 0 0.651 5 0 0.133 
C-reactive Protein (mg/L) <10 45 10  54 1  39 16  
 ≥10 24 1 0.090 23 2 0.180 17 8 0.794 
Albumin (g/L) ≥35 47 10  55 2  40 17  
 <35 22 1 0.123 22 1 0.859 16 7 0.957 
Modified Glasgow Prognostic 
Score (mGPS)  
0  45 10  54 1  39 16  
1 13 1  13 1  10 4  
2 11 0 0.078 10 1 0.182 7 4 0.687 
Neutrophil:Lymphocyte Ratio 
(NLR) 
<5 
≥5 
56 
13 
11 
0 
 
0.118 
64 
13 
3 
0 
 
0.440 
45 
11 
22 
2 
 
0.212 
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Tumour Related Variable  
(number of patients)  
Baseline Cortisol (nmol/L) p 
value 
Peak Cortisol (nmol/L) p 
value 
Change in Cortisol (nmol/L) p value 
  >200 <200  >450 <450  >200 <200  
T stage I 14 3  15 2  12 5  
II 41 5  46 0  31 15  
III 14 3 0.685 16 1 0.081 13 4 0.782 
TNM stage I 14 2  14 2  11 5  
II 23 4  26 1  21 6  
III 22 4  26 0  19 7  
IV 10 1 0.959 11 0 0.184 5 6 0.255 
Venous Invasion b No 33 4  35 2  25 12  
 Yes 33 7 0.405 39 1 0.513 29 11 0.639 
Tumour Site Colon 52 8  57 3  40 20  
Rectum 17 3 0.852 20 0 0.311 16 4 0.263 
Klintrup c  0-1 32 7  37 2  31 8  
 2-3 16 2 0.514 18 0 0.332 11 7 0.147 
Tumour Necrosis c Absent – 
Focal 
32 7  37 2  28 11  
 Moderate – 
Extensive 
16 2 0.510 18 0 0.328 14 4 0.633 
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Perioperative Inflammatory Response 
(median, range) mg/L 
Baseline Cortisol (nmol/L) p 
value 
Peak Cortisol (nmol/L) p 
value 
Change in Cortisol (nmol/L) p value 
>200 <200 >450 <450 >200 <200 
Preoperative C-reactive Protein 7 (1-86) 3 (1-17) 0.077 6 (1-86) 18 (2-56) 0.403 6 (1-86) 7 (1-59) 0.781 
Day 1 C-reactive Protein 111 (1-247) 94 (70-198) 0.531 111 (1-247) 86 (43-128) 0.607 117 (1-247) 79 (43-140) 0.022 
Day 2 C-reactive Protein  167 (60-373) 200 (36-295) 0.858 169 (36-373) 177 (135-219) 0.932 180 (36-373) 158 (75-305) 0.322 
Day 3 C-reactive Protein  164 (49-357) 164 (66-224) 0.674 164 (49-357) 177 (127-226) 0.850 166 (49-357) 161 (62-304) 0.956 
Day 4 C-reactive Protein  137 (30-330) 122 (49-253) 0.803 135 (30-330) 182 (76-288) 0.778 127 (37-330) 147 (30-291) 0.343 
Day 5 C-reactive Protein a 118 (17-333) 89 (28-216) 0.464 117 (17-333) 86 (48-298) 0.974 116 (17-333) 115 (48-298) 0.412 
Day 6 C-reactive Protein b 93 (8-352) 69 (17-131) 0.457 80 (8-352) 131 (76-186) 0.422 75 (8-352) 106 (35-186) 0.425 
Day 7 C-reactive Protein b 89 (9-310) 63 (12-128) 0.340 79 (9-310) 91 (15-167) 0.795 75 (9-310) 111 (15-173) 0.618 
 
an=68, bn=57  
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Table 3-4 Relationship between patient and tumour related variable and salivary free cortisol (n=30) 
Patient Related Variable  10pm Salivary Cortisol 
(nmol/L) 
p value 8am Salivary Cortisol 
(nmol/L) 
p value Absolute change in 
Salivary Cortisol 
(nmol/L) 
p value 
Age (years) <65 8.2 (1.7-61.0)  17.4 (7.5-225.0)  10.7 (0.8-164.0)  
65 – 74 8.3 (1.0-16.5)  13.4 (10.7-28.3)  6.2 (1.0-11.8)  
≥ 75 10.7 (8.2-13.2) 0.329 32.1 (32.0-32.2) 0.410 21.4 (19.0-23.8) 0.498 
Sex Female 8.2 (1.0-44.0)  15.5 (7.5-58.0)  10.7 (0.8-23.8)  
Male 11.4 (2.3-61.0) 0.139 20.2 (10.6-225.0) 0.081 12.5 (0.2-164.0) 0.096 
ASA 1 + 2 7.6 (1.0-44.0)  16.9 (8.4-62.5)  11.4 (0.8-22.3)  
 3 + 4 8.6 (4.2-61.0) 0.290 19.8 (7.5-225.0) 0.935 11.6 (0.5-164.0) 1.000 
White Cell Count (x109/L) ≤ 11 8.6 (1.0-61.0)  17.9 (7.5-225.0)  11.6 (0.8-164.0)  
> 11  6.9 (4.4-9.3) 0.352 15.9 (12.5-19.3) 0.861 9.1 (8.1-10.0) 0.837 
C-reactive Protein (mg/L) <10 8.3 (1.3-61.0)  15.0 (7.5-225.0)  8.3 (0.8-164.0)  
 ≥10 8.2 (1.0-44.0) 0.752 21.5 (7.5-62.5) 0.896 12.5 (2.9-22.3) 0.733 
Albumin (g/L) ≥35 9.0 (1.0-61.0)  16.3 (7.5-225.0)  10.7 (0.8-164.0)  
 <35 8.2 (4.4-44.0) 0.232 29.2 (7.5-62.5) 0.789 14.0 (2.9-23.8) 0.881 
Modified Glasgow Prognostic Score 
(mGPS)  
0  8.6 (2.3-61.0)  13.8 (7.5-225.0)  8.2 (0.8-164.0)  
1 7.1 (1.0-13.2)  22.0 (11.7-32.2)  14.9 (10.7-19.0)  
2 8.8 (7.7-44.0) 0.330 24.7 (19.3-58.0) 0.923 13.3 (10.0-21.0) 0.735 
Neutrophil:Lymphocyte Ratio (NLR) <5 
≥5 
8.2 (1.0-61.0) 
11.3 (4.4-44.0) 
 
0.048 
15.3 (7.5-225.0) 
25.8 (12.5-58.0) 
 
0.563 
11.0 (0.8-164.0) 
12.0 (8.1-19.0) 
 
0.879 
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Tumour Related Variable  10pm Salivary Cortisol 
(nmol/L) 
p value 8am Salivary Cortisol 
(nmol/L) 
p value Absolute change in 
Salivary Cortisol 
(nmol/L) 
p value 
T stage I 8.2 (2.7-12.1)  25.3 (11.6-34.4)  19.9 (0.2-23.8)  
II 9.1 (2.3-61.0)  14.8 (7.5-225.0)  8.2 (0.8-164.0)  
III 6.4 (1.0-42.0) 0.288 18.4 (9.1-62.5) 0.279 11.6 (7.4-20.6) 0.095 
TNM stage I  8.2 (2.7-12.1)  29.2 (15.5-34.4)  21.0 (11.3-23.8)  
II 9.2 (3.6-61.0)  20.3 (7.5-225.0)  12.0 (0.8-164.0)  
III 6.8 (1.0-42.0)  14.6 (10.6-62.5)  8.3 (0.2-20.5)  
IV 4.6 (1.7-9.1) 0.316 9.1 (7.5-21.5) 0.112 7.4 (2.9-12.4) 0.072 
Venous Invasion No 8.6 (1.0-61.0)  13.6 (7.5-225.0)  10.4 (0.8-164.0)  
 Yes 10.5 (2.3-44.0) 0.834 20.8 (10.6-58.0) 0.473 12.2 (1.0-19.0) 0.369 
Tumour Site Colon 8.2 (1.0-44.0)  15.3 (7.5-58.0)  10.4 (0.2-23.8)  
Rectum 12.9 (7.7-61.0) 0.301 24.3 (8.4-225.0) 0.227 12.2 (0.8-164.0) 0.214 
Klintrup  0-1 7.7 (1.0-16.5)  15.5 (10.6-32.0)  10.7 (0.2-23.8)  
 2-3 9.2 (7.0-61.0) 0.026 29.2 (7.5-225.0) 0.090 14.0 (0.8-164.0) 0.188 
Tumour Necrosis Absent – Focal 8.2 (1.0-61.0)  20.3 (7.5-225.0)  12.2 (0.2-164.0)  
 Moderate - Extensive 9.3 (2.3-44.0) 0.297 15.5 (8.4-58.0) 0.462 10.0 (0.8-14.0) 0.114 
 
median (range) 
 
 4 The systemic inflammatory response as a predictor of 
postoperative infective complications following 
curative resection in patients with colorectal cancer 
4.1 Introduction 
Despite improvements in surgery and perioperative care, in particular infection control 
measures and the use of preoperative antibiotic prophylaxis, infective complications still 
represent a major cause of morbidity and mortality following colorectal cancer resection 
(Fujita et al., 2007, Rovera et al., 2007, Tornqvist et al., 1981).  Overall complication rates 
have been reported to be approximately 30% and the perioperative mortality rate 
approximately 3-4% (Alves et al., 2005, Sjo et al., 2009).  
 
Postoperative infections have traditionally been classified into surgical site infection (SSI) 
and remote site infection (RSI) (Edwards, 1976, Miki et al., 2006, Matsuda et al., 2009, 
Mangram et al., 1999).  SSI can be further divided into incisional (wound infection) and 
organ/space (anastomotic leak and intra-abdominal collection).  RSI includes pneumonia, 
urinary tract infection (UTI), septicaemia, antibiotic enterocolitis and central line infection.   
 
Anastomotic leak is the most serious infective complication with an associated increase in 
postoperative mortality (Alves et al., 1999, Petersen et al., 1998, Buchs et al., 2008).  
Anastomotic leak can be clinically silent in the early stages and may only become 
clinically evident as late as post-operative days 8 to 12 when the patient is critically ill 
(Buchs et al., 2008, Hyman et al., 2007).  Furthermore, it has become clear that the 
development of anastomotic leak is also associated with poorer long term survival 
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(McArdle et al., 2005, Jung et al., 2008, Marra et al., 2009).  Therefore, infective 
complications, in particular an anastomotic leak, can be catastrophic for the patient, both in 
short and long term outcomes. 
 
Whilst subsequent leak of faeces into the peritoneal cavity may not be avoided, if these 
patients could be identified earlier, resultant sepsis and intervention may be reduced.  
There is increasing evidence that the magnitude of the systemic inflammatory response 
using the acute phase proteins, in particular C-reactive protein, during the perioperative 
period might usefully identify those patients at risk of developing a postoperative infective 
complication.  Welsch and co-workers reported that, in 48 patients with infective 
complications matched with 48 patients with no infective complications undergoing 
surgery for rectal cancer, increased C-reactive protein concentrations on postoperative day 
3 were associated with infective complications with an optimal predictive threshold value 
of 140mg/l (Welsch et al., 2007).  Matthiessen and co-workers reported that, in 32 patients 
undergoing anterior resection for rectal cancer, an early rise in serum CRP is a strong 
indicator of anastomotic leakage (Matthiessen et al., 2008).  Korner and co-workers 
reported that, in 231 patients undergoing surgery for colorectal cancer, increased C-
reactive protein concentrations on postoperative day 3 were associated with intra-
abdominal infections with an optimal predictive threshold value of 190mg/l (Korner et al., 
2009). 
 
More recently Woeste and colleagues reported that, in 342 patients undergoing surgery for 
colorectal cancer, a prolonged elevation in the C-reactive protein concentration with no 
subsequent decrease precedes the development of anastomotic leakage (Woeste et al., 
2010).  Ortega-Deballon et al demonstrated that, in 133 patients undergoing elective 
colorectal surgery, elevated C-reactive protein levels on postoperative day 4 were 
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associated with anastomotic leakage with an optimal predictive threshold value of 125mg/l 
(Ortega-Deballon et al., 2010).  Mackay and co-workers demonstrated that, in 160 patients 
undergoing surgery for colorectal cancer, increased C-reactive protein concentrations on 
postoperative day 4 were associated with infective complications with an optimal 
predictive threshold value of 145mg/l (MacKay et al., 2011).  In a larger study, 
Warschkow and co-workers demonstrated that, in 1,187 patients undergoing open resection 
of colorectal cancer, that C-reactive protein concentrations above 123mg/l on postoperative 
day 4 should raise suspicion of inflammatory complications (Warschkow et al., 2012b). 
 
Therefore, it is not clear what threshold concentration of C-reactive protein or what post-
operative day of measurement is most predictive of infective complications following 
colorectal cancer resection.  Establishing this is vital before instigating a change in clinical 
practice.  Therefore, the aim of the present study was to examine the value of serial daily 
markers of the systemic inflammatory response including white cell count, albumin and C-
reactive protein in the prediction of post-operative infective complications in patients 
undergoing potentially curative resection of colorectal cancer. 
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4.2 Patients and methods 
Patients with histologically proven colorectal cancer who, on the basis of laparotomy 
findings and pre-operative abdominal computed tomography, were considered to have 
undergone potentially curative resection between January 1997 and February 2007 in a 
single surgical unit at Glasgow Royal Infirmary, were included in the study.  Patient 
characteristics were collected in a prospective surgical database. This was approved by the 
Research Ethics Committee, Royal Infirmary, Glasgow as part of surgical audit and at this 
time consent was part of the surgical procedure.  All patient data was de-identified.  
 
The tumours were staged using conventional TNM classification.  All resections were 
performed by open surgery and involved either hand sewn or stapled anastomosis.  Low 
pelvic anastomoses were performed using a transanal circular stapling device.  The 
majority of operations involved an anastomosis (95%) with the remaining being either a 
Hartmann`s procedure or an abdominoperineal resection of rectum. Emergency 
presentation was defined as a patient who had an unplanned admission to hospital resulting 
in having their surgery during the same admission. 
 
Pre-operatively every patient received DVT and antibiotic prophylaxis as per local 
protocol.  Serial daily blood samples were taken for routine laboratory analysis of white 
cell count, albumin and C-reactive protein in the pre- and post-operative period (days 1-7).  
Postoperatively, all patients had a daily clinical assessment and additional investigations 
were carried out as indicated clinically. 
 
Patients were assessed for the following complications: infective and non-infective 
(cardiac events encompassing acute coronary syndrome and acute myocardial infarction, 
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and pulmonary embolism).  Infective complications were separated into surgical site 
infection (SSI) and remote site infection (RSI).  Surgical site infections were further 
classified into incisional (wound) and organ/space (anastomotic leak).  A remote site 
infection such as pneumonia is often exogenous and occurs at sites not directly associated 
with the surgical procedure.  The criteria used to define infective complications were the 
same as that previously described (Ytting et al., 2005).  (1) Wound infection was defined 
as the presence of pus, either discharged spontaneously or requiring drainage.  Wound 
infection included a subgroup of patients with perineal infection following abdomino-
perineal resection of the rectum.  (2) Intra-abdominal abscess was verified by either 
surgical drainage or by image guided aspiration of pus.  (3) Anastomotic leakage was 
defined as radiologically verified fistula to bowel anastomosis or diagnosed by 
relaparatomy.  (4)  Pneumonia was defined by fever above 38.5°C and a positive X-ray, 
requiring antibiotic treatment.  (5) Septicaemia was defined by clinical symptoms 
combined with a positive blood culture.  Non-symptomatic or minor urinary tract infection 
was not recorded, and therefore only included if complicated by septicaemia. 
 
The extent of deprivation was defined using the Carstairs deprivation index (Carstairs and 
Morris, 1990).  This is an area-based measure derived from the 1991 census, using the 
postcode of residence at diagnosis, which divides the score into a seven-point index.  For 
illustrative purposes, the results are presented by amalgamating the seven categories into 
three groups: affluent (categories 1 and 2), intermediate (categories 3–5) and deprived 
(categories 6 and 7).  The Carstairs deprivation index has been extensively utilised in 
cancer patients and is particularly appropriate for use in the central belt of Scotland (Hole 
and McArdle, 2002).    
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Methods 
The white cell count (reference range 4–10×109/L) was analysed using a haematological 
blood analyser (Advia 120, Bayer, or CellDyn, Abbott).  Serum concentrations of albumin 
(normal range 35-50 g/L) and C-reactive protein (normal range 0-10 mg/L) were measured 
by a BCG dye-binding method and turbidometric assay, respectively, using an auto-
analyser (Abbott Diagnostics, Abbott Park, IL).  The limit of detection of the assay was a 
C-reactive protein concentration lower than 6 mg/L prior to 2007, and 1mg/L thereafter.  
The coefficient of variation for these methods, over the range of measurement, was less 
than 10% as established by routine quality control procedures.   
 
Statistical analysis 
Data are presented as median (range).  Data from different time periods were tested for 
statistical significance using the Friedman test and where appropriate comparisons of data 
from different time periods were carried out using the Wilcoxon signed rank test.  The 
diagnostic accuracy of white cell count, albumin and C-reactive protein was assessed by 
ROC (Receiver Operator Curve) analysis (Robertson and Zweig, 1981, Zweig and 
Campbell, 1993, Soreide, 2009).  The area under the ROC curve (AUC) is a direct measure 
of the diagnostic accuracy of the test.  An AUC value greater than >50% indicates the 
ability of a test to significantly discriminate between positive and negative cases with 
regard to the classification variable (e.g., presence or absence of disease).  A test with an 
AUC greater than 0.75 was considered as having a high diagnostic accuracy and indicates 
that at least 75% of the patients with the disease were classified correctly.  A p-value <0.05 
(two-sided tests) was considered significant.  Statistical analysis was performed using 
SPSS version 15.0 for Windows (SPSS Inc, Chicago, IL). 
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4.3 Results 
Baseline characteristics of the 454 patients who underwent curative surgery for colorectal 
cancer are shown in Table 4.1.  The majority of patients were 65 or older (67%), male 
(55%), had colonic tumours (66%) and node negative disease (57%).  Most patients 
underwent elective resection (87%) and were from a deprived area (55%).  The majority of 
patients had pre-operative white cell count (89%), albumin (80%), and C-reactive protein 
(55%) in the normal range.  
 
During follow up 120 (26%) patients developed a postoperative complication; 104 (86%) 
of which were infective complications.  The 104 patients with infective complications 
included 53 RSIs (pneumonia n=36, septicaemia n=5, urinary tract infection n=4, central 
line tip infection n=3, peripheral cellulitis n=3 and antibiotic entercolitis n=2), 25 wound 
infections and 26 anastomotic leaks.  Of those with an infective complication, 9 patients 
developed a second infective complication and 6 patients developed an additional non-
infective complication.  The 16 non-infective complications were pulmonary embolism 
(n=2), atrial fibrillation (n=4), acute coronary syndrome (n=3), myocardial infarction 
(n=5), acute urinary retention (n=1) and ischaemic stoma (n=1).  Only infective 
complications were associated with emergency presentation (p<0.001), a deprived 
background (p<0.05), an elevated preoperative white cell count (p<0.001) and an elevated 
preoperative C-reactive protein (p<0.001). 
 
The relationship between circulating white cell count, albumin and C-reactive protein 
concentrations and infective and non-infective complications in the perioperative period 
are shown in Table 4.2 and Figures 4.1-4.4.  Compared with those patients who did not 
develop complications, the white cell count and C-reactive protein were significantly 
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higher, and albumin lower preoperatively (p<0.001, p<0.001, p=0.028 respectively) and on 
post-operative days 2 (p<0.001, p<0.001, p<0.001 respectively), 3 (p<0.001, p=0.001, 
p<0.001 respectively), 4 (p=0.002, p<0.001, p<0.001 respectively), 5 (p=0.002, p<0.001, 
p<0.001 respectively), 6 (p<0.001, p<0.001, p<0.001 respectively) and 7 (p<0.001, 
p<0.001, p<0.001 respectively) in those patients who developed infective complications 
(Table 4.2 and Figures 4.1-4.3).  Compared with those patients who did not develop 
complications white cell count, albumin and C-reactive protein were not significantly 
different on any perioperative day in those patients who developed non-infective 
complications (Table 4.2).  When those patients who presented as an emergency were 
removed from the analysis leaving elective patients only (n=396), white cell count was 
only significantly associated on post-operative day 7 (p=0.003) whereas C-reactive protein 
was significantly higher, and albumin lower on post-operative days 2 to 7 (all p<0.001 and 
all p<0.001 respectively) in those who developed infective complications.  Compared with 
those patients who did not develop complications white cell count, albumin and C-reactive 
protein were not significantly different on any perioperative day in elective patients who 
developed non-infective complications. 
 
In all patients, compared with those patients who did not develop an anastomotic leak 
(n=334), C-reactive protein was significantly higher from post-operative day 3 onwards 
(all p<0.001) in those patients who developed an anastomotic leak (n=26, Figure 4.4).   
 
The relationship between circulating white cell count, albumin and C reactive protein 
concentrations and surgical site and remote site infective complications in the perioperative 
period are shown in Table 4.3.  Compared with those patients who did not develop 
complications, the white cell count and C-reactive protein were significantly higher, and 
albumin lower preoperatively (p=0.041, p=0.003, p=0.018 respectively) and on 
 
95 
 
postoperative days 3 (p=0.009, p<0.001, p<0.001 respectively), 4 (p=0.013, p<0.001, 
p<0.001 respectively), 5 (p=0.024, p<0.001, p<0.001 respectively), 6 (p=0.001, p<0.001, 
p<0.001 respectively) and 7 (p<0.001, p<0.001, p<0.001 respectively) in those patients 
who developed surgical site infective complications (Table 4.3).  Compared with those 
patients who did not develop complications, the white cell count and C-reactive protein 
were significantly higher, and albumin lower on postoperative days 2 (p<0.001, p<0.001, 
p<0.001 respectively), 3 (p<0.001, p<0.001, p<0.001 respectively), 4 (p=0.021, p<0.001, 
p<0.001 respectively), 5 (p=0.015, p<0.001, p<0.001 respectively), 6 (p=0.002, p<0.001, 
p<0.001 respectively) and 7 (p=0.005, p<0.001, p<0.001 respectively) in those patients 
who developed remote site infective complications (Table 4.3).    
 
In order to establish a threshold for the relationship between the white cell count, albumin 
and C-reactive protein in predicting an infective complication following surgery for 
colorectal cancer Receiver Operator Curves were plotted for postoperative days 3 and 4 
(Figures 4.5-4.7).  The AUC day 3 and day 4 graphs for prediction of infective 
complications using white cell count, albumin and C-reactive protein were similar and 
therefore the day 3 thresholds for white cell count, albumin and C-reactive protein were 
examined further. For white cell count, the AUC on day 3 was 0.64 with an optimal 
threshold of 8.6x109/l, sensitivity 69% and specificity 52% (OR 1.09, 95% CI 0.57-0.71, 
p<0.05) (Figure 4.5). For albumin, AUC on postoperative day 3 was 0.68 with an optimal 
threshold of 25g/l, sensitivity 59%, specificity 67% (OR 0.87, 95% CI 0.62-0.74, p<0.001) 
(Figure 4.6). For C-reactive protein, the AUC was 0.80 with an optimal threshold of 
170mg/l, sensitivity 74%, specificity 75% (OR 1.02, 95% CI 0.74-0.85, p<0.001) (Figure 
4.7). When the threshold values of day 3 white cell count, albumin and C-reactive protein 
in predicting infective complications were compared in binary logistic regression analysis, 
both albumin (OR 0.21, 95% CI 0.12-0.39, p<0.001) and C-reactive protein (OR 0.10, 95% 
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CI 0.06-0.19, p<0.001) retained independent predictive value. Therefore, the value of a 
composite score on day 3 was considered. Receiver Operator Curves were plotted using the 
thresholds of albumin <25g/l and C-reactive protein >170mg/l on postoperative day 3, 
AUC was 0.79 (OR 1.44, 95% CI 0.73-0.85, p<0.001) which was similar to the predictive 
value of day 3 C-reactive protein alone. Therefore, only C-reactive protein at the threshold 
of >170mg/l was considered in further analysis.  
 
The threshold for the relationship between C-reactive protein and the development of an 
anastomotic leak following surgery for colorectal cancer Receiver Operator Curves were 
plotted for post-operative days 3 and 4 (Figure 4.8).  This demonstrated that the increased 
levels on postoperative day 3 were the earliest to be predictive of a postoperative 
anastomotic leak, with the AUC being 0.84 (p<0.001).  The optimal cut off value was 
190mg/l, sensitivity 77%, specificity 80% (Figure 4.8).  On post-operative day 4, for an 
anastomotic leak, the AUC was 0.83 (p<0.001).  The optimal cut off value was 125mg/l, 
sensitivity 77%, specificity 76% (Figure 4.8). 
 
The median length of hospital stay was 11 days. Of those patients who had a day 3 C-
reactive protein >170mg/l, the median length of hospital stay was 13 days compared with a 
median of 10 days in those who had a day 3 C-reactive protein <170mg/l (p<0.001).  On 
follow up there were 13 deaths (3% of all patients) after day 3 and within the 30 days 
following surgery. Of those patients who had a day 3 C-reactive protein >170mg/l, 8 
patients died within 30 days (6%), compared with 5 deaths (2%) in those who had a day 3 
C-reactive protein <170mg/l (p=0.046). Between 30 days and 1 year, there were a further 
23 deaths, 20 of whom had a day 3 C-reactive protein. Of those patients who had a day 3 
C-reactive protein >170mg/l, 11 patients died with 30 days and 1 year (8%), compared 
with 9 deaths (3%) in those who had a day 3 C-reactive protein <170mg/l (p=0.061).  
 
97 
 
4.4 Discussion 
The results of the present study show that the magnitude of the post-operative systemic 
inflammatory response, in particular C-reactive protein, is associated with the development 
of postoperative infective complications.  Furthermore, a C-reactive protein threshold can 
be used to predict the likelihood of an infective complication with very good diagnostic 
accuracy at an early pre-clinical stage prior to the development of clinical signs and 
symptoms.  
 
The results of the present study are consistent with previous studies and the C-reactive 
protein thresholds are remarkably similar, although not identical.  The present study also 
examines other routine markers of inflammation in the context of predicting a 
postoperative infective complication, and investigates the use of a combined predictive 
score. The differences in C-reactive protein thresholds are likely to be accounted for by 
different patient numbers and varying thresholds for diagnosis of an infective 
complication, which is difficult to standardize.  When the threshold values from different 
studies were applied to the data gained in the present study (Table 4.4), on POD 3 there 
was variation in the sensitivity between 74% and 82% and specificity between 50% and 
80% in predicting infections.  Also, on post-operative day 4 there was variation in the 
sensitivity between 54% and 77% and specificity between 75% and 84% in predicting 
infections.  Therefore, depending on the threshold value of C-reactive protein used and the 
post-operative day chosen there is a considerable variation in the predictive value of the C-
reactive protein concentration.  Nevertheless, monitoring of C-reactive protein 
concentrations in the post-operative period has considerable clinical potential.  
 
Clearly, when considering clinical application of post-operative monitoring of C-reactive 
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protein concentrations it will be used in the context of other existing clinical and 
biochemical parameters.  For example, it may be possible to predict the development of an 
infective complication at a pre-clinical stage (day 3 rather than approximately day 7) and 
therefore institute early investigation of a potential infective complication.  One approach 
to investigate this further would be to carry out a prospective randomized trial to study the 
impact of early diagnosis / intervention based on postoperative monitoring of C-reactive 
protein concentration. However, in light of the evidence from the present and previous 
studies this may be considered unethical since clinicians, certainly in our centre, might 
expect to have access to these C-reactive protein concentrations. Furthermore, the pre-
emptive investigations and treatments that might result from early identification (C-
reactive protein approximately 170 mg/l, on post-operative day 3) of a potential infective 
complication are as yet unclear. One approach, if an infective complication was suspected 
from postoperative C-reactive protein monitoring at day 3, would be to carry out a clinical 
review including respiratory and abdominal examination, together with appropriate blood, 
urine and sputum cultures and radiological investigation.  If these clinical investigations 
confirmed or heightened suspicion of an infective complication then it might be reasonable 
to institute pre-emptive antibiotic use or surgical intervention.  If this clinical protocol was 
proven to allow earlier treatment of infective complications, in particular an anastomotic 
leak, and therefore reduce post-operative morbidity and mortality this would be a 
significant contribution to improved care of patients undergoing resection for colorectal 
cancer.  
 
It is of interest that a small randomised trial investigating the effect of pre-emptive 
antibiotic treatment on infective complications following colorectal surgery, that used 
procalcitonin to identify high risk patients, reported a significant reduction in the rate of 
infective complications (Chromik et al., 2006).  However, it remains to be determined 
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whether such early identification of infective complications can improve the short term 
morbidity and mortality for patients undergoing potentially curative colorectal cancer 
resection.   
 
Usually, a rise in circulating C-reactive protein concentration is considered to be a result, 
rather than a cause, of an infective complication.  However, it may be that C-reactive 
protein is more than just a sensitive measure of the presence of infection.  Indeed, C-
reactive protein has an important role in innate immunity as an early defense against 
infection, assisting complement-binding to foreign and damaged cells and enhancing 
phagocytosis by macrophages.  For example, through activation of complement and 
interaction with Fc gamma receptors, C-reactive protein has been shown to provide a link 
between the innate and adaptive immune systems (Peisajovich et al., 2008, Coventry et al., 
2009, Du Clos and Mold, 2004, Sander et al., 2010).  Furthermore, with increasing 
concentrations of C-reactive protein there is a depression of T-lymphocyte function 
(Sander et al., 2010, Fietta et al., 2009) and an increase in the stress response and the 
degree of hyperglycaemia (Wichmann et al., 2005).  Also, postoperative hyperglycemia 
has recently been shown to be an important factor associated with the promotion of 
bacterial growth and the development of postoperative infective complications (Motoyama 
et al., 2010, Ramos et al., 2008, Ambiru et al., 2008).  Therefore, in addition to giving 
advance notice of a clinical infection, it may also play an important direct role in 
modulating the postoperative immune function of patients with colorectal cancer.   
 
In summary, early identification of postoperative infective complications in patients 
undergoing colorectal cancer resection is crucial to the implementation of adequate 
therapeutic interventions.  The present study shows that C-reactive protein measurements 
on postoperative day 3 can accurately predict infective complications, including 
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anastomotic leak, after resection for colorectal cancer.  Given that the average time for the 
development of an infective complication, including an anastomotic leak, is between post-
operative day 6 and day 8, daily monitoring of C-reactive protein concentrations may 
improve their early detection and subsequent management, thereby reducing post-operative 
morbidity and mortality.  Clearly, if this is proven to be the case in prospective trials, then 
this would be a major contribution to the post-operative management of patients 
undergoing surgery for colorectal cancer. 
  
 
Table 4-1 Clinical characteristics of 454 colorectal cancer patients with and without 
postoperative complications 
 
acompared with no complications  
(30 day mortality excluded for 1 year analysis) 
 
 No 
complications 
n=334 
Infective 
complications 
n=104 
aP-value Non-infective 
complications 
n=16 
aP-value 
Age (<65/ 65-74/ ≥ 75) 120/ 99/ 115  30/ 41/ 33 0.637 1/ 8/ 7 0.068 
Sex (Male/ Female) 181/ 153 62/ 42  0.367 8/ 8 0.801 
Emergency (No/ Yes) 306/ 28 75/ 29 <0.001 15/ 1 0.763 
Tumour site (Colon/ Rectum) 216/ 118 72/ 32 0.393 12/ 4 0.398 
TNM stage (I/ II/ III) 45/ 142/ 147 17/ 47/ 40 0.283 0/ 7/ 9 0.145 
Deprivation (1-2/ 3-5/ 6-7) 13/ 127/ 156 0/ 32/ 55 0.030 0/ 6/ 9 0.445 
Pre-operative white cell count 
(median, range) 
7.5 (3.0-23.5) 8.9 (3.4-23.8) <0.001 8.7 (5.2-15.5) 0.069 
Pre-operative white cell count 
(<11/ >11 x 109/l) 
242/ 37 69/ 25 0.003 13/ 2 0.994 
Pre-operative albumin 
(median, range) 
40 (16-52) 38 (18-47) 0.028 41 (29-47) 0.164 
Pre-operative albumin  
(≥35/ <35 g/l) 
269/ 63 79/ 25 0.262 15/ 1 0.200 
Pre-operative C-reactive 
protein 
(median, range) 
8 (1-222) 14 (1-317) <0.001 6.5 (1-120) 0.567 
Pre-operative C-reactive 
protein (≤10/ >10 mg/l) 
194/ 138 42/ 61 0.002 10/ 6 0.747 
Length of hospital stay (days) 10 (3-108) 16 (6-187) <0.001 12 (6-25) 0.603 
Mortality at 30 days (No/ 
Yes) 
334/ 0 93/ 11 <0.001 15/ 3 0.459 
Mortality at 1 year (No/ Yes) 317/ 16 85/ 7 0.370 13/ 0 0.346 
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Table 4-2 The relationship between serial postoperative values of white cell count, 
albumin and C-reactive protein and the development of infective and non-infective 
complications 
 No 
complications  
n=334 
Infective 
Complications 
n=104 
P-valuea 
 
Non-infective 
complications  
n=16 
 
P-valuea 
Pre-op WCC 7.5 (3.0-23.5) 8.9 (3.4-23.8) <0.001 8.7 (5.2-15.5) 0.069 
WCC day 1 11.0 (3.2-33.8) 11.4 (3.3-22.5) 0.359 11.4 (8.1-22.0) 0.442 
WCC day 2 10.3 (4.0-52.6) 11.7 (3.0-45.7) <0.001 10.1 (6.6-21.3) 0.681 
WCC day 3 8.4 (2.5-45.6) 9.9 (1.4-34.5) <0.001 9.6 (4.4-20.2) 0.230 
WCC day 4 7.4 (2.2-38.3) 8.7 (2.7-35.9) 0.002 8.2 (3.3-15.0) 0.301 
WCC day 5 7.3 (2.2-44.4) 9.1 (3.9-29.4) 0.002 8.3 (4.4-14.2) 0.332 
WCC day 6 8.0 (3.0-40.5) 9.6 (3.9-23.8) <0.001 8.7 (5-19.4) 0.374 
WCC day 7 8.5 (3.0-41.3) 10.4 (4.7-25.1) <0.001 9.3 (6.4-16.7) 0.190 
      
Pre-op Alb 40 (16-52) 38 (18-47) 0.028 41 (29-47) 0.164 
Alb day 1 28 (11-42) 24 (9-41) <0.001 28 (19-32) 0.640 
Alb day 2 27 (13-44) 23 (9-39) <0.001 28 (15-32) 0.916 
Alb day 3 28 (14-41) 24 (11-37) <0.001 28 (20-33) 0.736 
Alb day 4 29 (13-41) 24 (8-38) <0.001 30 (20-36) 0.753 
Alb day 5 30 (11-42) 26 (10-41) <0.001 31 (20-35) 0.904 
Alb day 6  31 (11-44) 26 (12-46) <0.001 32 (18-36) 0.582 
Alb day 7 32 (14-47) 26 (11-42) <0.001 32 (21-37) 0.959 
      
Pre-op CRP 8 (1-222) 14 (1-317) <0.001 6.5 (1-120) 0.567 
CRP day 1 108 (5-348) 125 (14-343) 0.064 130 (66-162) 0.116 
CRP day 2 163 (17-356) 215 (82-358) <0.001 180 (74-289) 0.753 
CRP day 3 132 (6-319) 208 (38-352) 0.001 150 (42-217) 0.604 
CRP day 4 90 (6-306) 149 (23-317) <0.001 101 (19-215) 0.339 
CRP day 5 59 (5-265) 108 (17-283) <0.001 65 (16-162) 0.665 
CRP day6 47 (5-285) 103 (13-354) <0.001 47 (12-106) 0.915 
CRP day 7 38 (5-347) 105 (6-329) <0.001 36 (9-91) 0.743 
 
Median (range), WCC white cell count, Alb albumin, CRP C-reactive protein 
a compared with no complications 
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Table 4-3 The relationship between serial postoperative values of white blood cell 
count, albumin and C-reactive protein and the development of surgical site and 
remote site infective complications 
 
 No complications 
n=334 
Surgical site 
infection  n=51 
P-valuea Remote 
infection n=53 
 
P-valuea 
Pre-op WCC 7.5 (3.0-23.5) 9 (3.4-19.2) 0.041 8.5 (5.1-23.8) 0.001 
WCC day 1 10.9 (3.2-33.8) 11.7 (5.4-22.5) 0.495 11 (3.3-22.3) 0.481 
WCC day 2 10.3 (4.0-52.9) 11.1 (4.7-45.7) 0.081 12.5 (3.0-
32.1) 
<0.001 
WCC day 3 8.4 (2.5-45.6) 9.7 (1.4-21.4) 0.009 10.6 (4.9-
34.5) 
<0.001 
WCC day 4 7.4 (2.2-38.3) 9.0 (2.8-24.3) 0.013 8.2 (2.7-35.9) 0.021 
WCC day 5 7.3 (2.2-44.4) 8.4 (4.0-17.2) 0.024 9.4 (3.8-29.4) 0.015 
WCC day 6 8.0 (3.0-40.5) 10 (3.9-23.8) 0.001 9.2 (5.3-22.6) 0.002 
WCC day 7 8.5 (3.0-41.3) 10.4 (4.8-25.1) <0.001 9.9 (4.7-22.4) 0.005 
      
Pre-op Alb 40 (16-52) 37 (21-47) 0.018 39 (18-44) 0.334 
Alb day 1 28 (11-42) 24 (13-41) 0.001 24 (9-34) <0.001 
Alb day 2 27 (13-44) 23 (12-39) <0.001 23 (9-34) <0.001 
Alb day 3 28 (14-41) 25 (12-37) <0.001 24 (11-32) <0.001 
Alb day 4 29 (13-41) 25 (12-38) <0.001 24 (8-34) <0.001 
Alb day 5 30 (11-42) 27 (12-41) <0.001 24 (10-38) <0.001 
Alb day 6  31 (11-44) 26 (12-46) <0.001 25 (12-37) <0.001 
Alb day 7 32 (14-47) 26 (11-42) <0.001 27 (13-40) <0.001 
      
Pre-op CRP 8 (1-222) 14 (1-306) 0.003 12 (2-317) 0.009 
CRP day 1 108 (5-348) 127 (14-264) 0.171 123 (25-343) 0.154 
CRP day 2 163 (17-356) 217 (82-317) <0.001 214 (82-358) <0.001 
CRP day 3 132 (6-319) 221 (38-308) <0.001 202 (80-352) <0.001 
CRP day 4 90 (6-306) 168 (23-317) <0.001 144 (49-295) <0.001 
CRP day 5 59 (5-265) 109 (17-283) <0.001 103 (24-277) <0.001 
CRP day6 47 (5-285) 125 (21-354) <0.001 80 (13-242) <0.001 
CRP day 7 38 (5-347) 122 (6-329) <0.001 69 (13-249) <0.001 
 
Median (range), WCC white cell count, Alb albumin, CRP C-reactive protein 
acompared with no complications  
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Table 4-4 Comparison of reported threshold values of C-reactive protein in predicting infective complications  
 
           Analysis of CRP threshold in the present study (n=454) 
Study C/R Patients 
(n) 
POD CRP 
Threshold  
Complication Infective Complications Anastomotic leak 
           Sensitivity 
(%) 
Specificity 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
Welsch et al R 48 3 140 All infections 82 50   
Kørner et al CR 231 3 190 AL   77 80 
This study CR 454 3 170  All infections 74 75   
Ortega-Deballon et al CR  133 4 125 AL   77 76 
MacKay et al CR 160 4 145 All infections 54 84   
Warschow et al CR 1187 4 123 All infections  69 78   
 
C/R colon or rectum, POD postoperative day, CRP C-reactive protein, AL anastomotic leak 
 
 
 Figure 4-1 The perioperative changes in white cell count in patients with infective 
complications (IC) and no complications (NC) 
 
White cell count (109/l). (median, IQR)   
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Figure 4-2 The perioperative changes in albumin in patients with infective 
complications (IC) and no complications (NC) 
 
(median, IQR) 
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Figure 4-3 The perioperative changes in C-reactive protein in patients with infective 
complications (IC) and no complications (NC) 
 
(median, IQR) 
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Figure 4-4 The perioperative changes in C-reactive protein in patients with 
anastomotic leak (AL) and no complications (NC) 
   
(median, IQR)   
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Figure 4-5 Diagnostic accuracy of white cell count with regard to the development of 
infective complications following surgery for colorectal cancer 
 
The AUC values were 0.64 (p<0.001) and 0.62 (p=0.002) for postoperative days (POD) 3 
and 4 respectively.  
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Figure 4-6 Diagnostic accuracy of albumin with regard to the development of 
infective complications following surgery for colorectal cancer 
 
The AUC values were 0.68 (p<0.001) and 0.72 (p<0.001) for postoperative days (POD) 3 
and 4 respectively.  
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Figure 4-7 Diagnostic accuracy of C-reactive protein with regard to the development 
of infective complications following surgery for colorectal cancer 
 
The AUC values were 0.80 (p<0.001) and 0.79 (p<0.001) for postoperative days (POD) 3 
and 4 respectively.  
 
 
 
 
 
 
 
112 
 
 
 
Figure 4-8 Diagnostic accuracy of C-reactive protein with regard to the development 
of anastomotic leak following surgery for colorectal cancer 
 
The AUC values were 0.84 and 0.83 for postoperative day (POD) 3 and 4 respectively.  
 
 
 
5 The impact of open vs laparoscopic resection for colon 
cancer on C-reactive protein concentrations as a 
predictor of postoperative infective complications   
5.1 Introduction 
Despite improvements in surgery and perioperative care, in particular infection control 
measures and the use of preoperative antibiotic prophylaxis, infective complications still 
represent a major cause of morbidity, resulting in prolonged hospital stay and increased 
health care costs, and mortality following colorectal cancer resection (Fujita et al., 2007, 
Rovera et al., 2007, Tornqvist et al., 1981).   Postoperative complication rates remain high, 
approximately 30%, and the perioperative mortality rate approximately 3-4% (Sjo et al., 
2009, Alves et al., 2005). Infective complications and anastomotic leak can be difficult to 
detect in the early postoperative stage and may only become clinically evident as late as 
postoperative day 8-12, when the patient is critically ill (Alves et al., 1999, Hyman et al., 
2007).  Furthermore, it has been shown that the development of an anastomotic leak is also 
associated with poorer long term survival (McArdle et al., 2005, Jung et al., 2008, Marra et 
al., 2009).  Therefore, infective complications can be serious for the patient both in the 
short term and in the long term.  
 
Recently, it has become clear that C-reactive protein, an acute phase protein almost 
exclusively synthesised in the liver and a reliable routinely available measure of the 
systemic inflammatory response, is a positive predictor of infective complications 
(Warschkow et al., 2012a) and an anastomotic leak (Singh et al., 2014).  In particular, C-
reactive protein concentrations on postoperative day 3 (< ~170 mg/l) and day 4 (< 
~130mg/l) have been proposed to be of clinical utility since they aid safe and early 
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discharge of selected patients following colorectal surgery.  However, since the majority of 
studies have examined such C-reactive protein thresholds in open colorectal surgery it is 
not clear whether such thresholds are applicable in laparoscopic surgery specifically.  
 
It is plausible that predictive C-reactive protein thresholds may be altered in laparoscopic 
surgery since postoperative C-reactive protein concentrations have been reported to be 
reduced in laparoscopic compared with open colorectal surgery in some studies (He et al., 
2009, Schwenk et al., 2000, Veenhof et al., 2012) but not all (Dunker et al., 2003).  Due to 
the increasing utilisation of the laparoscopic approach, whether similar thresholds apply is 
important for clinical practice.  If there were differences in these thresholds then this would 
have implications for the use of C-reactive protein as a negative predictor of infective 
complications in patients undergoing resection for colorectal cancer.  Alternatively, if there 
were no differences in the thresholds then this would confirm the immunological rationale 
for measuring C-reactive protein.  Therefore, the aim of the present study was to compare 
the value of C-reactive protein concentration as a predictor of postoperative infective 
complications in patients undergoing open versus laparoscopic resection for colon cancer. 
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5.2 Patients and Methods 
Patients with histologically proven colon cancer who, on the basis of intraoperative 
findings and preoperative abdominal computed tomography, were considered to have 
undergone potentially curative resection in one of two university teaching hospitals in 
Glasgow over a three year period were included in the study (n=344).  Patient 
characteristics were collected in a prospective surgical database. All patient data was de-
identified.  
 
The tumours were staged using conventional TNM classification.  All resections were 
elective cases and were performed using either open (n=191) or laparoscopic surgery 
(n=153).  All operations involved an anastomosis.  In order to reduce possible confounding 
factors patients undergoing emergency surgery, surgery for rectal cancer, or laparoscopic 
surgery converted to open were excluded from the analysis. 
 
Pre-operatively all patients received thromboembolism and antibiotic prophylaxis 
according to the local protocol (the same in both units).  Blood samples were taken for 
routine laboratory analysis of C-reactive protein in the pre- and postoperative period (days 
1-4).  Postoperatively, all patients had a daily clinical assessment and additional 
investigations were carried out as clinically indicated.  
 
Patients were assessed for the following complications: infective and non-infective 
(persistent ileus, cardiac events encompassing acute coronary syndrome and acute 
myocardial infarction, and pulmonary embolism).  Infective complications can be 
described as surgical site infections (SSI) and remote site infections (RSI).  Surgical site 
infections can be further classified into incisional (wound) and organ/space (intra-
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abdominal abscess / anastomotic leak).  A remote site infection such as pneumonia is often 
exogenous and occurs at sites not directly associated with the surgical procedure.  The 
criteria used to define infective complications were the same as previously described 
(Ytting et al., 2005).  Casenotes, clinic letters and the hospital computer system containing 
lab results were reviewed at 30 days postoperatively. 
 
Statistical analysis 
Data are presented as median (range).  Comparison between unpaired data was carried out 
using a Mann-Whitney U test.  A p-value <0.05 was considered significant.  The 
diagnostic accuracy of C-reactive protein was assessed by receiver operating characteristic 
(ROC) analysis. Statistical analysis was performed using SPSS version 21.0 for Windows 
(SPSS Inc, Chicago, IL). 
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5.3 Results 
Baseline characteristics of the 344 patients who underwent surgery for colon cancer are 
shown in Table 5-1.  The majority of patients were age 65 or older (75%), male (52%), had 
left sided tumours (54%), node negative disease (77%), and did not undergo neo-adjuvant 
treatment (94%).  Patients undergoing open and laparoscopic resection were similar in 
terms of age, sex, tumour site, TNM stage, comorbidity and infective complications.  In 
contrast, pre-operative and postoperative days 1 to 3 C-reactive protein concentrations 
were lower following laparoscopic compared with open resection in the whole cohort 
(n=344; all p<0.001) and in those who did not develop infective complications (n=251; 
Table 5-2; all p<0.001).  The median length of hospital stay was shorter in the laparoscopic 
resection (p<0.001).   
 
During follow up 127 (37%) patients developed a postoperative complication; 93 (73%) of 
which were infective complications.  The 93 patients with infective complications included 
43 remote site infections (pneumonia n=35, urinary tract infection n=4, peripheral cellulitis 
n=2, sepsis due to a central line tip infection n=2, and clostridium difficile n=1), 36 wound 
infections, 5 intra-abdominal abscess and 18 anastomotic leaks.  Of those with an infective 
complication, 10 patients developed a second infective complication and 17 patients 
developed an additional non-infective complication.  The 51 non-infective complications 
were persistent ileus (n=10), atrial fibrillation (n=8), myocardial infarction (n=6), acute 
urinary retention (n=5), haematoma or bleeding (n=3), acute renal failure (n=3), wound 
dehiscence (n=7), small bowel obstruction (n=4), pulmonary or deep vein thrombosis 
(n=3), port site hernia (n=1) and multi-organ failure (n=1).  Both infective and non-
infective complications were associated with an increased length of hospital stay (both 
p<0.001). 
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The relationship between open and laparoscopic resections, daily C-reactive protein 
concentrations and infective complications in the postoperative period are shown in Figure 
5-1 and Table 5-2.  In those who developed an infective complication there was no 
significant difference in the C-reactive protein concentrations between open and 
laparoscopic resections on postoperative days 1 to 4 (Figure 5-1, Table 5-2).   
             
In order to establish a threshold for the relationship between C-reactive protein 
concentrations in predicting an infective complication following surgery for colon cancer 
Receiver Operator Curves were plotted for postoperative days 3 and 4 (Figures 5-2 and 5-
3).  Following open surgery, the AUC for postoperative day 3 was 0.75 with an optimal 
threshold of 180mg/l, sensitivity 71%, specificity 61% (p<0.001).  For postoperative day 4 
the AUC was 0.78 with an optimal threshold of 140mg/l, sensitivity 75%, specificity 74% 
(p<0.001) (Figure 5-2).  Following laparoscopic surgery, the AUC for postoperative day 3 
was 0.74 with an optimal threshold of 180mg/l, sensitivity 71%, specificity 79% 
(p=0.001).  For postoperative day 4 the AUC was 0.72 with an optimal threshold of 
140mg/l, sensitivity 71%, specificity 72% (p=0.001) (Figure 5-3). 
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5.4 Discussion 
The results of the present study show, for the first time, that although the magnitude of the 
systemic inflammatory response, as evidenced by C-reactive protein, following surgery 
was greater in open compared with laparoscopic resection, the threshold concentrations of 
C-reactive protein for the development of postoperative infective complications were 
remarkably similar on days 3 and 4.  Taken together these results would suggest a 
mechanistic association between over-elaboration of the systemic inflammatory response 
and the development of infective complications. 
 
The results of the present study are consistent with and, in particular, the C-reactive protein 
thresholds remarkably similar to previous studies (Singh et al., 2014).  These present 
results appear to confirm the lesser magnitude of the systemic inflammatory response 
associated with laparoscopic resection in those patients who did not develop an infective 
complication.   Clearly, one possibility for this is that the systemic inflammatory insult is 
reduced with the use of laparoscopic surgery.  However, it was of interest that, in the 
present study, those patients who underwent a laparoscopic resection had a lower pre-
operative C-reactive protein concentration.  Therefore it might be that patients who 
undergo a laparoscopic resection for colon cancer have less of a baseline systemic 
inflammatory response, perhaps secondary to lesser comorbidity such as obesity and 
smoking, or have a lower inflammatory insult postoperatively, or both. 
 
One limitation of the present study is that it examines contemporaneous cohorts at two 
different hospitals, which  may lead to slight differences in patient factors such as deprivation (data 
not collected) and perioperative care other than surgical approach, a randomised control trial would  
reduce such confounding factors. Furthermore, the C-reactive protein threshold predictive of 
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infective complications in this chapter is similar, although not identical, to the threshold 
determined in chapter 4. This may be accounted for due to different patient numbers and 
the exclusion of emergency presentation. 
 
C-reactive protein thresholds predictive of infective complications following both open and 
laparoscopic surgery for colorectal cancer have important potential clinical application, for 
instance in raising suspicion of the development of complications and guiding 
investigations at an early stage prior to clinical symptoms evolving, or indeed aiding safe 
early discharge from hospital.  Moreover, these thresholds may be useful in identifying 
interventions targeted at reducing infective complications.  The basis of the relationship 
between a threshold concentration of C-reactive protein in the post-operative period and 
the development of infective complications is not clear.  However, given that this 
observation has been made across surgical procedures (Singh et al., 2014, Warschkow et 
al., 2012d, Warschkow et al., 2012c, Noble et al., 2013), and now across surgical 
techniques, with varying magnitudes of surgical injury would suggest an immunological 
process.  In particular, the elaboration of a systemic inflammatory response is associated 
with an up regulation of the innate immune response and a consequent down regulation of 
the adaptive immune response.  If this was indeed the case this would suggest a number of 
approaches (selective and unselective) to reduce the infective complication rate.  For 
example, in order to investigate the temporal relationship between the inflammatory 
response and infective complications, one approach would be to target the magnitude of 
the systemic inflammatory response using anti-inflammatory agents.  Another approach, 
given that post-operative hyperglycaemia promotes bacterial growth, would be to institute 
tight glycaemic control.  Furthermore, based on high C-reactive protein concentrations 
post-operatively, another approach would be to provide additional antibiotic therapy.  It 
remains to be determined what approach will best bring about a reduction of infective 
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complications in patients undergoing surgery for colon cancer.   
            
In summary, the results of the present study show that the magnitude of the postoperative 
systemic inflammatory response, as evidenced by C-reactive protein concentrations, was 
similar in patients who developed postoperative infective complications irrespective of 
whether they underwent open or laparoscopic surgery for colon cancer.  
 
Table 5-1 Clinicopathological characteristics of patients undergoing elective resection for colon cancer (n=344) 
 
Results shown as number (percentage) or median (range), C-reactive protein (mg/l) 
 Open surgery (n=191) 
 
Laparoscopic surgery (n=153) p-value 
Age (<65/ 65-74/ ≥ 75) 47/ 58/ 86 (25/ 30/ 45) 37/ 59/ 57 (24/ 39/ 37) 0.338 
Sex (Male/ Female) 95/ 96 (50/ 50) 85/ 68 (56/ 44) 0.284 
Neo-adjuvant (No/ Yes) 176/ 15 (92/ 8) 146/ 7 (95/ 5) 0.218 
ASA (1/ 2/ 3/ 4) 11/ 53/ 41/ 9 (6/ 28/ 21/ 5) 14/ 62/ 40/ 2 (9/ 41/ 26/ 1) 0.120 
TNM stage (0/ I/ II/ III) 8/ 30/ 84/ 63 (4/ 16/ 44/ 33) 3/ 39/ 58/ 48 (2/ 25/ 38/ 31) 0.344 
Tumour Site (Right / Left) 76/ 76 (40/ 40) 64/ 89 (42/ 58) 0.153 
Pre-operative C-reactive protein 9 (1-223) 5 (1-236) <0.001 
Day 1 C-reactive protein  110 (2-313) 79 (5-236) <0.001 
Day 2 C-reactive protein  175 (20-358) 128 (12-392) <0.001 
Day 3 C-reactive protein  169 (6-443) 122 (11-339) <0.001 
Day 4 C-reactive protein  124 (6-415) 94 (21-346) 0.182 
Any complication 77 (40) 50 (33) 0.145 
Non-infective complication 32 (17) 19 (12) 0.261 
Infective complication 54 (28) 39 (25) 0.564 
Surgical site infection 32 (17) 26 (17) 0.953 
Remote site infection 29 (15) 14 (9) 0.093 
Anastomotic leak 11 (6) 7 (5) 0.625 
Wound infection 20 (10) 16 (10) 0.997 
Pneumonia 23 (12) 12 (8) 0.201 
Length of hospital stay (days) 8 (3-78) 6 (2-27) <0.001 
Table 5-2 The relationship between serial postoperative values of  C-reactive protein and the development of infective complications following 
open versus laparoscopic surgery for colon cancer (n=344) 
 
 
 No infective complication (n=251)  Infective Complication (n=93)  
 Open surgery (n=137) Laparoscopic (n=114) p-value Open surgery (n=54) Laparoscopic (n=39) p-value 
Pre-op CRP 9 (1-209) 4 (1-45) <0.001 9 (1-101) 5 (2-28) 0.019 
CRP day 1 103 (4-229) 60 (18-173) <0.001 117 (2-240) 112 (43-236) 0.092 
CRP day 2 169 (20-320) 116 (32-317) <0.001 201 (82-358) 188 (60-392) 0.193 
CRP day 3 160 (6-352) 129 (44-316) <0.001 220 (78-430) 226 (40-339) 0.635 
CRP day 4 110 (6-388) 87 (28-346) 0.196 187 (23-415) 233 (27-314) 0.923 
 
Median (range), CRP C-reactive protein (mg/l) 
 
  
Figure 5-1 The perioperative changes in C-reactive protein in patients with infective 
complications following open and laparoscopic surgery for colorectal cancer 
Median, 95% Confidence Interval.   
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Figure 5-2 Diagnostic accuracy of C-reactive protein with regards to the development 
of infective complications following open surgery for colorectal cancer 
 
The AUC values were 0.75 (p<0.001) and 0.78 (p<0.001) for postoperative days 3 and 4 
respectively. 
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Figure 5-3 Diagnostic accuracy of C-reactive protein with regard to the development 
of infective complications following laparoscopic surgery for colorectal cancer 
 
The AUC values were 0.74 (p=0.001) and 0.72 (p=0.001) for postoperative days 3 and 4 
respectively.   
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6 The impact of the day 2 C-reactive protein on day 3 
and 4 thresholds associated with infective 
complications following curative surgery in colorectal 
cancer 
6.1 Introduction 
Colorectal cancer is the second most common cause of cancer death in the UK, accounting 
for 16,000 deaths annually (CRUK, 2014).  Outcomes are primarily dependent on stage at 
presentation but even with modern treatments, of those deemed suitable candidates for 
curative resections approximately 50% will suffer disease recurrence and die of their 
disease.  It is now recognised that postoperative complications contribute to poor cancer 
specific survival (Rizk et al., 2004, Khuri et al., 2005).  In particular, anastomotic leak 
following colorectal cancer resection has been negatively associated with survival, 
independent of tumour stage (McArdle et al., 2005, Law et al., 2007).  
 
It is of interest, therefore, that the postoperative systemic inflammatory response, as 
evidenced by C-reactive protein concentrations on day 3 and day 4, has been consistently 
reported to be associated with the development of infective complications and anastomotic 
leak (Welsch et al., 2007, Korner et al., 2009, Ortega-Deballon et al., 2010, MacKay et al., 
2011, Warschkow et al., 2012b).  However, patients in enhanced recovery after surgery 
programmes require earlier assessment as they are likely to be discharged from hospital 
earlier, around day 3. Therefore, assessment of the peak C-reactive protein response to 
surgery at day 2 would prove useful. As a result, it would be important to determine 
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whether the systemic inflammatory response, as measured by C-reactive protein, on 
postoperative day 3 and day 4 is influenced by the peak systemic inflammatory response to 
surgery, as measured by C-reactive protein on day 2 (Gabay and Kushner, 1999, Lane et 
al., 2013).  
 
 
The aim of the present study was to assess the impact of the peak systemic inflammatory 
response, as evidenced by day 2 C-reactive protein, on C-reactive protein concentrations 
and their thresholds on day 3 and day 4, and therefore its potential impact on the 
development of infective complications and anastomotic leak.  
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6.2 Patients and Methods 
Patients with histologically proven colorectal cancer who, on the basis of laparotomy 
findings and preoperative investigations, were considered to have undergone potentially 
curative resection in one of two university teaching hospitals, with C-reactive protein 
measurement carried out on postoperative days 1 to 4, were included in the study (n=357). 
Patient characteristics and postoperative complications within 30 days were recorded in a 
prospective database.  An enhanced recovery programme was utilised in one hospital 
(n=92). Patients with incomplete blood results or those who had other pre-existing 
inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease, 
metastatic disease, or who were admitted as an emergency were excluded from the study 
(n=157). This was approved by the research ethics committee, as part of surgical audit.  All 
patient data was anonymised.  
  
All tumours were staged according to the conventional tumour, node, metastasis (TNM, 5th 
Edition) staging system classification.  Daily blood samples were taken, as per hospital 
routine, for analysis of C-reactive protein in the pre- and postoperative period.  Prior to 
surgery, all patients received thromboprophylaxis and antibiotic prophylaxis as per hospital 
protocol.  Postoperatively, all patients were clinically assessed and additional 
investigations carried out as indicated. 
 
Patients were assessed for infective complications whilst inpatients and at their first routine 
outpatient follow up. Infective complications were defined as described previously (Ytting 
et al., 2005).  Briefly, superficial wound infection was defined as the presence of pus, 
either discharging spontaneously or requiring drainage. Intra-abdominal abscess was 
verified by either surgical or image guided drainage of pus.  An anastomotic leak was 
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diagnosed radiologically or at re-laparotomy.  Pneumonia was defined as a fever >38.5°C 
plus a positive chest X-ray or CT scan, requiring treatment with antibiotics.  Septicaemia 
was defined by clinical symptoms and a positive blood culture.  Urinary tract infection was 
only included if complicated by septicaemia. 
 
Statistics 
Data was compared using X2, Mann-Whitney U and Kruskal Wallis tests.  In order to 
assess the correlation between day 2 C-reactive protein and other perioperative days, 
scatter plots were drawn with a best fit line, and r2 calculated as a measure of correlation 
(Figures 6-1 and 6-2). r2 is the fraction of the total variance of day 3 or 4 C-reactive protein 
that is associated with variation in day 2 C-reactive protein concentrations. The 
corresponding postoperative day 2 C-reactive protein concentrations for various day 3 and 
4 thresholds from previous studies were calculated using the regression equation derived 
from the plot of data.  The diagnostic accuracy of day 2 C-reactive protein thresholds was 
assessed by receiver operating characteristic (ROC) analysis.  A p-value of less than 0.05 
was considered significant.  Statistical analysis was performed using SPSS version 19 for 
Windows (SPSS, Chicago, IL). 
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6.3 Results 
Baseline characteristics of the 357 patients who underwent curative surgery for colorectal 
cancer are shown in Table 6-1.  The majority of patients were 65 or older (72%), male 
(53%), underwent right or left hemicolectomy (63%) and had node negative disease (61%).  
Most patients had a preoperative CRP less than 10 mg/L (80%). 
 
During follow-up 84 of 357 patients developed postoperative infective complications 
(pneumonia n=28, septicaemia n=8, urinary tract infection with septicaemia n=7, central 
line tip infection n=3, peripheral cellulitis n=1, and antibiotic enterocolitis n=1).  Twenty 
two patients developed a superficial wound infection, 6 developed an intra-abdominal 
abscess or collection and 14 patients developed an anastomotic leak.  Of those with an 
infective complication, 6 patients developed a second infection and 7 developed a non-
infective complication.  In total, 26 patients developed a non-infective complication (acute 
coronary syndrome / myocardial infarction n=12, atrial fibrillation n=6, ileus n=3, 
pulmonary embolism n=2, acute urinary retention n=1, pulmonary oedema n=1, and renal 
failure n=1). 
 
The relationship between postoperative days 1 and 2 C-reactive protein and C-reactive 
protein concentrations on postoperative days 3 and 4 was examined.  Day 1 C-reactive 
protein was associated with day 3 (r2=0.153, p<0.001) and day 4 (r2=0.081, p<0.001) 
concentrations.  Day 2 C-reactive protein was not associated with age (p=0.204), sex 
(p=0.621), operation type (p=0.913), TNM stage (p=0.840), open surgery (p=0.692) or 
enhanced recovery (p=0.714).  Using scatter plots with a line of best fit drawn (Figures 6-1 
and 6-2) day 2 C-reactive protein was directly associated with day 3 (r2=0.601, p<0.001) 
and day 4 (r2=0.270, p<0.001) concentrations.   
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The relationship between day 2 C-reactive protein concentrations in the present study and 
previously published postoperative day 3 and 4 thresholds for the prediction of infective 
complications and anastomotic leak following colorectal surgery  is shown in Table 6-2 
(Welsch et al., 2007, Korner et al., 2009, Ortega-Deballon et al., 2010, MacKay et al., 
2011, Warschkow et al., 2012b, Almeida et al., 2012).  For infective complications, the 
median day 2 C-reactive protein concentrations associated with the previously published 
optimum day 3 and 4 thresholds was approximately 190mg/L.  For the development of an 
anastomotic leak, the median day 2 C-reactive protein concentrations associated with the 
previously published optimum day 3 and 4 thresholds was approximately 200mg/L.  
 
Regarding patients who developed an anastomotic leak, 8 out of 14 had a postoperative 
day 2 C-reactive protein concentration greater than 200 mg/L, 10 out of 14 had a 
concentration greater than 190 mg/L.  Using the C-reactive protein threshold of >200 mg/L 
the area under the curve (AUC) for the prediction of infective complications was 0.63 
(p<0.001) and 0.52 (p=0.072) for the prediction of anastomotic leaks.  Similarly, using the 
threshold of >190 mg/L the area under the curve (AUC) for the prediction of infective 
complications was 0.62 (p<0.001) and 0.52 (p=0.020) for the prediction of anastomotic 
leaks. 
 
In terms of length of hospital stay, four patients were discharged on postoperative day 3, 
none of whom developed infective complications at 30 days. Overall, the median length of 
hospital stay was 10 days (range 3 – 187 days).  
 
The relationship between clinicopathological characteristics and the day 2 C-reactive 
protein concentration threshold of >190 mg/L is shown in Table 6-3.  This day 2 threshold 
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was not significantly associated with sex, co-morbidity, operation type, TNM stage, open 
surgery, enhanced recovery or length of hospital stay.  However, it was associated with 
infective complications (p<0.001).   
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6.4 Discussion 
The results of the present study show that the magnitude of the peak systemic 
inflammatory response, as evidenced by C-reactive protein on postoperative day 2, has a 
significant impact on subsequent C-reactive protein concentrations on day 3 
(approximately 60% of the variation) and day 4 (approximately 30% of the variation) in 
patients following potentially elective curative resection of colorectal cancer.  The 
implications of this association are that a C-reactive protein concentration of more than 
190 mg/L on day 2 contributes substantially to a concentration above established 
thresholds on day 3.  Therefore, the peak systemic inflammatory response, as evidenced by 
day 2 C-reactive protein >190mg, contributes to increasing concentrations above the 
thresholds on day 3 and day 4 associated with the development of infective complications 
(Chapters 4 and 5). Previous chapters (Chapters 4 and 5) have also demonstrated that day 3 C-
reactive protein thresholds of 170-180 mg/l are the most sensitive and specific in predicting 
infective complications.  For the first time, we introduce the notion that postoperative infective 
complications may result from an increased inflammatory insult and suggest that day 2 C-reactive 
protein might be a useful measure of this “inflammatory hit” and could be used to assess 
interventions to reduce this. 
 
It is also of interest that a number of perioperative interventions have been shown to be 
associated with a reduced day 2 C-reactive protein concentration and the reduced 
development of infective complications.  Indeed, enhanced recovery programmes and 
laparoscopic surgery have been shown to attenuate the patient’s systemic inflammatory 
response to surgery (Wang et al., 2012, Kehlet, 2011, Lane et al., 2013).  However, 
objective data on this association remains scarce.  Clearly, the use of a well defined 
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objective measure of the systemic inflammatory response such as C-reactive protein has 
the potential to identify therapeutic interventions likely to improve patient outcomes.  
 
As the use of enhanced recovery after surgery programmes increases, particularly in 
colorectal surgery, patients are being discharged from hospital earlier than previously.  An 
early warning, prior to discharge, of the likelihood that complications might develop, 
perhaps leading to readmission, would prove useful.  In a recent study of 533 patients 
undergoing colorectal surgery within an enhanced recovery programme, Lane and co-
workers demonstrated that the measurement of C-reactive protein after elective surgery can 
identify those at risk of adverse events and prolonged hospital stay.  Furthermore, they 
highlight that patients within an enhanced recovery programme are often suitable for 
discharge on postoperative days 3 or 4, and that assessing C-reactive protein beyond these 
time points is becoming potentially redundant.   Earlier prediction would therefore be 
beneficial.  Equally, a low or falling C-reactive protein may be reassuring in an era of early 
discharge.  They note a C-reactive protein concentration of >150 mg/L on postoperative 
day 2 as well as a rising C-reactive protein on day 3 were independent predictors of 
adverse events, and should alert the surgeon at an early phase to an increased likelihood of 
such events (Lane et al., 2013).  When the threshold of 150 mg/L was applied to the 
present study the AUC for the prediction of infective complications was 0.57 (p=0.002) 
and 0.52 (p=0.044) for the prediction of anastomotic leaks, compared to the C-reactive 
protein threshold of >190 mg/L with an AUC of 0.62 (p<0.001) for the prediction of 
infective complications and 0.52 (p=0.020) for the prediction of anastomotic leaks. For 
both thresholds of 150 and 190 mg/L, the negative predictive value was 87%. A day 2 C-
reactive protein threshold of 100 mg/L determined a negative predictive value of 90%. 
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The present study has a number of limitations.  It was conducted over a seven year period 
and included patients from two teaching hospitals hence some variation in care, 
anaesthesia and surgeon may be a confounding factor.  However, in the present cohort, day 
3 and 4 C-reactive protein thresholds for predicting the development of infective 
complications were similar to previous studies.  Furthermore, trends in C-reactive protein, 
as demonstrated in Table 6-1, show a peak at postoperative day 2, in keeping with previous 
literature.   
 
The role of C-reactive protein as a reliable early predictor of postoperative infective 
complications (and anastomotic leak), prior to the traditional rise in white cell count and 
temperature and subsequent development of symptoms, is now increasingly recognised 
(Dutta et al., 2011, Korner et al., 2009, Ortega-Deballon et al., 2010, MacKay et al., 2011, 
Lane et al., 2013).  Furthermore, the development of an anastomotic leak post-operatively 
is now recognised to not only compromise short term but also longer term outcomes in 
patients undergoing surgery for colorectal cancer (Mirnezami et al., 2011).  However, the 
question of whether a high peak systemic inflammatory response following surgery is 
associated with an increased risk of developing infective complications has not been 
previously addressed directly.  Whether complications result from the peak systemic 
inflammatory response or whether the peak systemic inflammatory response is already 
raised due to the presence of an underlying infective complication remains uncertain.  If 
the former is the case then it might be expected that intervention to reduce this peak 
systemic inflammatory response might well improve outcomes, both short and long term.  
Conversely, if the later proves true, perhaps pre-emptive treatment such as antibiotic 
therapy would be beneficial.  In any case, measurement of the peak systemic inflammatory 
response, using day 2 C-reactive protein concentrations, and the establishment of clinically 
important thresholds is a step forward in such investigations.   
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Table 6-1 The clinicopathological characteristics of patients undergoing elective 
resection for colorectal cancer (n=357) 
 
Characteristic Number of Patients (%) 
Age (<65 / 65-74 / ≥75) 99 / 113 / 145 (28 / 32 / 40) 
Sex (male / female) 188 / 169 (53 / 47) 
Operation (RH or LH / AR or APR) 224 / 133 (63 / 37) 
TNM Stage (I / II / III) 75 / 142 / 132 (21 / 40 / 37) 
Laparoscopic Surgery (no / yes) 330 / 27 (92 / 8) 
Enhanced Recovery (no / yes) 265 / 92 (74 / 26) 
Infective Complication (no / yes) 274 / 83 (77 / 23) 
Anastomotic Leak (no / yes) 343 / 14 (96 / 4) 
Preoperative CRP (median, range) 8 (1-209) 
Day 1 CRP (median, range) 112 (5-245) 
Day 2 CRP (median, range) 172 (20-377) 
Day 3 CRP (median, range) 148 (6-443) 
Day 4 CRP (median, range) 99 (6-452) 
Length of hospital stay (median, range) days 10 (3-187) 
 
RH right hemicolectomy, LH left hemicolectomy 
AR anterior resection, APR abdominoperineal resection 
TNM tumour, node, metastasis staging system, 5th 
edition  
CRP C-reactive protein, mg/L 
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Table 6-2 Corresponding day 2 C-reactive protein concentration in present cohort with previously reported threshold values of C-
reactive protein in predicting infective complications 
 
Study Number of 
Patients 
Post- operative 
day 
CRP (mg/L) Complication Corresponding day 2 
CRP in present cohort 
(mg/L) 
Welsch et al(Welsch et al., 2007) 48 3 140 All infections 170 
MacKay et al(MacKay et al., 2011) 160 4 145 All infections 197 
Warschkow et al(Warschkow et al., 
2012b) 
1187 4 123 All infections 186 
Chapter 4 454 3 170 All infections 192 
     Median 189 
Kørner et al(Korner et al., 2009) 231 3 190 Anastomotic Leak 207 
Ortega-Deballon et al(Ortega-Deballon 
et al., 2010) 
133 4 125 Anastomotic Leak 187 
Almeida et al(Almeida et al., 2012) 173 3 140 Anastomotic Leak 170 
Chapter 4 454 3 190 Anastomotic Leak 207 
     Median 202 
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Table 6-3 The clinicopathological characteristics of patients with a day 2 C-reactive 
protein concentration (CRP) ≤190 / >190 mg/l (n=357) 
 
Characteristic Number of Patients p value 
Day 2 CRP ≤190 mg/L Day 2 CRP >190 mg/L 
Age (<65 / 65-74 / ≥75) 54 / 57 / 98 45 / 56 / 47 0.014 
Sex (male / female) 117 / 92 71 / 77 0.135 
Operation (RH or LH / AR or 
APR) 
128 / 81 96 / 52 0.486 
TNM stage (I / II / III) 44 / 82 / 79 31 / 61 / 56 0.974 
Laparoscopic Surgery  
(no / yes) 
191 / 18 139 / 9 0.373 
Enhanced Recovery  
(no / yes) 
155 / 54 110 / 38 0.973 
Infective Complication  
(no / yes) 
181 / 28 93 / 55 <0.001 
Anastomotic Leak (no / yes) 205 / 4 138 / 10 0.020 
Length of hospital stay 
(median, range) 
10 (3-108) 10 (3-187) 0.489 
 
RH right hemicolectomy, LH left hemicolectomy 
AR anterior resection, APR abdominoperineal resection 
TNM tumour, node, metastasis staging system 
  
 
 
  
Figure 6-1 The relationship between postoperative day 2 C-reactive protein and 
postoperative day 3 C-reactive protein concentrations (mg/l) 
 
r2=0.601 (p<0.001)  
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Figure 6-2 The relationship between postoperative day 2 C-reactive protein and 
postoperative day 4 C-reactive protein concentrations (mg/l) 
 
r2=0.270 (p<0.001) 
 
 
 
 
 7 Clinicopathological determinants of the magnitude of 
the systemic inflammatory response following 
colorectal cancer resection 
7.1 Introduction 
Colorectal cancer is the second most common cause of cancer death in the United 
Kingdom, accounting for 16,000 deaths annually (CRUK, 2014).  It is now recognised that 
the preoperative systemic inflammatory response is related to outcome, both short and long 
term, in patients following potentially curative surgery for colorectal cancer (Mohri et al., 
2014, Roxburgh and McMillan, 2010, Moyes et al., 2009).  It has also been shown that 
postoperative C-reactive protein concentrations above thresholds of approximately 
180mg/l and 140mg/l on days 3 and 4 respectively can be a useful early predictor of the 
development of postoperative infective complications and anastomotic leak following 
colorectal cancer resection , independent of surgical approach (i.e. open or laparoscopic) 
(Chapter 5).  Furthermore, such complications, particularly anastomotic leak, are in turn 
associated with poorer long term survival (Trencheva et al., 2013).  Moreover, the systemic 
inflammatory response, as demonstrated by day 2 postoperative C-reactive protein 
concentration (Crozier et al., 2007) and threshold above 190 mg/l, has a significant 
influence on the likelihood of having a C-reactive protein above these previously noted 
predictive thresholds on days 3 and 4 (Chapter 6).  Clinicopathological factors associated 
with the day 2, day 3 and day 4 C-reactive protein concentrations, and thresholds 
predictive of infective complications, are of considerable interest since they may be 
modifiable and could therefore potentially be considered as objective future therapeutic 
targets.  
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The aim of the present study was to examine the clinicopathological determinants of the 
systemic inflammatory response, as evidenced by C-reactive protein thresholds on 
postoperative days 2, 3 and 4, in patients following resection of colorectal cancer. 
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7.2 Patients and Methods 
 Patients with a histologically proven diagnosis of colorectal cancer who, based on 
preoperative investigations and operative findings, were thought to have undergone 
potentially curative resection during a period from 1999 to 2013, and in whom C-reactive 
protein concentrations were measured on postoperative days 2, 3 and 4 were included in 
the study (n=536).  Patient characteristics, including perioperative C-reactive protein 
concentrations, were recorded routinely in a prospective departmental audit database. All 
patient data were anonymised. 
 
All tumours were staged according to the conventional tumour, node, metastasis (TNM, 5th 
edition) classification.  Daily blood samples were obtained, as per hospital routine, for 
analysis of C-reactive protein during the perioperative period.  Prior to surgery, all patients 
received thromboprophylaxis and antibiotic prophylaxis as per local protocol.  Lesions 
from the caecum to the sigmoid colon were classified as colon cancers, lesions of the 
rectosigmoid junction and rectum were classified as rectal cancers.  An enhanced recovery 
programme was introduced during the data collection (period 2011 to 2013), the features of 
which are shown in Table 7-1. 
 
Emergency presentation was determined if the patient presented via an unplanned hospital 
admission and underwent surgery during the same admission. Surgeons were identified as 
a specialist if they had a major commitment to colorectal cancer surgery within the NHS, 
were regarded as a colorectal surgeon by their peers and colleagues, had access to a 
dedicated colonoscopy session, and were part of a colorectal cancer multi-disciplinary 
team (Oliphant et al., 2013a).  All other surgeons were classified as non-specialists in 
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colorectal cancer.  Surgeon volume was determined by the total number of cases per 
surgeon recorded in the database, divided by number of years they were included. 
 
Patient co-morbidity was classified using the American Society of Anaesthesiologists 
(ASA) grading system, where ‘1’ represents a normal healthy patient, ‘2’ a patient with 
mild systemic disease, ‘3’ a patient with severe systemic disease and ‘4’ a patient with 
severe systemic disease that is a constant threat to life.  This assessment was carried out by 
an anaesthetist preoperatively.  Body Mass Index (BMI) was categorised as underweight 
(<20), normal weight (20-25), overweight (>25-30), and obese (>30). 
 
The extent of deprivation was defined by the Carstairs deprivation index (Carstairs and 
Morris, 1990), an area based measure derived from the 1991 census, using the postal code 
of residence at diagnosis, which divides the score into a seven-point index.  For illustrative 
purposes, the results are presented by amalgamating the seven categories into three groups: 
affluent (categories 1 and 2), intermediate (categories 3-5) and deprived (categories 6 and 
7).  The Carstairs deprivation index has been extensively utilized in cancer patients and is 
particularly appropriate for use in the central belt of Scotland (Carstairs and Morris, 1990).  
 
Data were compared using the χ2 and Mann-Whitney U tests. Variables statistically 
significant on univariate analysis were subsequently entered into a multivariate model 
using a backwards conditional method. A p-value of <0.05 was considered significant.   
Statistical analysis was performed using SPSS version 21.0 for Windows (IBM 
Corporation, Armonk, NY, USA). 
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7.3 Results 
Baseline characteristics of the 536 patients who underwent surgery for colorectal cancer 
are shown in Table 7-2.  The majority of patients were 65 or older (68%), male (57%), 
were overweight or obese (59%), were from a deprived area (55%), had colonic tumours 
(67%), were not inflamed (60%) and had node negative disease (58%).  Most patients 
underwent elective resection (83%) and had an open resection (89%).  The peak systemic 
inflammatory response, as evidenced by C-reactive protein concentrations, was on 
postoperative day 2 (median 175mg/l, range 17-454mg/l). 
 
The relationships between clinicopathological characteristics and peak postoperative C-
reactive protein concentrations are shown in Table 7-3.  Postoperative day 2 C-reactive 
protein thresholds of ≥190 mg/l were significantly associated with deprivation (p=0.006), 
emergency presentation (p<0.001), preoperative systemic inflammation (p<0.001), and 
open surgery (p=0.001). Postoperative day 3 C-reactive protein thresholds of ≥180 mg/l 
were significantly associated with BMI (p=0.008), deprivation (p=0.024), emergency 
presentation (p=0.002), and an enhanced recovery programme (p<0.001). Postoperative 
day 4 C-reactive protein thresholds of ≥140 mg/l were significantly associated with BMI 
(p=0.004), emergency presentation (p=0.004), preoperative systemic inflammation 
(p=0.020), neoadjuvant treatment (p=0.004), tumour site (p=0.010), and an enhanced 
recovery programme (p<0.001).  
 
The relationships between clinicopathological characteristics and peak postoperative C-
reactive protein concentrations in elective cases only are shown in Table 7-4.  In elective 
cases, postoperative day 2 C-reactive protein thresholds of ≥190 mg/l were significantly 
associated with deprivation (p=0.026), preoperative systemic inflammation (p=0.006), and 
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open surgery (p=0.002). On multivariate analysis of significant variables, only deprivation 
(OR 1.43, 95% CI 0.99-2.08, p=0.059) and preoperative systemic inflammation (OR 1.37, 
95% CI 1.01-1.85, p=0.043) were independently associated with a postoperative day 2 C-
reactive protein concentration above the threshold. 
 
In elective cases, postoperative day 3 C-reactive protein thresholds of ≥180 mg/l were 
significantly associated with BMI (p=0.018) and an enhanced recovery programme 
(p<0.001). On multivariate analysis of significant variables only BMI (OR 1.46, 95% CI 
1.07-1.99, p=0.018) was independently associated with a postoperative day 3 C-reactive 
protein concentration above the predictive threshold.  
 
In elective cases, postoperative day 4 C-reactive protein thresholds of ≥140 mg/l were 
significantly associated with BMI (p=0.007), neoadjuvant treatment (p=0.005), tumour site 
(p=0.024), and an enhanced recovery programme (p<0.001). On multivariate analysis of 
significant variables, BMI (OR 1.42, 95% CI 1.02-1.98, p=0.039), enhanced recovery (OR 
2.86, 95% CI 1.40-5.84, p=0.004), and neoadjuvant treatment (OR 0.19, 95% CI 0.06-0.59, 
p=0.004) were all independently associated with a postoperative day 4 C-reactive protein 
above the predictive threshold. 
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7.4 Discussion 
The results of the present study show that several clinical factors were independently 
associated with the postoperative systemic inflammatory response, as evidenced by day 2, 
day 3 and day 4 C-reactive protein concentrations, following resection of colorectal cancer.  
In particular, emergency presentation, preoperative systemic inflammation, socioeconomic 
deprivation, BMI and an enhanced recovery programme were independently associated 
with a C-reactive protein concentration above predictive thresholds for the development of 
postoperative infective complications. In contrast, laparoscopic surgery and neoadjuvant 
treatment were associated with C-reactive protein concentrations below these thresholds. 
 
Emergency presentation has been repeatedly reported to be associated with high post-
operative complication and mortality rates (McArdle and Hole, 2004, Anderson et al., 
1992, Crozier et al., 2009).  Moreover, emergency presentation predicts poorer cancer 
specific survival independent of other clinicopathological factors, including tumour stage 
(McArdle et al., 2006).  Indeed, in the present study, it was of interest that patients 
undergoing emergency surgery had a higher preoperative C-reactive protein concentration 
and were twice as likely to breach the day 2 C-reactive protein threshold of 190 mg/l than 
those presenting electively.  Patients presenting as emergencies are also more likely to 
undergo surgery by a non-specialist surgeon, although only a small number of resections 
were performed by non-specialists in the present study.  Therefore, it may be that the 
impact of emergency presentation on both short and long term outcomes is, in part, 
determined by the magnitude of the systemic inflammatory response following surgery for 
colorectal cancer.  Tumour stenting may be advocated as a bridge to surgery in the 
emergency setting.    
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It has long been recognised that socioeconomic deprivation is independently associated 
with increased postoperative morbidity and mortality following colorectal cancer surgery, 
as well as with a raised systemic inflammatory response (Oliphant et al., 2013b, McMillan 
et al., 2003a).  It has been proposed that deprivation is associated with an aggregation of 
features that result in a low grade background systemic inflammation not fully explained 
by smoking or increased weight (O'Reilly et al., 2006).  Indeed, the presence of a raised 
systemic inflammatory response prior to surgery, as evidenced by an elevated C-reactive 
protein concentration, has been shown to predict overall and cancer specific survival, 
independent of tumour stage, in patients undergoing colorectal cancer resection (McMillan 
et al., 2003b, Oliphant et al., 2014, Crozier et al., 2009).  In the present study, in patients 
who presented electively, it was of interest that those patients who were deprived were 
twice as likely to breach the day 2 C-reactive protein threshold of 190 mg/l than those who 
were affluent.  Also, those patients who were deprived, presenting electively and who were 
not systemically inflamed (mGPS 0) were twice as likely to breach the day 2 C-reactive 
protein threshold of 190 mg/l than those who were affluent.  Therefore, the present results 
are consistent with the concept that deprivation impacts on poor outcomes through the 
magnitude of the post-operative systemic inflammatory response. 
 
In the present study, BMI was only available in approximately 50% of patients.  Therefore 
conclusions regarding the influence of BMI on the peak systemic inflammatory response 
should be limited.  However, increased BMI is an established risk factor for the 
development of colorectal cancer, and has been shown to influence C-reactive protein 
concentrations (O'Reilly et al., 2006).  Patients who are overweight or obese are more 
likely to have other pre-existing co-morbidities and perhaps longer operating times.  
Indeed, it is of interest that BMI and deprivation were directly associated and both have 
been associated with an increased inflammatory response (O'Reilly et al., 2006).  The exact 
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mechanism relating increased BMI and the postoperative systemic inflammatory response 
has yet to be explained.  However, it may be that surgery involving trauma to an increased 
amount of subcutaneous fat leads to a more profounding systemic inflammatory response.   
 
Surgery under the care of a specialist surgeon has been repeatedly reported to be 
independently associated with lower postoperative and long term mortality rates (Oliphant 
et al., 2013a).  A Cochrane review in 2012 reported that hospital volume, surgeon volume, 
and treatment by specialist surgeons to be important in determining 5 year survival 
(Archampong et al., 2012), whereas findings of a recent study of 6432 patients reported 
that hospital volume and specialist surgeons, but not surgeon volume, impacted on survival 
rates (Etzioni et al., 2014).  In the present study there was no significant association 
between surgical specialisation or volume and the magnitude of the post-operative 
systemic inflammatory response.  However, the number of non-specialists was small and 
the median peak C-reactive protein concentration was only slightly higher (188 mg/l vs 
173 mg/l) and therefore further work is required to examine whether association of 
specialisation and improved short term and long term outcomes is mediated in part by the 
postoperative systemic inflammatory response.  
 
Consistent with the results of the present study laparoscopic surgery has been repeatedly 
shown to attenuate the systemic inflammatory response to surgery (Lane et al., 2013, 
Srinivasa et al., 2011, Wang et al., 2012).  However, patients who undergo a laparoscopic 
resection for colon cancer are more likely to be fit enough to tolerate a pneumoperitoneum 
and longer anaesthetic times.  They therefore may be younger, and have fewer co-
morbidities.  Furthermore, it is less likely that those patients with emergency presentation 
will undergo laparoscopic resection.  Nevertheless, the results of the present study provide 
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objective evidence to support the laparoscopic approach, where possible, in patients 
undergoing surgery for colorectal cancer.  
 
It is accepted that neoadjuvant therapy may lead to immunocompromise in some patients. 
Therefore, it may be that the systemic inflammatory response is reduced as a result of this 
effect. Further investigation into the pathophysiological relationship between neoadjuvant 
treatment and the systemic inflammatory response in larger cohorts would be of interest. 
 
A number of advances in clinical care have taken place in the last decade or so that may 
also have had an impact on the magnitude of the postoperative systemic inflammatory 
response, such as enhanced recovery programmes. It is of particular interest that in this 
study enhanced recovery appears to be associated with an increased likelihood of 
developing a C-reactive protein concentration above predictive thresholds, and retains 
significance on multivariate analysis. This contradicts expectations and therefore merits 
further investigation. The multifactorial nature of an enhanced recovery programme leads 
to the effect of individual elements being notoriously difficult to study. 
 
A particular strength of this study is in establishing clinicopathological determinants of the 
magnitude of the postoperative systemic inflammatory response, and highlights C-reactive 
protein concentration as a potential tool to enable an objective assessment of such factors. 
Furthermore, C-reactive protein thresholds may prove a useful benchmark of the impact of 
future  innovations of clinical care, which may influence the postoperative systemic 
inflammatory response. 
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Table 7-1 Features of the enhanced recovery protocol used in the present study  
Preoperative preparation Written preoperative information. Free fluids and high 
calorie drinks up to 4 hours before surgery. No bowel 
preparation, except for those having left-sided surgery, who 
received a phosphate enema the night before and on the 
morning of surgery. 
Anaesthesia A standard protocol was used. Normothermia was 
maintained throughout. No nasogastric tubes or intra-
abdominal drains were used. 
Analgesia PCA morphine for 48 hours. Regular paracetamol with 
tramadol for breakthrough pain. Use of non-steroidal anti-
inflammatory drugs was with-held until the morphine PCA 
had been discontinued. 
Diet and Fluids Oral fluids and protein drinks encouraged immediately 
after surgery. Normal food introduced on postoperative day 
1. 
Mobilisation All patients received chest physiotherapy and commenced 
active mobilisation with a physiotherapist from 
postoperative day 1. 
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Table 7-2 Clinicopathological characteristics of patients undergoing colorectal cancer 
resection (n=536)  
Characteristic Number of Patients (%) 
Age (<65/ 65-74/ >75 years) 174 / 176 / 186 (33 / 33 / 35) 
Sex (male/ female) 307 / 229 (57 / 43) 
ASA (1 / 2 / 3 / 4) 37 / 158 / 173 / 25 (9 / 40 / 44 / 6) 
BMI (underweight/ normal/ overweight/ obese) 18 / 82 / 88 / 56 (7 / 34 / 36 / 23) 
Deprivation (affluent / intermediate / deprived) 21 / 164 / 230 (5 / 40 / 55) 
Emergency (no / yes) 461 / 75 (83 / 17) 
Pre-op CRP >10 mg/l (no / yes) 311 / 207 (60 / 40) 
Neoadjuvant treatment (no / yes) 447 / 89 (83 / 17) 
Tumour site (colon / rectum) 359 / 177 (67 / 33) 
T stage (T0 / T1 / T2 / T3 / T4) 6 / 34 / 72 / 266 / 151 (1 / 6 / 14 / 50 / 29) 
N stage (N0 / N1 / N2) 308 / 152 / 69 (58 / 29 / 13) 
Surgery (open / laparoscopic) 454 / 55 (89 / 11) 
Enhanced recovery (no / yes) 342 / 194 (64 / 36) 
Colorectal specialist (no / yes) 8 / 477 (2 / 98) 
Surgeon volume (<10 / 10-20 / >20) 23 / 310 / 152 (5 / 64 / 31) 
Day 2 CRP ≥190 mg/l (no / yes) 309 / 227 (58 / 42) 
Day 3 CRP≥180 mg/l (no / yes) 328 / 208 (61 / 39) 
Day 4 CRP≥140 mg/l (no / yes) 350 / 186 (65 / 35) 
 
Results are given as the number and percentage or as the median and range.  
ASA n=393, BMI n=244, Deprivation Category n=415 
TNM tumour, node, metastasis staging system, 5th edition 
CRP C-reactive protein concentration 
 
 
Table 7-3 The relationship between clinicopathological characteristics and postoperative C-reactive protein concentration thresholds in patients 
undergoing surgery for colorectal cancer (n=536)  
Characteristic  Day 2 CRP  
(<190 / ≥190 mg/l) 
 
p value Day 3 CRP  
(<180 / ≥180 mg/l) 
 
p value Day 4 CRP  
(<140 / ≥140 mg/l) 
 
p value 
Age (years) <65 99 / 75  105 / 69  112 / 62  
 65-74 91 / 85  103 / 73  109 / 67  
 >75 119 / 67 0.163 120 / 66 0.408 129 / 57 0.311 
Sex Male 178 / 129  181 / 126  190 / 117  
 Female 131 / 98 0.857 147 / 82 0.219 160 / 69 0.055 
ASA 1 24 / 13  25 / 12  25 / 12  
 2 99 / 59  107 / 51  116 / 42  
 3 105 / 68  110 / 63  118 / 55  
 4 12 / 13 0.238 16 / 9 0.471 17 / 8 0.595 
BMI Underweight 11 / 7  14 / 4  14 / 4  
 Normal 53 / 29  55 / 27  58 / 24  
 Overweight 57 / 31  59 / 29  62 / 26  
 Obese 28 / 28 0.180 26 / 30 0.008 26 / 30 0.004 
Deprivation Affluent 16 / 5  15 / 6  14 / 7  
 Intermediate 107 / 57  118 / 46  123 / 41  
 Deprived 124 / 106 0.006 139 / 91 0.024 153 / 77 0.204 
Emergency No 280 / 181  294 / 167  312 / 149  
 Yes 29 / 46 <0.001 34 / 41 0.002 38 / 37 0.004 
Pre-op CRP ≤10mg/l 198 / 113  201 / 110  217 / 94  
 >10mg/l 98 / 109 <0.001 117 / 90 0.064 124 / 83 0.020 
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Neoadjuvant treatment No 258 / 189  266 / 181  280 / 167  
Yes 51 / 38 0.942 62 / 27 0.073 70 / 19 0.004 
Tumour site  Colon 200 / 159  210 / 149  221 / 138  
 Rectum 109 / 68 0.196 118 / 59 0.068 129 / 48 0.010 
T stage T0 4 / 2  4 / 2  6 / 0  
 T1 19 / 15  19 / 15  20 / 14  
 T2 48 / 24  54 / 18  53 / 19  
 T3 151 / 115  155 / 111  165 / 101  
 T4 84 / 67 0.322 92 / 59 0.436 102 / 49 0.648 
N stage N0 182 / 126  194 / 114  205 / 103  
 N1 93 / 59  97 / 55  105 / 47  
 N2 31 / 38 0.116 33 / 36 0.068 36 / 33 0.104 
Surgery  Open 254 / 200  280 / 174  304 / 150  
Laparoscopic 44 / 11 0.001 39 / 16 0.181 36 / 19 0.823 
Enhanced recovery No 193 / 149  230 / 112  252 / 90  
 Yes 116 / 78 0.449 98 / 96 <0.001 98 / 96 <0.001 
Colorectal specialist No 4 / 4  4 / 4  4 / 4  
Yes 276 / 201 0.655 293 / 184 0.511 307 / 170 0.401 
Surgeon volume <10 14 / 9  14 / 9  13 / 10  
 10-20 173 / 137  190 / 120  199 / 111  
 >20 93 / 59 0.440 93 / 59 0.999 99 / 53 0.565 
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Table 7-4 The relationship between clinicopathological characteristics and postoperative C-reactive protein concentration thresholds in patients 
undergoing elective surgery for colorectal cancer (n=461)  
Characteristic  Day 2 CRP  
(<190 / ≥190 mg/l) 
 
p value Day 3 CRP  
(<180 / ≥180 mg/l) 
 
p value Day 4 CRP  
(<140 / ≥140 mg/l) 
 
p value 
Age (years) <65 91 / 63  96 / 58  103 / 51  
 65-74 81 / 68  90 / 59  94 / 55  
 >75 108 / 50 0.092 108 / 50 0.266 115 / 43 0.261 
Sex Male 159 / 102  162 / 99  169 / 92  
 Female 121 / 79 0.927 132 / 68 0.384 143 / 57 0.125 
ASA 1 24 / 12  25 / 11  25 / 11  
 2 94 / 51  100 / 45  107 / 38  
 3 96 / 61  99 / 58  105 / 52  
 4 9 / 9 0.218 12 / 6 0.359 12 / 6 0.366 
BMI Underweight 10 / 6  13 / 3  12 / 4  
 Normal 51 / 27  52 / 26  56 / 22  
 Overweight 55 / 28  57 / 26  60 / 23  
 Obese 28 / 25 0.262 26 / 27 0.018 25 / 28 0.007 
Deprivation Affluent 15 / 5  14 / 6  13 / 7  
 Intermediate 100 / 50  108 / 42  113 / 37  
 Deprived 
 
 
111 / 84 0.026 125 / 70 0.166 134 / 61 0.481 
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Pre-op CRP ≤10mg/l 191 / 104  194 / 101  207 / 88  
 >10mg/l 77 / 73 0.006 90 / 60 0.232 96 / 54 0.187 
Neoadjuvant treatment No 231 / 147  235 / 143  245 / 133  
Yes 49 / 34 0.726 59 / 24 0.126 67 / 16 0.005 
Tumour site  Colon 173 / 118  179 / 112  186 / 105  
 Rectum 107 / 63 0.459 115 / 55 0.186 124 / 44 0.024 
T stage T0 4 / 2  4 / 2  6 / 0  
 T1 19 / 14  18 / 15  19 / 14  
 T2 47 / 24  53 / 18  52 / 19  
 T3 142 / 95  145 / 92  153 / 84  
 T4 65 / 43 0.715 71 / 37 0.995 79 / 29 0.724 
N stage N0 167 / 107  177 / 97  187 / 87  
 N1 85 / 42  85 / 42  91 / 36  
 N2 25 / 29 0.267 29 / 25 0.308 31 / 23 0.343 
Surgery  Open 227 / 160  247 / 140  267 / 120  
Laparoscopic 44 / 11 0.002 39 / 16 0.304 36 / 19 0.597 
Enhanced recovery No 173 / 119  205 / 87  222 / 70  
 Yes 107 / 62 0.389 89 / 80 <0.001 90 / 79 <0.001 
Colorectal specialist No 2 / 4  3 / 3  3 / 3  
Yes 254 / 167 0.180 267 / 154 0.498 281 / 140 0.388 
Surgeon volume <10 12 / 9  13 / 8  12 / 9  
 10-20 159 / 108  170 / 97  179 / 88  
 >20 85 / 54 0.684 87 / 52 0.910 93 / 46 0.637 
 
 
8 The impact of enhanced recovery on the systemic 
inflammatory response and the infective complication 
rate following elective surgery for colorectal cancer 
8.1 Introduction 
In the 1990s, Kehlet introduced the idea of a multimodal approach to modifying the 
surgical stress response and subsequent increased demands on organ function. While no 
single technique or drug regimen has been shown to eliminate postoperative morbidity and 
mortality, multimodal interventions led to a reduction in the undesirable sequelae of 
surgical injury with improved recovery and reduction in postoperative morbidity and 
overall costs (Kehlet, 1997).  Over the past decade, there has been a revolution in the 
nature of perioperative care with the introduction of enhanced recovery after surgery 
(ERAS) protocols (Fearon et al., 2013).  More recently, this has been proposed for cancer 
surgery, particularly colorectal cancer resection.  Enhanced recovery programmes aim to 
attenuate the stress response to surgery, accelerate recovery, reduce the length of hospital 
stay and have been proposed to be associated with reduced hospital morbidity and 
mortality (Teeuwen et al., 2010).  For example, patients undergoing colorectal resection 
within an enhanced recovery programme have been reported to stay in hospital half as long 
as those receiving conventional care (King et al., 2006).   
 
Rates of infective complications following colorectal surgery may range from 15-30%. 
Despite improvements in surgery and care, in particular infection control measures and the 
use of pre-operative antibiotic prophylaxis, infective complications remain a major cause 
of morbidity and mortality following colorectal cancer resection (Velasco et al., 1996).  
Patients are at risk of surgical site infections, such as wound infections and intra-abdominal 
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abscess, as well as anastomotic leak, and remote site infections, such as urinary tract 
infections, respiratory tract infections and line sepsis.  These complications may require 
further surgery and can lead to prolonged hospital stay or, in an era of early discharge, 
readmission.  It has more recently been recognised that postoperative infective 
complications, particularly anastomotic leak, may also compromise long term outcomes 
(McArdle et al., 2006).  Recent studies have shown that the magnitude of the systemic 
inflammatory response following surgery can predict the development of infective 
complications (Welsch et al., 2007, MacKay et al., 2011, Welsch et al., 2008, Warschkow 
et al., 2012c, Dutta et al., 2011). However, data on the effect of enhanced recovery on the 
postoperative systemic inflammatory response and infective complications remains 
limited. 
 
The aim of the present study was to examine the impact of enhanced recovery on the 
length of hospital stay, the systemic inflammatory response and the rate of infective 
complications following elective surgery for colorectal cancer.  
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8.2 Patients and Methods 
All patients had a histological diagnosis of colorectal cancer and on the basis of pre-
operative imaging and operative findings, were thought to have undergone potentially 
curative resection.  All operating surgeons had a specialist interest in colorectal surgery.  In 
total, 310 consecutive patients undergoing elective resection were included in the study.  
The patients were admitted to one of two university teaching hospitals within the same 
city, between September 2003 and October 2006.  One unit employed ERAS procedures, 
and admitted 150 patients; the other was using conventional care methods and admitted 
164 patients (4 of these patients were excluded from the study due to incomplete data 
collection).  Patients undergoing emergency or palliative surgery were excluded from the 
data collection, as were patients who received neo-adjuvant chemotherapy. 
 
An enhanced recovery programme is multifactorial (Kehlet, 1997).  Features of the 
enhanced recovery protocols used in this study, as previously described in Chapter 7 
(Table 7.1), included pre-operative patient education, standardised anaesthetic technique, 
maintenance of normothermia intra-operatively, an opioid-sparing analgesic regime and 
early post-operative mobilisation and nutrition, as well as minimally invasive or 
laparoscopic surgery carried out by an experienced surgeon, as previously described 
(MacKay et al., 2007).  The decision on suitability for laparoscopic surgery was made on a 
case by case basis by the operating surgeon.  Examples of conservative care include 
prolonged preoperative fasting, placement of surgical drains, and soft diet until first bowel 
movement. All patients received pre-operative antibiotics and thomboprophylaxis.  
 
Data was extracted from a prospectively maintained database, including baseline patient 
characteristics, C-reactive protein concentrations on postoperative days 2, 3 and 4, 
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postoperative infective and non-infective complications, and length of hospital stay.  
Postoperative infective complications included surgical site infections (wound infection, 
anastomotic leak, intra-abdominal collection) as well as remote site infections (e.g. urinary 
tract infection, respiratory tract infection, line sepsis) as previously described (Chapter 4).  
 
Statistics 
Grouping of variables was carried out using standard or previously published thresholds. 
Associations between categorical and continuous variables were examined using X2 tests 
for linear trend and non-parametric tests.  A p-value <0.05 was considered statistically 
significant.  Statistical analyses were performed using SPSS version 19.0 (IBM SPSS, 
Chicago, IL, USA).   
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8.3 Results 
Baseline characteristics of the 310 patients who underwent potentially curative surgery for 
colorectal cancer are shown in Table 8-1.  Age and sex were similar in both the enhanced 
recovery and conventional care groups.  Co-morbidity, as demonstrated by ASA scores, 
was significantly less in the enhanced recovery group, and there were also fewer rectal 
cancers as well as earlier tumour stage (p<0.01, p<0.05, and p<0.01 respectively).  In the 
enhanced recovery group length of stay was significantly shorter and laparoscopic surgery 
was used in approximately 30% of cases (both p<0.001, Table 8-1).   
 
During follow-up 75 of 310 patients developed postoperative infective complications 
(pneumonia n=21, septicaemia n=7, urinary tract infection n=5, central line tip infection 
n=2, peripheral cellulitis n=2, and antibiotic enterocolitis n=2).  Twenty patients developed 
a wound infection and 16 patients developed an anastomotic leak.  Of those with an 
infective complication, 3 patients developed a second infection.  In total, 23 patients 
developed a non-infective complication (acute coronary syndrome / myocardial infarction 
n=6, atrial fibrillation n=6, ileus n=5, acute urinary retention n=2, pulmonary oedema n=2, 
haematoma n=1, and renal failure n=1). 
 
The relationship between the method of perioperative care and the postoperative systemic 
inflammatory response following elective colorectal cancer resection is shown in Table 8-
1. There was no significant association between the method of perioperative care and the 
magnitude of the systemic inflammatory response on postoperative days 2, 3 or 4, nor the 
rate of postoperative infective complications following elective resection for colorectal 
cancer. 
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Laparoscopic surgery was performed in the enhanced recovery group exclusively and so 
these cases were excluded from the analysis of enhanced recovery and conventional care 
groups.  Baseline characteristics of the 263 patients who underwent open surgery for 
colorectal cancer are shown in Table 8-2.  Patients in the enhanced recovery group were 
more likely to be elderly than those in the conventional care group (p<0.05).  Sex, co-
morbidity, tumour site and tumour stage were similar in both groups (Table 8-2).   
 
The relationship between the method of perioperative care and postoperative systemic 
inflammatory response following open resection for colorectal cancer is shown in Table 8-
2.  There was no significant association between the method of perioperative care and the 
magnitude of the systemic inflammatory response on postoperative days 2, 3 and 4.  
Enhanced recovery was significantly associated with a reduction in the development of 
pneumonia following elective surgery for colorectal cancer (p<0.05) and the length of 
hospital stay (p<0.001, Table 8-2).   
 
In the enhanced recovery group alone, baseline characteristics of the patients who received 
laparoscopic surgery compared to open surgery are shown in Table 8-3.  Age, sex, co-
morbidity, tumour site and tumour stage were similar in both groups.  
 
In the enhanced recovery group, the relationship between the method of surgery and post-
operative systemic inflammatory response following resection for colorectal cancer is 
shown in Table 8-3.  The method of surgery was not significantly associated with the 
magnitude of the systemic inflammatory response on postoperative days 2, 3 or 4, nor the 
rate of postoperative complications following elective surgery for colorectal cancer.  The 
length of hospital stay was also similar in those patients who received laparoscopic surgery 
compared with open surgery (Table 8-3). 
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8.4 Discussion  
In the present study, enhanced recovery was associated with a significant reduction in the 
development of pneumonia and the length of hospital stay following surgery for colorectal 
cancer.  These findings are in keeping with previous work demonstrating a reduction in 
respiratory complications but no difference in other complications (Basse et al., 2004, 
Teeuwen et al., 2011, Keane et al., 2012).  In contrast, the conventional care and enhanced 
recovery groups were similar in their postoperative systemic inflammatory response and 
overall complication rates.  Therefore, although enhanced recovery is associated with 
shorter length of hospital stay, it does not appear to be associated with a reduction in the 
postoperative systemic inflammatory response or a difference in overall infective 
complications.  Results in this study differ from results in Chapter 7, where enhanced 
recovery was unexpectedly associated with an increased systemic inflammatory response 
on day 4 postoperatively. It is possible this difference is a result of comparing data from 
two hospital sites in this study, as opposed to a single site in the previous chapter. Whilst 
the main guidance in each study with regards to enhanced recovery protocol was the same 
(Table 7.1), enhanced recovery programmes are multifactorial, with varying compliance, 
and therefore difficult to study.  This limitation could be overcome using a randomised 
control trial however, as each element of an enhanced recovery programme should be the 
best clinical practice based on current evidence, excluding elements in a control group may 
be viewed as unethical. Furthermore, as several elements are involved and there is no clear 
definition on how many are required (i.e. this varies between units), several large cohorts 
would be required. Hence, comparison in observational studies, whilst limited, is likely the 
most appropriate method to examine the differences between conventional care and 
enhanced recovery. 
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The implications of the present results are several.  Firstly, it would appear that the 
reduction in length of hospital stay in the enhanced recovery group may merely reflect a 
culture change in terms of time to hospital discharge rather than an actual reduction in 
post-operative stress and reduced complications in patients undergoing elective surgery for 
colorectal cancer.  Despite considerable advocacy (King et al., 2006, Basse et al., 2004, 
Fearon et al., 2013), whether enhanced recovery protocols equate to optimal treatment 
remains controversial.  Indeed, a recent randomized control trial attributed a reduction in 
the stress response to laparoscopic surgery as opposed to the approach to postoperative 
care and there were no significant differences in postoperative infective complications 
(Veenhof et al., 2012, Watt et al., 2015).  These results might also be interpreted as 
somewhat reassuring, in that despite earlier discharge, enhanced recovery was not 
associated with increased morbidity. 
 
Secondly, if there is indeed no apparent benefit to enhanced recovery over conventional 
care on the magnitude of the stress response or patient morbidity, then the decision on 
whether to pursue enhanced recovery protocols may come down to economic evaluation.  
However, it is not clear whether the costs of implementing an enhanced recovery protocol 
are outweighed by the difference in length of hospital stay. 
 
Finally, the results of the present study point to an insufficient understanding of the 
determinants of the postoperative systemic inflammatory response and infective 
complications following elective surgery for colorectal cancer.  Therefore, further work is 
required to identify the components of perioperative care that most significantly impact on 
these postoperative outcomes.  This will provide a rational basis for the incorporation of 
treatment modalities into enhanced recovery protocols. 
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For example, it has been reported that laparoscopic surgery, compared with open surgery, 
is associated with a reduction in the magnitude of post-operative C-reactive protein 
concentrations (Chapter 5) (Veenhof et al., 2012).  Furthermore, laparoscopic surgery, 
compared with open surgery, has been associated with less suppression of cell-mediated 
immune response postoperatively (Whelan et al., 2003).  However, with reference to C-
reactive protein, this was not the case in the present study and may reflect the relatively 
small effect size of laparoscopic compared with open surgery in this study.  
 
Current enhanced recovery protocols are multimodal with little consensus on the relative 
contribution of each component that should constitute an optimal protocol.  The evolution 
of enhanced recovery guidelines should be dynamic, allowing modifications of certain 
aspects of the protocol as new data on postoperative outcomes becomes available (Lyon et 
al., 2012). Further studies examining the effect of individual elements of the enhanced 
recovery protocol will prove challenging but are of the utmost importance in determining 
effective protocols.  The recent and present work would suggest that monitoring the 
postoperative C-reactive protein concentrations could provide an objective measure of the 
efficacy of each element in reducing the patient’s stress response and the risk of 
developing infective complications following surgery. For instance, the introduction of 
preoperative administration of anti-inflammatory medication could be assessed by measuring the 
magnitude of the postoperative systemic inflammatory response, as demonstrated by C-reactive 
protein concentrations and thresholds predictive of infective complications. An intervention 
successfully reducing postoperative inflammation, and the likelihood of developing complications, 
could improve patient outcomes.   
 
The present observational study has a number of limitations inherent to its design, such as 
the use of contemporaneous cohorts with potentially confounding factors, such as different 
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surgeons and anaesthetists, and in addition, that laparoscopic surgery was used in the 
enhanced recovery cohort exclusively.  The extent of deprivation was not assessed. Higher 
co-morbidity in the conventional care cohort may be due to a more deprived population, 
which may have an effect on the results (Oliphant et al., 2013b). 
 
In summary, enhanced recovery was associated with a significant reduction in length of 
hospital stay.  In contrast, the postoperative systemic inflammatory response and overall 
complication rates, both non-infective and infective, were similar to that of conventional 
care.  Therefore, enhanced recovery does not appear to be associated with a reduction in 
the postoperative systemic inflammatory response or a difference in overall infective 
complications. 
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Table 8-1 The relationship between the method of perioperative care, patient 
characteristics, the systemic inflammatory response and postoperative complications 
following elective resection for colorectal cancer (n=310)  
 
 Characteristics 
Conventional Care 
Group 
n=160 
Enhanced Recovery 
Group 
n=150 
p value 
Age (<65 / 65-74 / >75) 49 / 61 / 50 37 / 48 / 65 0.088 
Sex (Male / Female) 86 / 74 74 / 76 0.437 
ASA score (1 / 2 / 3 / 4) 13 / 57 / 60 / 7a 12 / 93 / 42 / 3 0.005 
Site (Colon / Rectum) 100 / 60 111 / 39 0.030 
TNM Stage (I / II / III) 28 / 66 / 66 38 / 53 / 44b 0.008 
Operation (Open / Lap) 160 / 0 103 / 47 <0.001 
Systemic Inflammatory 
Response 
Conventional Care 
Group 
n=160 
Enhanced Recovery 
Group 
n=150 
p value 
Day 2 CRP <190 / ≥190 (mg/L) 90 / 65 85 / 48 0.311 
Day 3 CRP <180 / ≥180 (mg/L) 105 / 45 87 / 45 0.462 
Day 4 CRP <140 / ≥140 (mg/L) 103 / 32 89 / 37 0.300 
Complications 
Conventional Care 
Group 
n=160 
Enhanced Recovery 
Group 
n=150 
p value 
All Complications 52 (33%) 46 (31%) 0.729 
Non-infective Complications 10 (6%) 13 (9%) 0.417 
Infective Complications 42 (26%) 33 (22%) 0.383 
Surgical Site Infections 20 (13%) 17 (11%) 0.752 
Remote Site Infections 22 (14%) 16 (11%) 0.408 
Anastomotic Leak 9 (6%) 7 (5%) 0.703 
Wound Infection 11 (7%) 9 (6%) 0.754 
Pneumonia 15 (9%) 6 (4%) 0.060 
Length of hospital stay 
Conventional Care 
Group 
median (range) 
Enhanced Recovery 
Group 
median (range) 
p value 
Days 11 (3-351) 6 (3-78) <0.001 
aASA not defined for 23 patients 
bTNM not defined for 15 patients 
CRP C-reactive protein 
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Table 8-2 The relationship between the method of perioperative care, patient 
characteristics, the systemic inflammatory response and postoperative complications 
following open surgery for colorectal cancer (n=263)  
 Characteristics 
Conventional Care 
Group 
n=160 
Enhanced Recovery 
Group 
n=103 
p value 
Age (<65 / 65-74 / >75) 49 / 61 / 50 27 / 28 / 48 0.037 
Sex (Male / Female) 86 / 74 54 / 49 0.834 
ASA score (1 / 2 / 3 / 4) 13 / 57 / 60 / 7a 8 / 60 / 32 / 3 0.082 
Site (Colon / Rectum) 100 / 60 74 / 29 0.118 
TNM Stage (I / II / III) 28 / 66 / 66 26 / 37 / 28b 0.082 
Systemic Inflammatory 
Response 
Conventional Care 
Group 
n=160 
Enhanced Recovery 
Group 
n=103 
p value 
Day 2 CRP <190 / ≥190 (mg/L) 90 / 65 59 / 34 0.403 
Day 3 CRP <180 / ≥180 (mg/L) 105 / 45 59 / 33 0.343 
Day 4 CRP <140 / ≥140 (mg/L) 103 / 32 62 / 27 0.270 
  
Complications 
Conventional Care 
Group 
n=160 
Enhanced Recovery 
Group  
n=103 
p value 
All Complications 52 (31%) 34 (33%) 0.931 
Non-infective Complications 10 (6%) 11 (11%) 0.196 
Infective Complications 42 (26%) 23 (22%) 0.472 
Surgical Site Infections 20 (13%) 12 (12%) 0.837 
Remote Site Infections 22 (14%) 11 (11%) 0.463 
Anastomotic Leak 9 (6%) 5 (5%) 0.786 
Wound Infection 11 (7%) 6 (6%) 0.735 
Pneumonia 15 (9%) 2 (2%) 0.017 
Length of hospital stay 
Conventional Care 
Group 
median (range) 
Enhanced Recovery 
Group 
median (range) 
p value 
Days 11 (3-86) 6 (3-78) <0.001 
aASA not defined for 23 patients 
bTNM not defined for 12 patients  
CRP C-reactive protein 
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Table 8-3 The relationship between the method of surgery, patient characteristics, the 
systemic inflammatory response and postoperative complications following elective 
surgery for colorectal cancer within an enhanced recovery programme (n=150)  
Characteristics  Open Surgery  (n=103) 
Laparoscopic Surgery  
(n=47) p value 
Age (<65 / 65-74 / >75) 27 / 28 / 48 10 / 20 / 17 0.173 
Sex (Male / Female) 54 / 49 20 / 27 0.262 
ASA score (1 / 2 / 3 / 4) 8 / 60 / 32 / 3 4 / 33 / 10 / 0 0.356 
Site (Colon / Rectum) 74 / 29 37 / 10 0.373 
TNM Stage (I / II / III) 7 / 19 / 37 / 28a 1 / 11 / 16 / 16b 0.548 
Systemic Inflammatory 
Response 
Open Surgery 
(n=103) 
Laparoscopic Surgery 
(n=47) p value 
Day 2 CRP <190 / ≥190 (mg/L) 59 / 34 26 / 14 0.864 
Day 3 CRP <180 / ≥180 (mg/L) 59 / 33 28 / 12 0.513 
Day 4 CRP <140 / ≥140 (mg/L) 62 / 27 27 / 10 0.710 
Complications Open Surgery  (n=103) 
Laparoscopic Surgery 
(n=47) p value 
All complications 34 (33%) 12 (26%) 0.357 
Non-infective Complications 11 (11%) 2 (4%) 0.195 
Infective Complications 23 (22%) 10 (21%) 0.885 
Surgical Site Infections 12 (12%) 5 (11%) 0.856 
Remote Site Infections 11 (11%) 5 (11%) 0.994 
Anastomotic Leak 5 (5%) 2 (4%) 0.872 
Wound Infection 6 (6%) 3 (6%) 0.894 
Pneumonia 2 (2%) 4 (9%) 0.057 
Length of hospital stay Open Surgery median (range) 
Laparoscopic Surgery 
median (range) p value 
Days 6 (3-78) 6 (3-27) 0.317 
aTNM not defined for 12 patients 
bTNM not defined for 3 patients 
CRP C-reactive protein 
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9 Daily C-reactive protein concentration thresholds and 
infective complications following colorectal cancer 
resection: Effect of pre-emptive antibiotic therapy 
9.1  Introduction 
Colorectal resection is associated with relatively high rates of postoperative infective 
complications.  Approximately 20-40% are at risk of complications such as respiratory, 
wound or urinary tract infection, anastomotic leak, intra-abdominal abscess and 
septicaemia of unknown origin (Velasco et al., 1996).  Many of these infections can be 
treated with antibiotics alone, whilst others, such as anastomotic leak, may require further 
intervention.  Whether the administration of antibiotics prior to a clinically evident 
anastomotic leak may reduce the need for surgical intervention is not known.  During the 
early postoperative period, sepsis can be difficult to distinguish from the normal 
postoperative systemic inflammatory response related to surgical trauma.  Recognition 
during this period is challenging and lacks sensitivity at a stage when early diagnosis may 
significantly improve outcome (Welsch et al., 2007).  Patients who encounter postoperative 
infective complications, in particular anastomotic leak, have been shown not only to have 
poorer short term outcomes, but also an increased recurrence rate in the long term 
(McArdle et al., 2005, Mirnezami et al., 2011).   
 
A number of studies have investigated the association of the systemic inflammatory 
response and postoperative complications, with previous studies suggesting that an 
abnormally elevated C-reactive protein concentration or persistent elevation may be a 
useful predictor of infective complications (Table 9-1) (Welsch et al., 2007, Bianchi et al., 
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2004, Matthiessen et al., 2008, Welsch et al., 2008, MacKay et al., 2011, Ortega-Deballon 
et al., 2010, Korner et al., 2009, Woeste et al., 2010) (Chapters 4-6).  A recent systematic 
review and meta-analysis included 7 studies (2483 patients) and concluded that C-reactive 
protein was a useful predictive test for the development of anastomotic leak following 
colorectal resection, with derived thresholds of approximately 170 mg/l on postoperative 
day 3 and approximately 145 mg/l on day 4, prior to the development of clinical symptoms 
(Singh et al., 2014).  Similar findings exist in studies looking at patients with pancreatic 
and oesophagogastric cancer (Welsch et al., 2008, Dutta et al., 2011).  In contrast, white 
blood cell count contributes little to the early detection of complications (Warschkow et 
al., 2012b).  This pre-clinical warning is of particular importance in an era of enhanced 
recovery and early discharge. 
 
Only one previous study has addressed the utility of pre-emptive antibiotics used in 
conjunction with a biochemical predictor of infective complications following elective 
colorectal surgery. This study examined serum procalcitonin as a predictive marker for 
postoperative complications and the effect of administration of pre-emptive antibiotics in 
ten patients with elevated procalcitonin compared with standard treatment.  They 
concluded that a significant reduction in the rate of postoperative infective complications 
in patients with an elevated procalcitonin was achieved by means of pre-emptive antibiotic 
treatment (Chromik et al., 2006). 
 
Moreover, in patients undergoing resection for colorectal cancer, it has previously been 
demonstrated that a raised peak postoperative C-reactive protein concentration on day 2 
above 190 mg/l leads to patients being more likely to meet thresholds predictive of 
infective complications on days 3 and 4, prior to the traditional rise in white cell count or 
clinical symptoms developing. Whether intervention to attenuate this post-operative 
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systemic inflammatory response will improve postoperative complication rates has yet to 
be determined and whether a raised systemic inflammatory response, as evidenced by C-
reactive protein concentrations, is potentially the cause or consequence of the development 
of infective complications remains unclear.   
 
Therefore, the aim of the present study was to examine the relationships between 
postoperative predictive thresholds of C-reactive protein and infective complications, in 
the context of the administration of pre-emptive antibiotic therapy, in patients undergoing 
resection for colorectal cancer. 
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9.2  Patients and Methods 
Consecutive patients with histologically proven colorectal cancer who, on the basis of 
intraoperative findings and preoperative abdominal computed tomography, were 
considered to have undergone potentially curative resection in one of two university 
teaching hospitals in Glasgow between May 2011 and January 2013 were included in the 
study (n=223).  Patient characteristics were collected in a prospective surgical database.  
All patient data was de-identified.  Emergency admissions were excluded from the study, 
along with those who had a penicillin allergy, were on immunosuppressant medications, or 
had neo-adjuvant chemotherapy. Two patients were admitted to intensive care 
postoperatively and commenced on antibiotics prior to postoperative day 3, they were also 
excluded. 
 
The tumours were staged using conventional TNM classification.  All resections were 
elective cases and were performed using either open (n=121) or laparoscopic surgery 
(n=102).  All operations involved an anastomosis.  Pre-operatively all patients received 
thromboembolism and antibiotic prophylaxis according to the local protocol.  Blood 
samples were taken for routine laboratory analysis of C-reactive protein in the pre- and 
postoperative period (days 1-7).  Postoperatively, all patients had a daily clinical 
assessment by the operating team and additional investigations were carried out as 
clinically indicated.   
 
On the basis of previous observations of antibiotic prescribing and clinical suspicion 
secondary to high postoperative C-reactive protein concentrations in each unit, it was 
considered that using C-reactive protein thresholds shown to be predictive of infective 
complications to guide the administration of antibiotics may help to rationalise antibiotic 
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prescribing and short term outcomes could be audited prospectively.  Published evidence 
was presented (MLR) at a minimum of two departmental meetings in each unit.  Guidance 
on prescribing pre-emptive antibiotics based on C-reactive protein thresholds was proposed 
(MLR and GM) and agreed by the consultant colorectal teams.  Guidance was then 
disseminated to staff via meetings, phone calls and posters.  Patients who underwent 
elective colorectal cancer resection had daily monitoring of postoperative C-reactive 
protein concentrations, as per standard practice in both units.  Patients underwent clinical 
review and appropriate investigations based on clinical findings.  Thresholds where 
derived from previous studies in both units (MacKay et al., 2011) (Chapters 4 and 5).  
Those who had a C-reactive protein >180mg/l on postoperative day 3 or >125mg/l on day 
4 were considered at high risk of developing infective complications and the operating 
team was then prompted to prescribe pre-emptive antibiotics.  Co-amoxiclav was 
recommended by our lead microbiologist due to its broad spectrum of activity and its 
availability in oral and intravenous forms.  A course of 5 days was prescribed via the most 
appropriate route of administration.  Antibiotics were changed accordingly if and when 
positive culture results were obtained.  Patients were monitored until discharge and then 
reviewed at approximately 30 days following that in routine outpatient clinics.  Outcome 
measures were the systemic inflammatory response, as evidenced by C-reactive protein 
concentrations, infective complications and length of hospital stay (Figure 9-1).  Adverse 
effects of antibiotics were also to be monitored, however none were apparent. Data was 
recorded in a prospective database and audited at 18 months. This intervention was 
intended as an audit to rationalise antibiotic prescribing based on published evidence 
regarding C-reactive protein thresholds predictive of infective complications from both 
units (Chapters 4 and 5) (MacKay et al., 2011) therefore ethical approval was not sought 
and this study was not formally powered. 
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Patients were assessed for the following complications: infective and non-infective 
(persistent ileus, cardiac events encompassing acute coronary syndrome and acute 
myocardial infarction, and pulmonary embolism).  Infective complications can be 
described as surgical site infections (SSI) and remote site infections (RSI).  Surgical site 
infections can be further classified into incisional (wound) and organ/space (intra-
abdominal abscess / anastomotic leak).  A remote site infection such as pneumonia is often 
exogenous and occurs at sites not directly associated with the surgical procedure.  The 
criteria used to define infective complications were the same as previously described 
(Ytting et al., 2005).   
 
Initially, comparison was planned between patients who received antibiotics based on C-
reactive protein concentrations above predictive thresholds and a historical control group. 
Due to compliance issues with the agreed guidance, not all patients meeting criteria for 
pre-emptive antibiotics received them, hence two contemporaneous groups were generated: 
those who received antibiotics and those who did not, all of whom met day 3 or 4 C-
reactive protein thresholds predictive of postoperative infective complications.  
 
Statistical analysis 
Data are presented as median (range) or number (percentage).  Comparison between data 
was carried out using a Chi-square or Mann-Whitney U test.  A p-value <0.05 was 
considered significant.  Statistical analysis was performed using SPSS version 21.0 for 
Windows (IBM Corporation, Armonk, NY, USA). 
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9.3  Results 
Baseline characteristics of the 223 patients who underwent surgery for colorectal cancer 
are shown in Table 9-2.  The majority of patients were age 65 or older (70%), male (62%), 
had colonic tumours (87%), node negative disease (64%), and underwent open resection 
(54%).   
 
During follow up, of the 223 patients, 117 (52%) patients developed a postoperative 
complication; 89 (40%) of which were infective complications.  The 89 patients with 
infective complications included 38 remote site infections (pneumonia n=28, urinary tract 
infection n=6, peripheral cellulitis n=2, and clostridium difficile n=2), 42 wound 
infections, 11 intra-abdominal abscesses and 13 anastomotic leaks.  Clostridium difficile 
was diagnosed in two patients, neither of whom had received pre-emptive antibiotics.  Of 
those with an infective complication, 15 patients developed a second infective 
complication and 27 patients developed an additional non-infective complication.  The 55 
patients with non-infective complications suffered from persistent ileus (n=16), atrial 
fibrillation (n=10), myocardial infarction (n=4), acute urinary retention (n=4), haematoma 
or bleeding (n=6), acute renal failure (n=6), wound dehiscence (n=8), small bowel 
obstruction (n=6), deep vein thrombosis (n=1), and multi-organ failure (n=2).   
 
Of those patients who met the C-reactive protein thresholds predictive of infective 
complications, patients who did not receive antibiotics (n=55) and patients who did (n=64) 
were similar in terms of sex, tumour site, TNM stage, comorbidity and preoperative C-
reactive protein concentration.  Patients who received antibiotics as per protocol tended to 
be older (p=0.018) and had a longer median length of hospital stay (p=0.015) than those 
who did not receive antibiotics (Table 9-2). 
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Of those patients who had C-reactive protein concentrations above the threshold for pre-
emptive antibiotics on days 3 or 4 postoperatively, patients who were prescribed antibiotics 
had significantly more infective complications (p<0.001).  In particular, the incidence of 
postoperative pneumonia was higher in those who received antibiotics (p=0.005) (Table 9-
2). 
 
Of those patients who had C-reactive protein concentrations above the threshold for pre-
emptive antibiotics on days 3 or 4 postoperatively, patients who were prescribed antibiotics 
had significantly higher C-reactive protein concentrations on postoperative days 5, 6 and 7 
(p=0.004, p=0.001, p=0.041 respectively) than those who did not receive antibiotics (Table 
9-3). 
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9.4  Discussion 
The results of this prospective non-randomised observational study suggest that, in those 
patients who received antibiotics, infective complication rates and C-reactive protein 
concentrations were subsequently higher than those who were not prescribed antibiotics.  
Therefore, the administration of pre-emptive antibiotics guided by C-reactive protein 
thresholds predictive of infective complications did not appear to reduce infective 
complication rates or the magnitude of the postoperative inflammatory response following 
elective resection for colorectal cancer.  
 
The present study has a number of limitations.  In particular, deviation from the agreed 
protocol.  The reasons for such deviation from the protocol are likely to be several.  
Initially, a randomised controlled trial had been proposed to study the impact of pre-
emptive antibiotics guided by C-reactive protein concentrations.  However, in light of the 
evidence from previous studies, some clinicians considered this unethical, and certainly 
expected access to post-operative C-reactive protein concentration results.  Conversely, 
some may have favoured clinical judgement alone and been less influenced by C-reactive 
protein concentrations or wished to wait for a trend on subsequent days.  Whilst used as a 
guide, it seems likely that perhaps pre-emptive antibiotics were only utilized in patients 
who clinically appeared to be at higher risk of developing an infective complication. This 
may have been due to a longer or more difficult operation, to these patients being older, or 
having persistently elevated C-reactive protein concentrations on postoperative day 4.  
Perhaps they simply appeared more clinically unwell.  Furthermore, this protocol was 
intended as an exploratory pilot study, and therefore not formally powered.  Both units 
followed the pre-emptive antibiotic guidance to a similar extent.  Throughout the period 
observed there was changeover of junior staff at regular intervals, therefore it is possible 
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that some staff were not aware of the pre-emptive antibiotic guidance.  One approach to 
eliminate these factors would be to carry out a formally powered prospective randomized 
trial with a strict protocol that was ethically approved. This may prove difficult due to 
issues of blinding clinicians, for instance, to blood results. 
 
Irrespective, almost one third of patients receive antibiotic therapy following elective 
colorectal cancer resection.  This is currently under close scrutiny due to the prevalence of 
opportunistic infections such as Clostridium difficile and MRSA, plus concerns regarding 
increasing antibiotic resistance.  A strategy of pre-emptive antibiotics guided by 
postoperative day 3 or 4 CRP may rationalise antibiotic prescribing by flagging up patients 
at high risk of developing infective complications and lead to earlier treatment. 
 
Conventionally, a rise in circulating C-reactive protein concentration has been interpreted 
as a consequence, rather than a cause, of an infective complication.  However, it may be 
that C-reactive protein is more than just a sensitive measure of the presence of infection.  
Indeed, C-reactive protein has an important role in innate immunity as an early defense 
against infection, assisting complement-binding to foreign and damaged cells and 
enhancing phagocytosis by macrophages.  For example, through activation of complement 
and interaction with Fc gamma receptors, C-reactive protein has been shown to provide a 
link between the innate and adaptive immune systems (Peisajovich et al., 2008, Coventry 
et al., 2009, Du Clos and Mold, 2004, Sander et al., 2010).  Furthermore, with increasing 
concentrations of C-reactive protein there is a depression of T-lymphocyte function 
(Sander et al., 2010, Fietta et al., 2009) and an increase in the stress response and the 
degree of hyperglycaemia (Wichmann et al., 2005).  Also, postoperative hyperglycemia 
has been shown to be an important factor associated with the promotion of bacterial growth 
and the development of postoperative infective complications (Motoyama et al., 2010, 
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Ramos et al., 2008).   
 
Whether infective complications result from a raised systemic inflammatory response, as 
evidenced by C-reactive protein concentrations, or whether the systemic inflammatory 
response is already raised due to the presence of an underlying infective complication 
remains uncertain.  The results of the present study demonstrate that the administration of 
early antibiotic therapy did not normalise C-reactive protein concentrations and helps to 
provide unique insight into the underlying mechanism between postoperative C-reactive 
protein concentrations and infective complications following resection for colorectal 
cancer. Hence, the persistence of an elevated C-reactive protein concentration may suggest 
that the systemic inflammatory response is a cause, rather than a consequence, of infective 
complications following colorectal cancer resection. In addition to giving advance notice 
of a clinical infection, C-reactive protein may also play an important direct role in 
modulating the postoperative immune function of patients with colorectal cancer.  If this is 
indeed the case then it might be expected that investigation into the influence of 
perioperative factors and intervention to reduce this systemic inflammatory response might 
well improve outcomes, both short and long term.  The nature of this relationship warrants 
further investigation.   
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Figure 9-1 Scheme of an 18 month audit of C-reactive protein guided pre-emptive 
antibiotics in patients undergoing resection for colorectal cancer 
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Table 9-1 Previous studies examining C-reactive protein as a predictor of infective 
complications and anastomotic leak following colorectal surgery  
Study Patients C-reactive protein threshold (sensitivity) 
Welsch 2007 (Welsch et al., 2007) 383 >140mg/l on day 3 (80%) 
Korner 2009 (Korner et al., 2009) 231 >190mg/l on day 3 (82%) 
Ortega-Deballon 2010 (Ortega-
Deballon et al., 2010) 
133 >125mg/l on day 4 (82%) 
Mackay 2010 (MacKay et al., 2011) 160 >145mg/l on day 4 (85%) 
Chapter 4 454 >170mg/l on day 3 (78%)  
Warschkow 2011 (Warschkow et 
al., 2012b) 
1,187 >123mg/l on day 4 (66%) 
Almeida 2012 (Almeida et al., 2012) 173 >140mg/l on day 3 (78%) 
Lagoutte 2012 (Lagoutte et al., 2012) 100 >130mg/l on day 4 (80%) 
Garcia-Granero 2013 (Garcia-
Granero et al., 2013) 
205 >147mg/l on day 3 (91%) 
Chapter 5 344 >180mg/l on day 3 (71%) 
>140mg/l on day 4 (71%) 
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Table 9-2 Clinical characteristics of patients undergoing elective resection for colorectal cancer (n=223)  
 Day 3 and 4 CRP below 
threshold for antibiotics 
(n=104) 
Day 3 or 4 CRP above threshold,  
no antibiotics prescribed (n=55) 
Day 3 or 4 CRP above threshold,  
antibiotics given (n=64) 
p-valuea 
Age (<65/ 65-74/ ≥ 75) 29/ 31/ 44 21/ 10/ 24 18/ 27/ 19 0.018 
Sex (Male/ Female) 63/ 41 38/ 17 37/ 27 0.206 
ASA (1/ 2/ 3/ 4) 12/ 33/ 25/ 2 3/ 9/ 16/ 2 1/ 24/ 16/ 2 0.128 
Hospital (a/ b) 67/ 37 37/ 18 38/ 26 0.376 
TNM stage (I/ II/ III/ IV) 29/ 44/ 28/ 3 7/ 26/ 17/ 5 17/ 20/ 23/ 3 0.120 
Tumour Site (Colon/ Rectum) 93/ 11 48/ 7 53/ 11 0.500 
Surgical approach (Open/ Lap) 39/ 65 43/ 12 39/ 25 0.044 
Preoperative CRP 3 (1-236) 10 (1-249) 9 (1-65) 0.933 
Day 2 CRP ≤190/ >190 85/ 9 23/ 30 24/ 37 0.663 
Length of hospital stay (days) 6 (2-70) 8 (3-72) 10 (6-63) 0.015 
Any complication 33 (32) 31 (56) 53 (83) 0.002 
Non-infective complication 19 (18) 16 (29) 20 (31) 0.799 
Infective complication 21 (20) 21 (38) 47 (73) <0.001 
Surgical site infection 13 (13) 18 (33) 32 (50) 0.058 
Remote site infection 8 (8) 8 (15) 22 (34) 0.013 
Anastomotic leak 1 (1) 6 (11) 6 (9) 0.783 
Wound infection 12 (12) 10 (18) 20 (31) 0.103 
Pneumonia 4 (4) 5 (9) 19 (30) 0.005 
Results shown as number (percentage) or median (range),  CRP C-reactive protein (mg/l)   
acompared with those who had day 3 or 4 CRP above thresholds for antibiotics, but no antibiotics prescribed 
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Table 9-3 Trends in C-reactive protein in patients undergoing elective resection for colorectal cancer (n=223)  
 
 
Results shown as median (range) 
CRP C-reactive protein (mg/l) 
acompared with those who had day 3 or 4 CRP above thresholds for antibiotics, but no antibiotics prescribed  
C-reactive protein  Day 3 and 4 CRP below threshold 
for antibiotics (n=104) 
Day 3 or 4 CRP above threshold,  
no antibiotics prescribed (n=55) 
Day 3 or 4 CRP above threshold, 
antibiotics given (n=64) 
p-valuea 
Preoperative  3 (1-236) 10 (1-249) 9 (1-65) 0.933 
Day 1  70 (2-203) 91 (4-309) 111 (7-313) 0.456 
Day 2 98 (1-224) 214 (48-337) 224 (39-454) 0.946 
Day 3 100 (2-175) 217 (89-426) 264 (110-601) 0.012 
Day 4 75 (16-125) 181 (119-403) 241 (97-528) 0.006 
Day 5  62 (11-213) 147 (53-351) 218 (64-397) 0.004 
Day 6  55 (15-304) 110 (40-399) 176 (59-406) 0.001 
Day 7  52 (12-265) 107 (21-348) 157 (33-393) 0.041 
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10 Conclusions 
It has previously been demonstrated that patients with a raised systemic inflammatory 
response prior to surgery for colorectal cancer have poorer short and longer term outcomes 
than those who are not inflamed preoperatively.  This has been thought to be due to 
inflammation promoting tumour growth and spread.  Patients undergoing colorectal 
surgery are at a relatively high risk of developing postoperative infective complications 
and anastomotic leak.  It is known that patients who develop these complications, 
particularly an anastomotic leak, have poorer cancer specific survival.  The aims of this 
thesis were to further examine the nature of the postoperative systemic inflammatory 
response and its relationship with infective complications following resection for colorectal 
cancer. 
 
Some patients have an increased systemic inflammatory response preoperatively.  We 
hypothesised that this might be due to impaired cortisol production.  Chapter 3 examines 
the relationship between the perioperative systemic inflammatory response and cortisol 
production, i.e. to determine whether this results from an impaired anti-inflammatory 
response rather than a pro-inflammatory response.  The opening chapter was a prospective 
study assessing the preoperative adrenocortical function, using short Synacthen testing, in 
80 patients undergoing colorectal cancer resection.  This study showed that the 
perioperative systemic inflammatory response was not significantly associated with 
impaired cortisol production.  This suggests that the systemic inflammatory response is 
likely a result of a pro-inflammatory stimulus rather than an impaired anti-inflammatory 
response in patients with colon cancer. 
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As previously mentioned, infective complications particularly anastomotic leak represent 
serious morbidity after colorectal cancer surgery.  They can be difficult to detect in the 
early postoperative period due to the systemic inflammatory response to surgery.  Some 
blood tests help to provide clues but their relative predictive value was unclear.  Chapter 4 
was a retrospective observational study to examine the diagnostic accuracy of serial 
postoperative white cell counts, albumin and C-reactive protein concentrations in 
predicting infective complications in 454 patients undergoing resection for colorectal 
cancer. C-reactive protein was the most sensitive test in detecting the development of an 
infective complication, with an optimal predictive threshold of 170 mg/L on postoperative 
day 3.  Indeed, in a review of 7 studies (n=2483), Singh et al concluded that C-reactive 
protein was a useful negative predictive test for the development of anastomotic leak 
following colorectal resection, furthermore the pooled C-reactive protein thresholds were 
remarkably similar (Singh et al., 2014).  In conclusion, C-reactive protein measurements 
on postoperative day 3 can accurately predict infective complications, including 
anastomotic leak, following colorectal cancer resection, prior to the development of 
clinical signs and symptoms. 
 
It was not clear whether the same predictive thresholds would apply in patients undergoing 
laparoscopic surgery.  Chapter 5 was a retrospective observational study, comparing the 
value of daily C-reactive protein concentrations in the prediction of postoperative infective 
complications in 334 patients undergoing open versus laparoscopic resection for colon 
cancer.  C-reactive protein thresholds predictive of infective complications were the same 
on postoperative day 3 (180 mg/L) and day 4 (140 mg/L) following both open and 
laparoscopic resection for colorectal cancer.  In patients who develop postoperative 
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infective complications, the magnitude of the postoperative systemic inflammatory 
response, as evidenced by C-reactive protein concentration, was similar regardless of 
surgical approach.  Although there is considerable variation in the C-reactive protein 
response following open versus laparoscopic surgery in patients who did not develop 
infective complications, the basis for this variation is not clear and worthy of further 
investigation. 
 
Whether the C-reactive protein thresholds predictive of infective complications are high 
because the patient already has an underlying infective complication earlier than expected, 
or whether a raised systemic inflammatory response means they are then more likely to 
develop a subsequent infective complication is not known.  The peak systemic 
inflammatory response, as evidenced by C-reactive protein, has been shown to occur on 
postoperative day 2.  Chapter 6 examined the impact of the peak inflammatory response on 
the C-reactive protein thresholds predictive of infective complications on days 3 and 4 in 
357 patients undergoing resection for colorectal cancer.  This study demonstrated that a 
postoperative day 2 C-reactive protein of ≥190 mg/L corresponded to previously 
determined day 3 and 4 thresholds predictive of infective complications.  If background 
inflammation makes patients at higher risk of developing complications, this would 
suggest that the magnitude of the peak inflammatory response may influence who will 
meet day 3 and 4 thresholds.  To test this hypothesis, intervention to lower the peak 
systemic inflammatory response should be investigated in future work to determine 
whether this is beneficial in the care of patients with colorectal cancer. 
 
Postoperative C-reactive protein concentration on days 3 and 4 can be a useful early 
predictor of the development of postoperative infective complications and anastomotic leak 
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following colorectal cancer resection.  Moreover, the systemic inflammatory response as 
demonstrated by day 2 postoperative C-reactive protein concentration >190mg/L has a 
significant influence on the likelihood of having a C-reactive protein above predictive 
thresholds on days 3 and 4.  Therefore, chapter 7 examined the clinicopathological 
determinants of the postoperative systemic inflammatory response, as evidenced by day 2, 
day 3 and day 4 C-reactive protein concentrations, in 686 patients following resection of 
colorectal cancer.  Emergency presentation was associated with a higher systemic 
inflammatory response on days 2-4 postoperatively.  In elective cases, preoperative 
systemic inflammation, BMI, socioeconomic deprivation and an enhanced recovery 
programme were associated with a higher systemic inflammatory response.  In contrast, 
laparoscopic surgery was associated with a lower systemic inflammatory response.  
 
Chapter 8 examined further the impact of an enhanced recovery programme on the 
systemic inflammatory response and the rate of infective complications in 310 patients 
following elective surgery for colorectal cancer.  There were no significant differences in 
the magnitude of the systemic inflammatory response or rates of infective complications in 
those who underwent colorectal cancer resection within an enhanced recovery programme 
compared to conventional care.  However, the multifactorial and variable nature of 
enhanced recovery programmes makes them notoriously difficult to study.  It may be that 
only some elements used in an enhanced recovery programme, such as laparoscopic 
surgery, actually modify the systemic inflammatory response.  Therefore, the use of 
markers such as C-reactive protein could objectively determine which components reduce 
the magnitude of the systemic inflammatory response after surgery. 
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To try to answer the question as to whether a raised C-reactive protein on days 3 and 4 was 
cause or consequence of the development of an infective complication, Chapter 9 
examined the effect of giving antibiotics based on previously determined thresholds. 
Whether infective complications result from a raised systemic inflammatory response or 
whether the systemic inflammatory response is already raised due to the presence of an 
underlying infective complication remains uncertain.  This pilot study would provide 
insight into the underlying mechanism between postoperative C-reactive protein 
concentrations and infective complications following resection for colorectal cancer. 
 
Chapter 9 examined the relationship between postoperative predictive thresholds of C-
reactive protein and infective complications, in the context of pre-emptive antibiotic 
therapy, in 223 patients undergoing surgery for colorectal cancer.  Patients who were 
prescribed antibiotics had more infective complications than those patients with similar C-
reactive protein concentrations who were not given antibiotics.  Administration of pre-
emptive antibiotics guided by C-reactive protein thresholds did not reduce rates of 
infective complications or the magnitude of the systemic inflammatory response. 
Hence a raised systemic inflammatory response may be a cause, rather than a consequence, 
of infective complications following colorectal cancer resection.  C-reactive protein may 
play a role in modulating the postoperative immune function of patients with colorectal 
cancer.  Further investigation into the influence of perioperative factors in order to reduce 
the systemic inflammatory response to surgery is required.  Therefore, future randomised 
studies that examine the effect of a reduced systemic inflammatory response on 
postoperative complications are of particular interest. 
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In conclusion, the work presented herein demonstrated that the systemic inflammatory 
response in patients with colorectal cancer is likely an innate pro-inflammatory process. 
This may in fact create a pro-tumorigenic environment and lead to increased rates of 
cancer recurrence and reduced cancer specific survival, therefore these outcomes should 
also be examined in future work.  Postoperative C-reactive protein concentrations on days 
3 and 4 following colorectal cancer resection are useful early predictors of the 
development of infective complications, prior to clinical signs and symptoms being 
apparent.  These predictive thresholds are useful in patients undergoing open or 
laparoscopic colorectal resection, and in those treated within an enhanced recovery 
programme or with conventional care.  The postoperative peak systemic inflammatory 
response, as evidenced by day 2 C-reactive protein, influences the systemic inflammatory 
response on subsequent days and therefore may determine patients at high risk of 
developing complications.  The peak systemic inflammatory response has a number of 
clinicopathological associations.  A raised peak systemic inflammatory response was 
associated with emergency presentation, deprivation, high BMI, and enhanced recovery.  
In contrast, laparoscopic surgery was associated with a reduced peak systemic 
inflammatory response.  C-reactive protein threshold guided pre-emptive antibiotics did 
not act to reduce the postoperative systemic inflammatory response or the rate of infective 
complications following colorectal cancer resection.  
Therefore, the development of postoperative infective complications following resection 
for colorectal cancer may be the consequence of a raised systemic inflammatory response 
and relative immunocompromise of the patient.  This insult may also influence 
tumorigenesis and lead to increased recurrence rates and poorer cancer specific survival.  
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The implications of this are profound.  Firstly, the utility of postoperative C-reactive 
protein thresholds as a prognostic tool, particularly with regards to the development of 
infective complications following colorectal cancer resection is demonstrated.  It has 
recently been reported that C-reactive protein concentrations can also be used to predict 
both the type and severity of postoperative complications in a small study (n=127) of 
patients undergoing surgery for colorectal cancer (Selby and Prabhudesai, 2014). 
Secondly, postoperative C-reactive protein concentrations may be a useful objective 
therapeutic target by which the efficacy of future interventions to reduce the systemic 
inflammatory response, and therefore risk of postoperative infective complications, could 
be assessed.  For instance, the effect of therapeutic interventions to reduce the 
perioperative systemic inflammatory response, such as the use of steroids or NSAIDs, 
could be assessed using postoperative C-reactive protein concentrations and the likelihood 
a patient is to breech the described thresholds.  If an elevated postoperative inflammatory 
response is a pro-inflammatory process, then NSAIDs may work to reduce this response 
and hence reduce susceptibility to postoperative infection.  Randomised trials are required 
to confirm this hypothesis. 
In summary, the objective measurement of the postoperative systemic inflammatory 
response and its relationship with postoperative outcomes has profound implications for 
assessment and treatment of the surgical stress response in patients with colorectal cancer.  
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